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This thesis presents the results achieved during the research developed at Instituto 
de Medicina Molecular, under the supervision of Prof. Doutora Maria Manuel 
Mota, from August 2004 to September 2006, aiming to be awarded a degree of 
Doctor of Philosophy in Biomedical Sciences by Faculdade de Medicina da 
Universidade de Lisboa. 
 
This thesis is structured in 6 chapters, preceded by an abstract (both in English 
and Portuguese). The first chapter provides an insight on Malaria Liver Stage 
research, with an emphasized focus on Genomics and Vaccines, and the Aims of 
this work. The three following chapters (second to fourth) contain the original 
data attained regarding this project. The fifth chapter present an overall discussion 
of all data obtained. The last chapter concerns the methodologies, materials and 
experimental techniques used during the execution of this project. The scientific 
publications which outcome from this work are included in Appendixes 1 and 2.  
 
 
The data presented in this dissertation is purely the result of my 
own work and it is clearly acknowledged in the text whenever 
data or reagents produced by others were utilized. This work has 
not been previously submitted for any degree at this or any other 
University. 
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                                                                                                                            SUMÁRIO                               
A Malária, causada pelo parasita Apicomplexa da espécie Plasmodium, ceifa a 
vida de mais de 1 milhão de crianças anualmente. Infelizmente, não existe 
nenhuma vacina contra esta doença está actualmente disponível, sendo crucial 
encontrar uma solução para diminuir as devastadoras consequências provocadas 
por esta doença, e é de consenso geral no mundo científico que novas 
intervenções são realmente necessárias para controlar a Malária. A infecção do 
fígado é o primeiro estadio que os parasitas Plasmodium, na forma de 
esporozoítos, têm de realizar (em hospedeiros mamíferos) para assegurar o seu 
desenvolvimento para o estadio seguinte, os merozoítos. Durante este estadio, 
com a duração aproximada de uma semana em humanos, os sintomas associados à 
doença não se manifestam, o que o torna ideal para uma terapia de intervenção, 
como uma vacina. Actualmente, os parasitas atenuados por radiação são, por 
excelência, uma referência nas vacinas contra o estadio hepático da Malária, uma 
vez que têm demonstrado uma elevada capacidade de immunizar humanos, outros 
primatas e ratinhos. Embora se consiga deste modo conferir uma protecção 
duradoura, esta metodologia foi considerada inapta para se conseguir immunizar 
pessoas em larga escala, devido a problemas de ordem logística, clínica e técnica. 
Este método apresenta ainda outra devantagem, não ser considerado seguro, dado 
que é necessário um controlo rígido da dose de radiação aplicada aos 
esporozoítos: se esta for demasiado pequena, os parasitas permanecerão 
infecciosos e, se for excessiva, o efeito protector induzido pelos esporozoítos 
irradiados é completamente anulado. 
Neste projecto, estudamos a capacidade de conferir imunidade contra a Malária 
por parasitas que foram atenuados através de modificações genéticas, os P. 
berghei (um parasita que infecta ratinhos) pb36p-, pbcrmp3- e pbcrmp4-. 
Os nossos resultados mostram claramente que os esporozoítos pb36p- são capazes 
de conferir protecção, podendo potencialmente ser aplicados como uma vacina 
experimental que previna contra a Malária. Estes parasitas são incapazes de 
produzir a proteina Pb36p, uma proteína de superfície encontrada nos 
micronemas, e actualmente, de função desconhecida. Caracterizámos a protecção 
conferida por estes parasitas mutantes e, sempre que possível, comparámo-la com 
a induzida por esporozoítos atenuados por radiação. Observámos que a protecção 
induzida pelos pb36p- é específica para o estadio hepático, uma vez que os 
ratinhos imunizados não estão protegidos contra a inoculação com eritrócitos 
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infectados com merozoítos P. berghei. Ratinhos das estirpes BALB/c e C57BL6, 
após imunização com pb36p-, ficaram protegidos contra sucessivas re-infecções 
até 18 e 12 meses, respectivamente. Adicionalmente, ratinhos BALB/c, após 
imunização, ficaram protegidos até 6 meses após a última inoculação de 
imunização, sem ser necessário recorrer re-infecções intermédias para 
continuarem protegidos. Imunizações com doses menores de esporozoítos pb36p- 
e utilizando métodos de administração clinicalmente aprovados (nomeadamente 
intramuscular, subcutanea e intradermal) também protegem ratinhos C57BL6 
contra a doença, embora não sejam tão eficientes como as imunizações efectuadas 
pelo modo intravenoso, no que respeita aos níveis de protecção total. A 
capacidade de imunização do pb36p- e dos parasitas atenuados por radiação não 
se restringe apenas contra a infecção com a espécie homóloga P. berghei, mas 
também contra a espécie heterologa P. yoelii, um outro parasita de ratinho. O 
desenvolvimento intrahepático deste último é também fortemente inibida, levando 
a uma redução do nível de parasitémia máxima no sangue. Este estudo é o 
primeiro, do nosso conhecimento, a abordar este tópico.  
Os mecanismos, despoletados pelos parasitas pb36p-, que induzem esta protecção 
foram também alvo de estudo. Observámos que os hepatócitos infectados com 
esporozoítos pb36p- in vitro apresentam uma elevada taxa de apoptose, bem como 
níveis bastante altos da proteina apoptótica Procaspase-3. Os níveis de apoptose in 
vivo também são bastante elevados nos fígados de ratinhos imunizados com 
parasitas pb36p- quando comparados com os imunizados com parasitas atenuados 
por radiação ou infectados com parasitas infecciosos, confirmando os resultados 
obtidos in vitro. A taxa de eliminação dos esporozoítos pb36p- é, 
consequentemente, bastante rápida. Imunização com parasitas pb36p- induz um 
aumento nas células T de memória CD8+ no fígado, que eventualmente se dissipa 
nos meses seguintes.  
Adicionalmente, foram também caracterizados os parasitas pbcrmp3- e pbcrmp4-. 
Estes parasitas não produzem proteinas que se sabe conterem domínios funcionais 
relacionados com adesão ou invasão. Estes parasitas não conseguem romper a 
membrana dos oocistos e, consequentemente, são incapazes de migrar para as 
glândulas salivares do mosquito. Dado este fenótipo aberrante, estes parasitas são 
incapazes de serem transmitidos para o hospedeiro através da picada do mosquito 
infectado. Nós observámos que os oocistos formados por ambos os parasitas 
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apresentam uma forma normal e sem defeitos aparentes, tal como os resultantes 
de parasitas da estirpe selvagem. Uma vez extraídos os esporozoítos pbcrmp3- e 
pbcrmp4- dos oocistos, observámos que eles, tal como os da estirpe selvagem, são 
capazes de executar o gliding, de migrar através de vários hepatócitos e de 
infectar uma célula final, iniciando assim o seu desenvolvimento para o próximo 
estadio. Estes parasitas mutantes infectam um número de células semelhante ao 
observado para a estirpe selvagem 24 horas após infecção. Contudo, os vacúolos 
parasitóforos dos parasitas pbcrmp3- e pbcrmp4- são menores que os da estirpe 
selvagem, e apresentam uma forma aberrante. Mesmo mantendo estes parasitas 
em cultura até 56 horas após infecção, não se verifica qualquer aumento no 
tamanho dos seus vacúolos parasitóforos. 
Os parasitas pbcrmp3- e pbcrmp4-, tal como os parasitas atenuados por radiação e 
os pb36p-, são incapazes de se desenvolverem completamente no fígado. Visto 
apresentarem um fenótipo semelhante ao observado para os parasitas pb36p- e os 
atenuados por radiação, surgiu a hipótese de os esporozoítos pbcrmp3- e 
pbcrmp4- também poderem ser utilizados como uma vacina experimental contra 
Malária. Infelizmente, esta hipótese revelou não ser válida. Ratinhos BALB/c e 
C57BL6 imunizados com parasitas pbcrmp3- ou pbcrmp4- não ficaram protegidos 
contra uma infecção posterior com a estirpe selvagem. Pensamos que esta 
deficiência em conferir protecção advem do facto destes parasitas mutantes terem 
sido extraídos dos oocistos, estando ainda “imaturos”, uma vez que não passaram 
pelo estadio de maturação nas glândulas salivares que alguns investigadores 
consideram ser fundamental para que os esporozoítos adquiram a sua capacidade 
infectiva.  Ambos os parasitas pb36p- e atenuados por radiação necessitam de 
infectar e iniciar o desenvolvimento intrahepático, de modo a conferir imunidade 
contra a Malária. Outra alternativa derivaria do facto destes parasitas atenuados 
conseguirem inibir eficientemente a apoptose das células hospedeiras, tal como a 
estirpe selvagem. Dada a falta de corpos apoptóticos, os parasitas pbcrmp3- ou 
pbcrmp4- não conseguiriam montar uma resposta imune eficiente como os pb36p- 
ou os atenuados por radiação.Contudo, ainda estão a ser realizados os estudos que 
demonstrarão quais as verdadeiras razões responsáveis pela incapacidade dos 
parasitas pbcrmp3- e pbcrmp4- em conferir protecção contra a Malária. Embora 
estes parasitas não apresentem qualquer potencial como estratégia de vacinação 
contra a Malária, o seu fenótipo durante o estadio hepático é bastante interessante 
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e irá fornecer indubitavelmente novas perspectivas ácerca das interacções 
parasita-célula hospedeira a este nível. 
Os nossos resultados demonstram claramente que os parasitas pb36p- possuem 
um forte potencial para serem aplicados como uma vacina experimental contra a 
Malária, ao contrário dos parasitas pbcrmp3- e pbcrmp4-. Os parasitas pb36p- 
conseguem conferir imunidade a longo termo e protecção contra outra espécie de 
parasita de ratinho, o P. yoelii. Imunizações utilizando rotas de administração 
utilizadas regularmente em vacinação humana, bem como doses com reduzido 
número de esporozoítos pb36p- são também eficazes. Torna-se agora fundamental 
compreender os mecanismos que permitem aos parasitas pb36p- conferir 
protecção. Os nossos esforços iniciais demonstram que a protecção induzida por 
esporozoítos pb36p- está dependente de interferão gama (IFN-γ) e de células T 
gama-delta. A apoptose também aparenta ter um papel primordial no efeito 
protectivo mediado por estes parasitas atenuados. Estes são apenas os passos 
iniciais nesta matéria. Novos esforços com o intuito de compreender e descobrir 
os mecanismos que levam à protecção induzida por estes e outros parasitas 
geneticamente modificados, o que, sem dúvida, fornecerá dados inovadores e de 
importância vital para o desenvolvimento de uma vacina dirigida ao estadio 
hepático da Malária. Esses esforços conduzirão a novas estratégias de vacinação 
contra esta doença. 
 
Palavras-chave: Malaria, esporozoíto, parasitas geneticamente modificados, 
vacina, apoptose, mecanismos do sistema imune 
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Malaria claims the lives of more than 1 million children in Sub-Saharan Africa 
annually. Yet, no vaccine is currently available against this disease caused by the 
Apicomplexa parasites known as Plasmodium. There is no doubt that novel 
intervention strategies are required to control malaria. Liver infection is the first 
obligatory step, allowing parasites, in the form of sporozoites, to develop into the 
next infective stage, merozoites. This stage is clinically silent (no illness-related 
symptoms arise) and lasts around a week in human malaria, making it an ideal 
target for a vaccine. So far, the golden standard for a vaccine against the malaria 
liver stage is immunization with radiation attenuated sporozoites, a whole 
organism approach which has proved to be able to confer long lasting protection 
to humans, non human primates and mice, but considered unfeasible for mass 
immunization, due to logistical, clinical and technical obstacles. This approach 
was also considered unsafe, since strict control of radiation dose is vital to achieve 
effective protection: if parasites are underirradiated, they remain infectious, and if 
overirradiated, the protective effect elicited by them is completely lost. 
In this work, we have focused on another whole organism approach 
immunization, by exploiting the potential of three P. berghei (a rodent parasite) 
genetically-attenuated sporozoites, pb36p-, pbcrmp3- and pbcrmp4-.  
pb36p- based immunizations proved that these attenuated parasites may be used 
as an experimental vaccine against malaria. These parasites are unable to 
synthesize the protein Pb36p, a surface protein found in the sporozoite 
micronemes and without a known function. Thus, further studies were undertaken 
to characterize pb36p- mediated protection. We observed that the protection 
induced by pb36p- is stage specific, being unable to protect mice against 
challenge with P. berghei infected erythrocytes. BALB/c and C57BL6 mice are 
found to be protected against continuous challenges up to 18 months and 12 
months post final immunization respectively (last time point tried). Moreover, 
BALB/c mice immunized with three doses of pb36p- sporozoites are protected up 
to 6 months after last immunization with no additional challenge. Protection in 
C57BL6 mice can be attained even with low doses of pb36p- sporozoites (1,000 
sporozoites), a feature not observed in RAS based immunizations. pb36p- 
sporozoites still confer protection to C57BL6 mice when administered through 
routes commonly used as public health measures, namely intramuscular, 
subcutaneous and intradermal, although never attaining complete sterile 
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protection as seen with intravenous inoculation. pb36p- and RAS mediated 
immunity are not species specific, since mice immunized with these attenuated 
parasite have a high level of inhibition of intrahepatic parasite development and 
reduction in blood stage parasitemia when challenged with P. yoelii sporozoites, a 
heterologous species. 
Preliminary studies regarding the mechanisms elicited by pb36p- to confer 
immunity to mice were also performed. We observed that pb36p- infected 
hepatocytes have a much higher rate of apoptosis and Procaspase-3 (the precursor 
of active caspase-3 which is necessary for apoptosis) was also detected in vitro. 
Apoptosis in vivo was also observed in pb36p- infected mice, and its clearance 
rate in livers of immunized mice is greatly increased to that observed under 
similar conditions in RAS immunized mice. Moreover, pb36p- immunization lead 
to an increase in CD8+ T memory cells in the liver which eventually decreases 
with time. 
In addition, we characterized pbcrmp3- and pbcrmp4- parasites, which are unable 
to express Plasmodium proteins containing motifs implicated in invasion or 
adhesion (Plasmodium berghei cysteine repeat modular protein). These parasites 
are unable to breach oocysts membrane and, therefore, to migrate to the salivary 
glands, abrogating transmission to host via mosquito bite. We observed that 
oocysts derived from pbcrmp3- and pbcrmp4- parasites have the normal shape 
seen for WT parasites. pbcrmp3- and pbcrmp4- sporozoites from oocysts are able 
to glide and migrate through several cells as WT sporozoites do. They also have 
the same infection level as WT 24 hours post infection. However, pbcrmp3- and 
pbcrmp4- EEFs are small and present aberrant shapes, compared to WT EEFs. 
Development in culture up to 56 hours does not promote any further increase in 
the size of these attenuated EEFs.  
The characterization of pbcrmp3- and pbcrmp4- parasites’ intrahepatic 
development led us to think these two attenuated parasites could be possible 
candidates for a genetically attenuated sporozoite vaccine. Like RAS and pb36p-, 
they arrest during liver development, never forming mature EEFs like WT 
sporozoites. Regrettably, this similarity is not reflected in their immunization 
potential. No protection is achieved with pbcrmp3- and pbcrmp4- parasites in 
either BALB/c or C57BL6 mice. The lack of protective effect demonstrated by 
pbcrmp3- and pbcrmp4- sporozoites could derive from their immature stage, 
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resulting in inefficient infection in vivo, an essential step attenuated sporozoites 
must perform to confer immunity, or from the ability of efficiently inhibit host 
cell apoptosis as WT, therefore not eliciting an immune response against the 
parasite as RAS and pb36p- do. However, this remains to be further investigated. 
Although these attenuated parasites lack potential as immunization agents, their 
phenotype in liver stage development is quite interesting and will hopefully 
provide undoubtedly new insights into parasite-host interactions. 
Our results clearly confirm the potential of pb36p- as an experimental vaccine 
against malaria, whilst pbcrmp3- and pbcrmp4- failed to achieve the same goal. 
Furthermore, pb36p- is able to confer long-lasting immunity and cross-species 
protection against P. yoelii. This protection can be achieved even with low 
immunization doses and using the most common routes of immunization. 
Understanding the mechanisms by which pb36p- parasites induce immunity will 
help us to design a vaccine against the malaria liver stage. We have already made 
an attempt to initiate studies regarding this issue, and observed that pb36p- 
mediated immunity is dependent on IFN-γ and γδ T cells. Moreover, apoptosis 
seems to play a key role in the protection induced by these attenuated parasites. 
These are just the first steps on this subject, and further studies are already 
underway to unravel the mechanisms of this and other GAS mediated protection, 
which will no doubt provide ground-breaking relevant data for the development of 
a vaccine targeting the pre-erythrocytic stage of Malaria.  
 
 
Keywords: Malaria, sporozoite, genetically attenuated sporozoites, vaccine, 
apoptosis, immune mechanisms 
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APC – Antigen Presenting Cells 
CD – Cluster of Differentiation 
CelTOS – Cell traversal Protein for Ookinete and sporozoite 
CSP – Circumsporozoite Protein 
DAPI – Diamidino-phenyl-indole 
DC – Dendritic CellS 
DMEM – Dulbecco's Modified Eagle Medium
EEF – Exoerythrocytic Form 
FACS – Flow Activated Cell Sorting 
FCS – Fetal Calf Serum 
GAS – Genetically Attenuated Sporozoites 
HGF – Hepatocyte Growth Factor 
HLA – Human Leucocyte Antigens 
HPRT – Hypoxanthine Guanine Phosphoribosyltransferase 
HSPG – Heparan Sulfate Proteoglycan 
i.d. – intradermal  
IFN-γ – interferon γ 
Ig – Immunoglobulin  
IL – interleukin 
i.m. – intramuscular  
i.p. – intraperitoneal 
ISIF – Infection Susceptibility-Inducing Factor 
i.v. – intravenous  
MHC – Major Histocompatibility Complex 
NK – Natural Killer cells 
PCR – Polymerase Chain Reaction 
PS – Penicilin-Stretpomycin 
PV – Parasitophorous Vacuole 
RAS – Radiation Attenuated Sporozoites 
RPMI – Roswell Park Memorial Institute (medium) 
RT – Room Temperature 
RT-PCR – Reverse Transcriptase Polymerase Chain Reaction 
RTS,S – Repeat T cell epitopes Surface antigens plus S antigen from hepatitis B 
virus 
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s.c. – subcutaneous  
SCS – solution of Sodium Cacodylate 0.1 M plus Sucrose 3.7% pH 7.4 (buffer) 
SDS – Sodium Dodecyl Sulfate 
SPECT – Sporozoite (micronemes) Protein Essential for Cell Traversal 
spp. – species  
TBS – Tris Buffered Saline (buffer) 
TRAP – Thrombospondin-Related Adhesive Protein 
WT – Wild Type 
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1. Introduction 
 
1.1. General Overview on Malaria 
 
Malaria exists for millennia. The name of this plague comes from the Italian word 
for “bad air”. Nowadays, is still a major global health problem, which affects 
around 500 millions people worldwide. It is responsible for the high level of 
mortality and morbidity in emerging countries, killing more individuals than any 
other cause, including civil wars (Sherman, 1998). In addition, it is a huge 
obstacle to the economical development of those regions (Fig. 1.1).   
 
 
 
Figure 1.1. Endemic areas of Malaria worldwide according World Health Organization, in 
January of 2004 (adapted from http://www.who.int/) 
 
Malaria alone is considered the “public health enemy number one” in Africa, 
where 90% of all global cases of this disease occur, leading to the loss of 2 billion 
of euros annually. Every 30 seconds, an African child dies from malaria 
(http://www.who.int/). Several attempts of eradicating the disease were made, 
such as the use of drugs and insecticides. However, these strategies were not 
successful due to advent of the Plasmodium parasites resistance to drugs widely 
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used to prevent and fight malarial infection, as chloroquine, and of the Anopheles 
mosquitoes to insecticides such as dichlorodiphenyltrichloroethane (DDT) and 
others. In fact, in the most recent years, malaria has re-emerged in many parts of 
the world where it was assumed to be eradicated (http://www.who.int/). The 
global failure to effectively reduce malaria supports the need of finding a cost-
effective vaccine against this disease. 
The genus Plasmodium, the causative agent of malaria, is a member of the 
Apicomplexa phylum of protozoa that contains more than 5000 named species 
(spp.), mostly obligatory intracellular parasites, and all with a complex of 
organelles at the apical end of the invasive stages. The phylum includes other 
human pathogens like Toxoplasma and Cryptosporidium, which cause 
opportunistic infections, or Babesia and Theileria, that cause huge animal stock 
losses (Sherman, 1998). 
Different Plasmodium spp. can infect different vertebrates, including human, 
other primates, rodents, birds, and even reptiles. Four distinct Plasmodium spp. 
are known to be pathogenic to man, Plasmodium falciparum, P. malariae, P. 
vivax and P. ovale. A significant amount of research has been made in 
Plasmodium spp. that infect rodents, due to the many limitations of working with 
humans samples and/or subjects, such as lack of clinical history of infections in 
patients, legal authorization procedures, amongst others. These are P. berghei, P. 
yoelii and P. chabaudi (Sherman, 1998).  
 
1.2. Plasmodium Life Cycle
 
The Plasmodium life cycle is quite complex and comprises two hosts: (i) the 
definitive host, which is the female Anopheles mosquito, and (ii), a vertebrate 
host.  
In the mosquito, the sporogonic stage is initiated in the Anopheles mosquito after 
a blood meal from a vertebrate infected host that contains gametocytes in the 
blood. The gametocytes will develop into male and female gametes inside the gut 
of the mosquito, a process that is triggered by the shift of temperatures between 
vertebrate host (37ºC, in the case of mammal hosts), and invertebrate hosts 
(around 20ºC, for the mosquitoes). Fusion of the gametes occurs, forming an 
ookinete. This new form traverses the gut wall of the mosquito (part of digestive 
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tract that resembles to stomach), developing into an oocyst which can reach 30 to 
40 µm diameter (Sherman, 1998; Vanderberg, 1967). Inside this new form, 
sporozoites (around 10 µm length per 1 µm width) will be formed, being released 
after 3-4 days of maturation (which corresponds to 10-14 days after the blood 
meal). The sporozoites aim towards mosquitoes salivary glands, from where they 
will be injected into a new vertebrate host (along with anticoagulants and 
vasodilators), when the anopheline mosquito collects its next blood meal 
(Sherman, 1998).  
Sporozoite migration from gut to salivary glands occurs through the haemolymph 
(circulatory fluid of molluscs and insects that have an ‘open’ circulatory system) 
and is mediated by a major surface protein of the parasite, the circumsporozoite 
protein (CSP). CSP can be found all over Plasmodium sporozoite surface, being 
highly conserved between the different species and presenting homology with 
other apicomplexan parasite proteins (Myung, 2004). Antibodies against CSP can 
block sporozoite infection of mosquito salivary glands (Sidjanski, 1997). Besides, 
this, CSP seems also to be essential for sporozoite formation inside oocysts. 
Parasites with a targeted disruption for this gene produce a normal number of 
oocysts like wild-type (WT), but sporozoite formation is blocked (Ménard, 1997).  
In the mammalian host, the schizogonic stage takes place after the injection of 
sporozoites. Here, the parasites proliferate in two different sites, first on liver cells 
(exoerythrocytic site) and later, in a series of cycles, on red blood cells 
(erythrocytic site) (Sherman, 1998).  Once inside the host, the sporozoites make 
their journey to the liver through blood vessels. Each mosquito bite injects around 
15 to 200 sporozoites under the skin of the host, which will remain in that area 
approximately 2 minutes (on mice) or 15 up to 30 minutes (on humans). Once in 
the liver, Plasmodium schizont development only occurs inside hepatocytes. The 
schizont will develop progressively until it gives rise to tens of thousands 
merozoites (Sherman, 1998). During the schizont development in the liver, no 
symptoms of the disease are observed in infected individuals. After complete 
maturation in the hepatocytes (around 2 days on mice and 5.5-7 days in humans), 
merozoites leave these cells and enter the bloodstream. The Exoerythrocytic Stage 
is now complete, and the parasite development will proceed from now on in the 
Erythrocytic Stage. Here, unlike exoerythrocytic stage, the malaria symptoms 
arise, which comprise fever, anaemia, nausea and headaches (reviewed in 
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Stevenson, 2004). Once in the blood stream, merozoites will invade erythrocytes. 
This is a cyclic process, progressively amplified by repeated cycles of invasion, 
intracellular growth, multiplication and re-invasion, which varies from 24 to 72 
hours, depending on the Plasmodium spp, being 24 hours in P. falciparum. Each 
mature parasite develops into 8 up to 32 new merozoites (depending on the 
Plasmodium spp., being around 20 in P. falciparum and P. vivax) (Bannister, 
2003; Sherman, 1998). Some merozoites will not develop into more merozoites, 
instead they form gametocytes (male, or microgametocyte, and female, or 
macrogametocyte). When a mosquito collects blood for feeding, and ingests 
gametocytes, the cycle continues, as mentioned before. The entire life cycle can 
be observed in figure 1.2. 
 
 
Figure 1.2. Plasmodium Life Cycle. An infected Anopheles mosquito feeds on a host, injecting 
Plasmodium sporozoites into the blood stream. Sporozoites will reach the liver within minutes, 
infecting a hepatocyte for further development. There, they multiply into the new infective form, 
merozoites, which will leave the liver and aim to the blood. Once there, they will infect cyclically 
erythrocytes, developing into more merozoites. However, some of them will develop not in more 
merozoites, but in gametocytes (male and female). When an Anopheles mosquito take a blood feed 
on this host, it will collect these gametocytes, which will fecundate and develop into an ookinete, 
and later in an oocyst. Oocysts will attach to midgut for maturation, giving rise to sporozoites, 
which will burst the oocyst and migrate to the mosquito salivary glands, ready to infect a new host 
upon the next mosquito blood feed. 
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1.3. Malaria Liver Stage
 
The liver infection is the first obligatory step for an efficient malaria infection. 
Shortly after injection into mammalian host, sporozoites are rapidly found in the 
liver, a crucial step for their further development into merozoites. This step is 
clinically silent, since no symptoms of illness are observed. Thus, it is an 
attractive target for a vaccine against malaria, since it represents the first step in 
infection, presents no symptoms and the development of sporozoites into 
merozoites has a time span which would allow an immune response to stop the 
infection at an early stage. However, the hepatic stages of infection are poorly 
known and understood, and almost none Plasmodium molecules are known to 
have an impact on the parasite development inside hepatocytes (Sherman, 1998).  
 
1.3.1. Sporozoite Gliding Motility 
 
Sporozoites, as the majority of the invasive stages of all apicomplexan parasites, 
present a form of locomotion, which is not based on cilia or flagella (which they 
do not possess). Instead, they move in a substrate-dependent manner, named 
gliding motility. This feature seems to be related with secretion of certain proteins 
(namely CSP and Thrombospondin-Related Adhesive Protein – TRAP) by the 
apical complex of Plasmodium parasites, translocated to its surface by an actin-
myosin dependent process, spreading this way to its posterior end, reaching by 
this mean the substrate.  As the substrate, in parasite membrane, is immovable, the 
posterior translocation of the receptor-ligand complexes results in the forward 
movement of the parasite. This process is easily observed in vitro, using 
antibodies against CSP (Fig. 1.3). CSP and TRAP are expressed by all 
Plasmodium spp. members, and it was observed not only actin-depolymerizing 
agents, such as cytochalasin-D or anti-CSP monoclonal antibodies as well as 
Plasmodium lines containing null mutations for TRAP, are unable to move and, 
consequently, of invading liver cells or mosquitoes salivary glands (Mota, 2002; 
Mota and Hafalla, 2002; Sultan, 1999). Thus, it has been shown unequivocally 
that gliding motility is required for invasion of both the mosquito and the 
hepatocytes. 
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Figure 1.3. Gliding sporozoite, leaving a trail of CSP behind (Adapted from Mota, 2002) 
 
1.3.2. Next stop: the Liver 
 
Once inside the host, sporozoites enter in circulatory system. Only those which 
enter the blood capillaries will reach the liver. The remaining will be drained by 
lymphatic vessels and degraded by leukocytes (Amino, 2006). Specific 
recognition of hepatocytes by sporozoites is very efficient and TRAP and CSP 
also play a pivot role in this process. Both are essential for parasite migration to 
mosquito salivary glands, and also for invasion of liver cells (Akhouri, 2004; 
Kappe, 2003; Rathore, 2003).  These proteins are crucial during this period of the 
parasite life cycle, a vital step for further parasite development and the 
establishment of infection therefore they represent ideal targets for vaccines 
against malaria (Bodescot, 2004; Bruña-Romero, 2001).  
In order to leave the blood vessels and reach the liver, the sporozoites have to 
traverse either endothelial cells (cells which form those vessels wall) or Kupffer 
cells, and the space of Disse, which separates the endothelial layer from liver cells 
(Fig. 1.4).  
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Figure 1.4. Schematic representation of sporozoites migrating in a liver blood vessel.  
Sporozoites (in green), in order to leave the blood vessel (BV) and reach the hepatocytes (H), need 
to traverse either endothelial  cells (EC) or Kupffer cells (K) and the space of Disse (SD). 
 
It has been demonstrated that CSP binds to the glycosaminoglycan chains of 
heparan sulfate proteoglycans (HSPGs), present in the basolateral pole of 
hepatocytes. Liver endothelial cells possess fenestrations, but not wide enough to 
allow sporozoite passage. It has been proposed that HSPGs would be extended 
through these fenestrations, allowing the sequestration of sporozoites. Although 
this process is necessary for the attachment to the hepatocytes, it is not required 
for cell invasion (Kappe, 2003; Mota, 2002). CSP and TRAP recognize distinct 
cell type-specific surface proteoglycans, not only on hepatocytes, but also on 
Kupffer cells, the resident macrophages in the liver, and stellate cells. Moreover, 
because stellate cells synthesize 8× more sulfated proteoglycans than hepatocytes 
and incorporate twice the amount of sulfate into HSPGs, stellate cell 
proteoglycans protruding through the endothelial fenestrations have been 
suggested to mediate the initial arrest of Plasmodium sporozoites in the liver 
sinusoid (Pradel, 2004; Pradel, 2002). It has been proposed that sporozoites 
migrate to the space of Disse through Kupffer cells. Sporozoites have been found 
preferentially inside Kupffer cells shortly after sporozoites infection, but mostly 
surrounded by a vacuole. However, it is likely that sporozoites may use more than 
one cellular pathway to cross the sinusoidal cell layer, as a proportion of cell 
traversal deficient parasites can still infect the liver and propagate in mice (Ishino, 
2004; Mota, 2002). 
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1.3.3. Migration 
 
Plasmodium sporozoites migrate through several cells before infecting a final host 
cell. During this migration, sporozoites enter and leave the cells by disrupting cell 
membrane. Usually, cells can repair this damage and survive, but, in some cases, 
death occurs (Fig. 1.5). This process does not lead to the formation of a 
Parasitophorous Vacuole (PV) inside the cell, which is only observed when the 
parasite reaches a final hepatocyte for infection. 
 
 
 
 
Figure 1.5. Plasmodium sporozoites migration in HepG2 cells. Plasmodium sporozoites enter 
and exit a host cell within a minute, as seen above in these time-lapse video images of a P. berghei 
sporozoite entering and exiting a HepG2 hepatocyte (adapted from Mota, 2001) 
 
Migration was confirmed in experiments in vitro (using human and mouse 
hepatoma cell lines) and in vivo (using a mouse model for malarial infection) (Fig. 
1.6), and only viable and motile sporozoites were able of migrate through cells. In 
fact, heat-inactivated, as well as sporozoites treated with anti-CSP monoclonal 
antibody or cytochalasin-D were unable to migrate through cells (Mota, 2002; 
Mota and Hafalla, 2002; Mota, 2001; Mota and Rodriguez, 2001).  
It has been proposed that sporozoites migration through cells might provide a 
biological advantage in establishing a successful infection. It might supply an 
unimpeded view of the local host cytoplasmic environment, allowing the 
sporozoites to confirm whether or not they reached the liver, and triggers 
pathways required for invasion and infection. Migration is commonly observed in 
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other apicomplexan parasites at similar stages of the life cycle. Toxoplasma and 
Eimeria bovis (a cattle pathogen) sporozoites are also able to migrate through host 
endothelial cells, disrupting the cell membrane and without the formation of a 
parasitophorous vacuole (Mota, 2002; Mota and Hafalla, 2002; Mota, 2001; Mota 
and Rodriguez, 2001).  
Breaching of the cell membranes by the Plasmodium sporozoite is likely to 
involve specific lipases, proteases or pore-forming proteins. Four distinct P. 
berghei proteins have been shown to play important roles during cell traversal. 
They are sporozoite microneme protein essential for cell traversal (SPECT), 
SPECT2, cell traversal protein for ookinete and sporozoite (CelTOS) and a 
phospholipase (PbPL) (Kariu, 2006; Bhanot, 2005; Ishino, 2005A; Ishino, 2004). 
At least two of these, SPECT2 and PbPL, seem to be involved in pore formation 
activity while CelTOS has been proposed to be required for movement through 
host cell cytosol. 
 
 
 
 
Figure 1.6. Migration of Plasmodium sporozoites in hepatoma cell lines can be quantified 
using a cell-impermeant fluorescent tracer. Cells incubated with P. yoelii sporozoites (A and B, 
Hepa 1-6 cell line, C, Balb/c 6 weeks old mice). Dextran-FITC, a marker for wounded cells, was 
used, so, cells traversed by sporozoites appear with a bright green colour (adapted from Mota, 
2001) 
 
 
1.3.4. Invasion and Development inside Hepatocytes
 
After migration through several cells, the sporozoite enters the host cell, with the 
formation of a PV. Once inside, the sporozoite starts a new stage of infection, 
commonly named Exoerythrocytic Form (EEF). Little is known about the process 
of invasion and formation of EEFs in Plasmodium. Usually, host cell invasion by 
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Toxoplasma tachyzoites is used as a model for Plasmodium. Gliding is crucial at 
this point. Molecules excreted at the apical end of the parasite bind to a fixed 
substrate on cell surface, being transported for the posterior, leading to forward 
locomotion. During this process, when the parasite finds and binds to host cell 
receptors, invasion takes place. The anterior end forms a tight junction with the 
host cell surface. Penetration occurs, and a vacuole is formed around the parasite, 
being sealed once invasion process is complete (Silvie, 2004; Mota, 2002).  
Another host molecule that seems to interact directly or indirectly with 
sporozoites is tetraspanin CD81, a membrane protein that is expressed on the 
surface of hepatocytes and a putative receptor for hepatitis C virus (Silvie, 2003). 
CD81 seems to play an essential role in the invasion of mouse hepatocytes by P. 
yoelii and human hepatocytes by P. falciparum but is not required for cell traverse 
by sporozoites. CD81 mechanism is exclusive in hepatic stage of malarial 
infection but, most interesting, were not reproducible in another rodent parasite, 
P. berghei, a model widely used in malaria research. P. berghei sporozoites seem 
to invade hepatocytes by using a CD81-independent pathway. Interestingly, in the 
presence of CD81, P. berghei sporozoites can use this molecule to invade 
hepatocytes. However, they are still able to invade cells if CD81 is absent 
suggesting, again, that P. berghei sporozoites can use alternative invasion 
pathways. The same authors have also shown that host cell membrane cholesterol 
contributes to CD81-dependent infection by P. yoelii and P. falciparum 
sporozoites but not to CD81-independent infection by P. berghei sporozoites 
(Silvie, 2006).  
Another strategy used by Plasmodium parasites explains the need for a migration 
process prior to the final invasion. In order to be ready to infection, hepatocytes 
must contact with an Infection Susceptibility-Inducing Factor (ISIF). This was 
first observed when cells in culture presented a higher level of infection if treated 
with medium where previously other cells have been subjected to infection 
instead of fresh medium. Later, this ISIF was identified as been hepatocyte growth 
factor (HGF). HGF is released from hepatocytes after wounding, and traversed 
cells present a higher level of production of this factor. Cells incubated with 
antibodies against HGF show a decrease in sporozoite infection of around 90% 
than the matched untreated control. MET is the tyrosine kinase receptor for HGF, 
and is activated when HGF is released from neighbour cells. Activation of MET 
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by HGF enhances sporozoite infectivity in hepatocytes. Downmodulation of MET 
(e.g., using RNA interference) leads to a reduction in infection. It was seen that 
HGF/MET signalling might be required for early parasite establishment and 
development inside the host cell. The HGF/MET requirement in infection was 
also shown in vivo (Carrolo, 2003). Recently, it has been shown that Plasmodium 
parasites exploit HGF to activate anti-apoptotic signalling pathways in the host 
cell through HGF/MET signalling (Leirião, 2005). HGF/MET signalling is able to 
protect cells from apoptosis by using mainly PI3-kinase/Akt pathway, 
contributing to a successful infection by Plasmodium sporozoites. Interestingly, in 
the context of infection, apoptosis is being redefined based on a number of studies 
demonstrating that apoptotic death of host cells after pathogen infection can 
trigger powerful innate and adaptive immune responses. In fact, apoptosis-
induced inflammation is actively being investigated as a way of enhancing 
vaccine function improving accessibility of the effector cells of the immune 
system to the site of infection (reviewed in Restifo, 2000). The mechanisms and 
(parasite) molecules involved in preventing host cell apoptosis by intracellular 
parasites including apicomplexans are being investigated (Blaho, 2004; Luder, 
2001). 
Once inside the final hepatocyte, the sporozoite starts its EEF formation 
procedure. Its nucleus increases progressively, giving rise to a spherical form. 
Inside an EEF, a single sporozoite develops into a schizont, which contains tens of 
thousands uninucleate merozoites (Hoffman, 2000) (Fig. 1.7). 
 
 
 
Figure 1.7. P. berghei developing inside a hepatocyte. P. berghei EEF (green) developing inside 
a HepG2 cell. Inside the EEF, merozoites in formation can be observed (blue). The nucleus of 
host/neighbour cell (great blue circles) and cells cytoskeleton (red staining for actin) also can be 
observed (adapted from Mota, 2002) 
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The process of formation of the Plasmodium parasites intracellular vacuole is 
widely studied in the erythrocytic stage, but very little is known how it occurs in 
hepatocytes. The two types of host cells are completely different, as are their 
surrounding environment (Sherman, 1998). So, very few assumptions that what 
occurs in one cell type can be made for the other. Only recently have host 
molecules that influence parasite development inside the hepatocytes started to be 
identified. Signalling pathways are abundant within cells and represent potential 
targets upon which a pathogen can interact with its host as well as likely key 
elements of the host’s response to infection. Intracellular signalling mechanisms 
rely heavily on phosphorylation, a process that is enzymatically catalyzed by 
kinases. A genome wide RNA interference screen of all the human kinases and 
kinase associated proteins is currently being performed in our lab to identify 
signalling pathways that are involved in the interactions that occur between the 
parasite and its host. Our preliminary results indicate that infection is significantly 
modulated by kinases involved in cytoskeleton regulation, suggesting a crucial 
role for cytoskeletal dynamics in infection. An unbiased microarray approach to 
identify genes that are differentially expressed at various time points following 
Plasmodium infection of a mouse hepatoma cell line is also being undertaken by 
us. Interestingly, it was observed that the number of differentially expressed host 
genes decreases as infection proceeds. A host molecule that seems to play an 
important role is alipoprotein A1 (ApoA1), which localizes 24 hours post 
infection at the parasitophorous vacuole, and seems to interact with the parasite 
molecule UIS4 (A. K. Mueller, 2005 Molecular Parasitology Meeting). The 
implications of such behaviour remain to be elucidated.  
 
1.3.5. Leaving the Hepatocyte
 
A final important step in the intracellular life of pathogens is their ability to exit 
the host cell after replication, to continue their life cycle. Nevertheless, the 
mechanisms which mediated such processes are still poorly understood. The 
release of Plasmodium merozoites from hepatocytes is usually referred to as 
occurring after hepatocyte rupture. Still, this has never been directly observed and 
the signal(s) that trigger their exit remain unknown. Very recently, it has been 
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reported that Plasmodium merozoites are released not by rupture of the hepatocyte 
but by the formation of merozoite-filled vesicles (merosomes), which bud off the 
infected hepatocyte into the lumen of liver sinusoids (Fig. 1.8). Initially, 
merozoites are released from the parasitophorous vacuole membrane and mix 
freely with the host cell cytoplasm (Meis, 1985). The plasma membranes of 
merosomes are of host cell origin and are thus not recognised by Kupffer cells, 
which guide the parasites safely, back to the blood stream. The molecular basis of 
the process is not fully understood but it has been shown that proteases mediate 
liberation of merozoites from the PV and the formation of merosomes (Sturm, 
2006). 
 
 
Figure 1.8. Schematic representation of a merosome leaving a hepatocyte.  Merozoites (Mz), 
in order to abandon hepatocytes (H) and reach blood vessel (BV), traverse the layer of endothelial 
cells (EC) and the space of Disse (SD) in a merozoites-filled vesicle, or merosome (M), thus 
avoiding elimination by Kupffer cells (K). 
 
 
1.4. Vaccine against Malaria
 
1.4.1. Aims and History
 
Vaccination, in principle, is an attempt to mimic certain aspects of an infection for 
the purpose of causing an immune response that will protect the individual from 
that infection. Vaccine research has three goals: induction of strain-transcending 
and durable immune responses, identification of protective antigens for stage 
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specific immunity and successful combination of candidate immunogens 
(Artavanis-Tsakonas, 2003; Kilama, 2003). Promising candidate biomolecules, 
with proven potential by research institutions, can be selected by industry for 
manufacture, and posterior validation phases, till they reach clinical trials 
(Kilama, 2003). 
In 1967, mice immunized with X-radiation-attenuated rodent malarial sporozoites 
have shown protection against challenge with live and infectious sporozoites 
(Nussenzweig, 1967). In 1973, this approach had the same result in humans 
(Clyde, 1973). Volunteers infected with irradiated P. falciparum sporozoites were 
protected against challenge within nine weeks of immunization. This protection 
lasted 23-42 weeks post immunization, in five of the six volunteers. However, this 
vaccination consists in the bite of several irradiated mosquitoes that is an 
unpractical mean when planning a mass vaccination. Many potential candidate 
vaccines against hepatic and also blood stage have been tested in clinical trials in 
the last decade, and other warrant preclinical assessment. But, so far, there is not a 
single effective vaccine available against malaria (reviewed in Hill, 2005). In the 
90s, vaccination with a synthetic peptide, Spf66, against malarial blood stage 
parasites, generated much speculation and excitement, but it revealed lack of 
efficacy in protection against this disease (Moorthy, 2004; Molano, 1992). 
The aim of most vaccines is to induce antibody and T-cell responses to one or a 
few antigens, but for effective vaccination, these will need to be of greater 
magnitude, duration (and not strain-specific) than in naturally acquired immunity. 
At the moment, it is unknown and not understood which responses are needed, 
except that is necessary to produce T-cell help for an antibody response. An 
alternative approach is to use a cocktail of several antigens, attempting to mimic 
natural immunity, but it is a complex and costly process (Moorthy, 2004). Other 
problems, which arose from combination with multiple antigens, are interference 
and competition. In the last decade a huge effort been allocated to design a 
subunit vaccine, which means, to use partial or complete antigens (previously 
identified by a proteomics approach from host-pathogen interactions), which 
could induce immunity to the whole pathogen in vaccination, e.g., the hepatitis B 
vaccine. Nevertheless, these type of vaccine are usually ineffective in induce long-
term immune responses, as effector T cells responses, like CD8+ cytotoxic T 
lymphocytes (Moorthy, 2004). Another subunit vaccine type is DNA based. DNA 
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sequences of Plasmodium parasites (namely P. falciparum) have been inserted 
into plasmid DNA molecules (DNA vaccine) or various recombinant attenuated 
DNA viruses (recombinant vaccines), to generate vaccine candidates. The 
delivered DNA molecules are uptaken by host cells, parasites then proteins are 
expressed, and T cell epitopes bound to Human Leukocyte Antigens (HLA, the 
human Major Histocompatibility Complexes) molecules prime naïve T cells to 
form memory T cell population. Recombinant subunit vaccines act similarly, but 
are more active in infecting cells and expressing parasite proteins, before infection 
process is aborted. DNA based vaccines can induce high levels of effector T cell 
immune responses, and permits the combination of multiple antigens, but poor 
antibody responses are observed (reviewed in Hill, 2005). The development of an 
effective vaccine also requires research into antigenic polymorphism, duration of 
efficacy, and means of antigen combination. For a vaccine be licensed for use, the 
entire process (from first observations to demonstrations of high level of efficacy) 
can take more then a decade (reviewed in Hill, 2005).           
  
1.4.2. Vaccine against Plasmodium Liver Stage 
 
The hepatic stage of the life cycle is an ideal target for vaccine-induced protective 
immune responses, because this stage lasts around 5.5-7 days and is not associated 
with symptoms. A vaccine that would efficiently target the infected hepatocytes 
would prevent both the clinical symptoms of the disease, since they arise only in 
the erythrocytic stage, and the transmission of malaria, since formation of 
gametocytes occurs during gametogenesis, also in the blood stage (Hoffman, 
2000). 
An ideal vaccine against parasites at this stage would induce high titres of 
functional antibody against sporozoites, to prevent their entry inside hepatocytes, 
and stimulate potent cytotoxic T lymphocyte immunogenicity against infected 
liver cells, while not harming remaining host tissues. Actually, the leading 
candidate vaccine is a recombinant protein vaccine, named RTS,S/A02, developed 
by GlaxoSmithKline, in which Hepatitis B surface antigen was fused to DNA 
encoding CSP, and mixed in an adjuvant AS02. Although has proven efficacy, it 
confers only 30% of protection against parasites of the same strain after infectious 
sporozoite challenge. In field trials held in Mozambique, none of the vaccinees 
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inoculated with RTS,S was protected 6 months post immunization, being a case of 
a successful vaccine which misses its target unfortunately (reviewed in Hill, 
2005). Although more than 10 vaccines designed to induce protective antibody- or 
cell-mediated immune responses against the infected hepatocyte have been 
evaluated in humans, only a small number of humans have been protected 
(reviewed in Hill, 2005). Other vaccines using viral vectors such as adenoviruses 
and modified vaccinia virus Ankara are being developed (Ophorst, 2006; Hill, 
2005), by other biotech companies, such as Crucell Holland BV 
(http://www.crucell.com/) and Oxxon Therapeutics (http://www.oxti.com/), 
respectively. 
So far, the golden standard for an exoerythrocytic malaria vaccine is protection 
conferred by immunization with radiation attenuated sporozoites (RAS). It has 
conferred protection to more than 90% of animal subjects and human volunteer 
hosts who were subjected to that immunization. Irradiated sporozoites enter 
hepatocytes, but only partially develop within these cells (Surhbier, 1990; Sigler, 
1984). As so, the host will never suffer from the symptoms caused by parasites in 
blood stage. There is no immunogenic response against blood stage malarial 
antigens, because they are not expressed in liver stage. Sexual differentiation, 
which also occurs in blood, will not take place as well and consequently, nor will 
transmission. Immunization of human volunteers with radiation-attenuated 
sporozoites demonstrated that this type of vaccine is feasible in developing 
protection against malaria, and provides foundation for further studies aiming to 
achieve a subunit pre-erythrocytic stage malaria vaccine. The actual data indicates 
that this type of vaccine is not strain-specific, meaning an immunization with 
irradiated P. falciparum sporozoites will induce responses not only against that 
strain, but that will also confer protection against other strains within the same 
spp. (Hoffman, 2002; Doolan, 2000; Hoffman, 2000). RAS mediated protection is 
dependent on CD8+ and CD4+ T cells, nitric oxide, cytokines (such as interleukin 
12 (IL-12) and γ interferon (IFN-γ)) and natural killer cells (NK cells), although 
this varies according with the background of the host (Doolan, 2000). 
Immunization strategies using P. falciparum RAS have been considered 
impossible due to technical, clinical and logistical hurdles: route of 
administration, large quantities of sporozoites needed and regulatory, potency and 
safety requirements (Luke, 2003). However, some are pursuing this approach and 
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already have overcome some of those obstacles (S. L. Hoffman, personal 
communication; http://www.sanaria.com/). 
 
1.5. Comparative Genomics in Plasmodium
 
1.5.1. General Features
 
In October 2002, fruit of seven years of labour resulted in the publication of an 
almost complete annotated genome sequence of P. falciparum (PlasmoDB, 
http://www.plasmodb.org/; Gardner, 2002). Other simultaneous initiatives have 
allowed comparative genomics of this human parasite with P. vivax and the rodent 
parasites P. yoelii, P. berghei and P. chabaudi (Thompson, 2001). Comparative 
analysis of these genomes can provide substantially more information on parasites 
physiology and biology, and expand the ability to assign putative functions to 
predicted coding sequences. More than 60% of expressed genes have no known 
function. Comparative genomics has given the opportunity to deduce the function 
of many of the predicted proteins through the identification of orthologous genes 
(genes with high rate of homology, in different species or strains) and motifs in 
other organisms, and to analyse genome organization and the phylogenetic 
profiles of protein families. It will be also possible to discover orthologues and 
paralogues (genes with high rate of homology, within the same specie or strain) of 
less well conserved genes, and enhance studies that seek to discover and evaluate 
the vaccine and drug target potential of Plasmodium proteins (Hall, 2005; Waters, 
2003; Thompson, 2001). 
        
1.5.2. Applications
 
1.5.2.1. Orthology
 
Model malaria parasite orthologues of P. falciparum have an important use as 
vaccine and drug targets research and development. Some of those orthologues 
were previously identified by biochemical, molecular biology and immunological 
assays. Accessing to PlasmoDB resources, the identification of orthologues 
between P. falciparum and other Plasmodium, as well as paralogues, may be 
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performed in silico, using BLAST analysis. Once those genes have been 
identified, the biology and the function of the encoded proteins can be 
investigated in the most appropriate Plasmodium species, using mice as animal 
models, to test their potential as vaccines or drug targets. Another rich source of 
information will be parasite mutants that fail to undergo specific developmental 
phases, such as intrahepatic growth, enabling specific transcription programs to be 
elucidated (Waters, 2003; Thompson, 2001).  
 
1.5.2.2. Genetic Tools
 
In the 90s, several genetic tools for the study of malaria parasite biology were 
developed (van Dijk, 1995). Transfection systems for this haploid unicellular 
organism are now available, for human and animal Plasmodium spp. Transient 
transfection has been used to provide insight into the regulation of gene 
expression, while stable transfection has given the opportunity of expressing 
transgenes, as well as elucidating the function of proteins by disrupting, 
modifying or replacing the genes encoding them. These genetic tools, added to the 
information now available of the P. falciparum genome, represent an important 
breakthrough for malaria research, contributing significantly to the understanding 
of the hugely complex biology of this parasite. Their potential is vast, since more 
rational approaches to vaccine and drug design can be achieved, by altering the 
parasite genome (Koning-Ward, 2000). 
Stable transfections in P. falciparum, P. berghei, P. yoelii and the nonhuman 
primate parasites P. knowlesi and P. cynomolgi have proven feasibility, by drug 
selection (Mota and Thathy, 2001; Koning-Ward, 2000). Unlike transient 
transfections, this system requires that transfected DNA contain a selectable 
marker gene encoding a protein that confers a selectable phenotype, such as drug 
resistance (pyrimethamine is the commonly used), on the recipient parasite. 
Mature schizonts containing fully developed merozoites (in P. berghei, P. yoelii 
and P. knowlesi) or intraerythrocytic blood stage parasites (in P. falciparum) are 
chosen as target cells for introduction of DNA, because these stages are not 
dependent on the erythrocyte for survival, minimizing the problem of host cell 
damage during the process. This technology has provided the opportunity to 
produce specific gene knockout parasites and to express foreign genes within the 
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parasite. Transient transfections, per turn, provided the opportunity to identify 
elements that control gene expression, and to temporarily express or overexpress 
genes thought to be lethal to Plasmodium. Although its efficiency is fifty times 
higher than in stable transfections, this method is often of little value to 
researchers performing transfections experiments with Plasmodium spp., namely 
P. falciparum (Skinner-Adams, 2003; Koning-Ward, 2000).        
 
1.5.2.3. Genetic Modification elucidates the role of targeted genes in 
Plasmodium infection
 
Thanks to genetic modifications, a powerful tool was finally accomplished: GFP-
expressing constitutively throughout all life cycle P. berghei parasites were 
achieved (Franke-Fayard, 2004). These GFP-expressing lines will, for example, 
provide a means to purify by flow sorting cultured, infected hepatocytes or 
erythrocytes containing parasites allowing a detailed analysis of the transcriptome 
and proteome of both parasite and host cells and as a consequence shed more light 
on the parasite strategies used to influence host cell pathways. Luciferase 
expressing P. berghei parasites are also available and can be used when GFP 
technology fails to provide the insights about host-Plasmodium interactions 
(Franke-Fayard, 2005; Koning-Ward, 1999). 
Depletion of genes using these tools also led to important findings about 
Plasmodium biology. An example is P48/45 gene, member of a gene superfamily 
with 10 elements containing six-cysteine (6-cys) structural domain, unique to 
Plasmodium. This family appears to be well distributed among Plasmodium spp. 
Most of the members are conserved in the genome of P. vivax, P. yoelii, P. 
chabaudi and P. berghei. To date, all the members of 6-cys domain superfamily 
are conserved. Disruption of p48/45 gene in P. berghei parasites led to the 
formation of infertile male gametocytes, making it an excellent candidate for 
transmission blocking vaccines (van Dijk, 2001). Other members of this family, 
namely P47, the paralogue of P48/45 and P230 are also being studied as 
transmission blocking vaccines (Thompson, 2001).  
Our previous work with another member of this family, P36p led to a completely 
different and unexpected phenotype. Unlike seen for p48/45 gene, disruption of 
p36p in P. berghei does not impair the parasite development inside the mosquito. 
 21
INTRODUCTION                                                                                                            _ 
However, when injected in mice, these attenuated parasites do not give rise to a 
patent blood stage infection. We observed that p36p- sporozoites perform all 
features necessary for a successful hepatocyte infection (gliding motility, 
activation of apical complex and invasion), at the same level WT sporozoites do. 
Nevertheless, their intrahepatic development is strongly arrested, never leading to 
formation of merozoites and, consequently, to a blood stage infection (van Dijk, 
2005). This phenotype is similar to the one observed for RAS (Suhrbier, 1990; 
Sigler, 1984) and to other P. berghei genetically-attenuated sporozoites (GAS) 
lacking either uis3 (upregulated in sporozoites gene 3) or uis4 genes (Mueller, 
2005; Mueller and Camargo, 2005). As mentioned before, RAS can be used as an 
immunization strategy against malaria (Nussenzweig, 1967). Interestingly, uis3- 
and uis4-, with a similar aborted intrahepatic development also confer protection 
to mice against later challenge with WT P. berghei sporozoites (Mueller, 2005; 
Mueller and Camargo, 2005). The reasons which lead to this phenotype are still 
unclear. So far, we only know that ApoA1 co-localizes with UIS4 protein at the 
PV membrane inside the hepatocyte, most probably due to the cholesterol need 
for parasite development (A. K. Mueller, 2005 Molecular Parasitology Meeting). 
pb36p- sporozoites are able to reduce parasite liver burden in mice upon challenge 
with infectious WT sporozoites (van Dijk, 2005). P36p protein localizes in 
sporozoites micronemes, and is excreted during gliding (Ishino, 2005B). The 
function of P36p is still unknown and is currently being investigated. 
Interestingly, another study regarding pb36p- sporozoites demonstrate that they 
have a much smaller infectivity in HepG2 cells, leading to a continuous traversal 
of cells. Consequently, these attenuated parasites possess a 6× higher rate of 
migration through hepatocytes than WT sporozoites (Ishino, 2005B). The 
discrepancy between this study and our results is presently unknown.  
The examples just described show that the use of these genetic tools in 
Plasmodium can lead to groundbreaking discoveries about aspects still 
unidentified of this parasite biology and interaction with its host molecules, and 
provide insight about novel vaccine and drug targets candidates to fight this 
plague. 
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1.6. Aims and Strategies
 
Our previous results have shown that P. berghei GAS lacking a gene denominated 
pb36p were not fully capable of developing inside hepatocytes and demonstrate 
potential to be used as a novel vaccine strategy. In this project, we decided to 
focus on pb36p- parasites immunization potential, characterizing several features 
of this GAS based vaccine, using the mouse strains BALB/c and C57BL6. More 
precisely, we proposed (i) to determine the number of doses required to confer 
sterile protection, (ii) to determine the minimum dose of attenuated parasites 
required to elicit a full protective immune response, (iii) to elucidate the 
administration routes by which these parasites (as well as RAS) are still able to 
confer protection, (iv) to access the potential of pb36p- and RAS on conferring 
protection to a distinct rodent Plasmodium species, P. yoelii, (v) to elucidate the 
mechanisms by which pb36p- confers immunity and (vi) to determine whether 
two other GAS, pbcrmp3- and pbcrmp4- were also able to protect against 
subsequent challenge.   
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Chapter II 
 
pb36p- as an experimental GAS based vaccine 
against Malaria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  pb36p- AS AN EXPERIMENTAL GAS BASED VACCINE AGAINST MALARIA 
2.1. Introduction 
 
The current rationale for the characterization of Plasmodium molecules involved 
in liver infection lies in the development of a (subunit) vaccine that protects 
against liver and subsequent blood stage infection (Tsuji, 2001). However, 
vaccination studies with subunit vaccines that contain only (parts of) single 
proteins of sporozoites have failed so far to provide any significant, long-lasting 
protective immunity (reviewed in Hill, 2005). Contrastingly, immunization 
studies using complete radiation-attenuated sporozoites (RAS) showed full 
protection against subsequent challenge with infectious sporozoites in both animal 
models of malaria (Gwadz, 1979; Nussenzweig, 1967) and in human volunteers 
(Clyde, 1975). So far, only P. falciparum RAS immunizations have conferred 
long-lasting protection to human volunteers against challenge with infectious 
sporozoites (lasting up to 10.5 months) but failed to give protection against cross-
species challenges in humans, not protecting against a challenge with another 
human malaria parasite, P. vivax (Hoffman, 2002). The lack of significant 
progress with subunit vaccines stimulated recent attempts to produce a vaccine 
based on non-replicating, metabolically active RAS (Luke, 2003). Nonetheless, 
some major hurdles may impair the development a RAS-based Plasmodium 
sporozoites vaccine, namely production of adequate number of sporozoites for 
such a vaccine and viability of applying delivery routes commonly used as public 
health measures (Luke, 2003). Furthermore, RAS-based approach suffers from 
significant drawbacks, not least the question of safety and reproducibility because 
the amount of radiation that generates the attenuated state is strictly defined. 
Parasites that are underirradiated remain infectious, and those that are 
overirradiated do not induce protective immunity (Suhrbier, 1990). Recently, it 
has been shown that genetically attenuated sporozoites (GAS) that lack sporozoite 
specific conserved genes (uis3- and uis4-) that are apparently important for 
sporozoite development in the hepatocyte can induce significant or complete 
protective immunity in the P. berghei rodent model of malaria when different 
immunization protocols are used (Mueller, 2005; Mueller and Camargo, 2005). 
Generation and analysis of biological and immunogenic characteristics of multiple 
 27
pb36p- AS AN EXPERIMENTAL GAS BASED VACCINE AGAINST MALARIA_ 
GAS models are essential for further development of GAS as a potential malaria 
vaccine. 
In this study, we characterized the immunization potential of a recent GAS in P. 
berghei, which lacks the protein P36p, a sporozoite-specific microneme protein 
that is excreted to surface during gliding (Ishino, 2005B; van Dijk, 2005). P36p is 
a member of the 6-cys protein family, which comprises 10 members, some of 
them constituting potential vaccine candidates (van Dijk, 2001; Thompson, 2001). 
Development of pb36p- parasites aborts within the hepatocyte and immunization 
with pb36p- sporozoites reduces significantly or even abolish completely parasites 
liver burden after subsequent challenges with wild-type sporozoites, (van Dijk, 
2005).  
Here, we show that P. berghei p36p- sporozoites are able to induce full protection 
in rodent models against Malaria, as seen before for P. berghei RAS, uis3- and 
uis4- parasites, and can last up to 18 months. Furthermore, pb36p- sporozoites 
require low immunization doses to confer complete immunity, and confer 
protection when administered through feasible routes for human vaccination, such 
as intramuscular, subcutaneous and intradermal. But, more surprisingly, this 
protection is not restricted to challenges with P. berghei homologous parasites. 
Both RAS and pb36p- sporozoites also protect mice against challenge with a 
heterologous rodent species, P. yoelii, strongly inhibiting this species intrahepatic 
development, and some mice even achieve sterile protection. To our knowledge, 
our results show for the first time that whole parasite attenuated malaria 
sporozoite vaccine is capable of inducing cross-species protection.  
 
2.2. Results
 
2.2.1. Immunization with pb36p- sporozoites protects BALB/c and 
C57BL6     mice against subsequent infection 
 
We have shown that pb36p- development within hepatocytes is arrested, similarly 
to which occurs with RAS sporozoites (van Dijk, 2005). Because RAS has been 
successfully used in immunization studies for generation of protection against 
subsequent challenge with WT sporozoites, we investigated the immunization 
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potential of pb36p- sporozoites. Mice were i.v. immunized with pb36p- 
sporozoites by using different immunization protocols and subsequently 
challenged with WT parasites. Our previous results, using real-time PCR assays to 
quantify A-type ribosomal RNA transcripts produced by developing trophozoites 
in the liver (van Dijk, 2005), show that mice immunized with RAS and pb36p- 
sporozoites had a very strong and comparable reduction (>99%) in liver stage 
development of WT parasites compared to unimmunized mice. In several 
independent experiments groups of BALB/c and C57BL6 mice were immunized 
with a single dose of 50,000 pb36p- sporozoites or multiple times (one to three 
immunizations), with a prime of 50,000 and subsequent boosts of 20,000 pb36p- 
sporozoites, respectively, and challenged i.v. with 10,000 WT sporozoites on 
different days after immunization (Table 2.1). Protection was determined by 
monitoring mice daily for blood stage parasitemia in blood smears or using FACS 
analysis from day 3 to 3 weeks after challenge. A single immunization dose of 
pb36p- sporozoites fully protected BALB/c mice, whereas three subsequent 
immunizations with pb36p- sporozoites were required to completely protect 
C57BL6 mice, as shown by the absence of subsequent blood stage infection after 
challenge with WT sporozoites. C57BL6 mice were partially protected when 
immunized only twice (Table 2.1), with either RAS (33%) or pb36p- sporozoites 
(25%). The protective immune response induced by pb36p- sporozoites as well as 
RAS sporozoites seemed to be parasite stage-specific, because BALB/c mice were 
not protected from a challenge with 1×106 parasite-infected erythrocytes and 
developed a normal blood stage infection comparable to the control group (Table 
2.1). 
Occasionally, some mice from both host strains (10% C57BL6, i.e., 5 of 48 mice; 
4% BALB/c, i.e., 1 of 26 mice) did develop a 7-day delayed blood stage infection 
upon i.v. injection of pb36p- sporozoites. Interestingly, blood stage infections 
were never observed when pb36p- sporozoites were transmitted naturally through 
mosquito bites (van Dijk, 2005). The resulting blood stage parasites still contained 
the knockout genotype, as analyzed by PCR in Leiden University Medical Center, 
The Netherlands, by Milly van Dijk (van Dijk, 2005). 
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TABLE 2.1. Immunization with pb36p- sporozoites protects against a subsequent 
infection with WT sporozoites 
 
No. protected           
(no. challenged) Mouse 
Strain 
Immunizationa, 
RAS/pb36p -  × 
1,000 
Challengeb, 
× 1,000 
Control RAS pb36p- 
BALB/c 50 10 0 (5) ND 5 (5) 
C57BL6 50 10 0 (3) 0 (3) 0 (1) 
C57BL6 50/20 10 0 (3) 1 (3) 1 (4) 
C57BL6 50/20/20 10 0 (5)  5 (5) 4 (4) 
BALB/c 50 1,000 iRBC 0 (3) 0 (5) 0 (4) 
 
a Groups of mice were immunized i.v. with one dose of RAS or pb36p - sporozoites isolated from 
different mosquitoes batches. Multiple immunizations with RAS or pb36p- sporozoites were 
performed with weekly intervals. ND, not determined. 
b Mice were challenged intravenously (i.v.) with WT P. berghei sporozoites, isolated from 
different mosquitoes batches, or intraperitoneally (i.p.) with infected red blood cells (iRBC), 10 
days after last immunization. The pre-patent period was monitored by FACS analysis. All 
unimmunized mice become positive on day 3 or 4 after challenge. 
 
 
2.2.2. pb36p- sporozoites induce long-lasting protection against 
continuous challenges with P. berghei sporozoites 
 
BALB/c animals shown protected when challenged 10 days after last 
immunization (Table 2.1) were rechallenged, 1, 2, 4 and 6 months after 
immunization, respectively, with 10,000 WT sporozoites and did not develop 
blood stage infections up to 3 weeks after challenge (Table 2.2, group 1; adapted 
from van Dijk, 2005).  
In contrast, blood stage parasites could be observed in control mice on day 3.0 
after challenge (Table 2.2, group 1). We next sought to test if this protection could 
last up to 1 year. The same group of protected BALB/c mice was again challenged 
i.v. with 20,000 WT sporozoites nearly 12 months (351 days) after immunization. 
A higher dose was used, since although age has no effect on lethality in P. berghei 
in mice, older rats are able to completely control the infection (Pierrot, 2003; 
Greenberg, 1953; Singer, 1955). Interestingly, mice were fully protected and 
failed to develop blood stage parasites up to 3 weeks after the challenge, while 
blood stage parasites could be detected on day 3.5 in control animals (Table 2.2; 
group 1). 
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TABLE 2.2. Immunization with pb36p- sporozoites lead to protection against 
subsequent multiple challenges 
 
No. protected           
(no. challenged) Group Mouse Strain 
Immunizationa, 
RAS/pb36p -  × 
1,000 
Challengeb, 
× 1,000 
Challenge at 
... days post 
last 
immunization Control RAS pb36p-
1 BALB/c 50 10/10/10 30/60/120 0 (5) ND 5 (5) 
1 BALB/cc 50 10/20 180/351 0 (5) ND 4 (4) 
1 BALB/cd 50 20 531 0 (5) ND 3 (3) 
2 C57BL6 50/20/20 10/10/10/20 30/60/90/180 0 (5)  5 (5) 4 (4) 
2 C57BL6 50/20/20 20 365 0(5) 5 (5) 2 (4) 
3 BALB/c 50/20/20 10/20 60/180 0 (5) 3 (3) 4 (4) 
3 BALB/ce 50/20/20 20 365 0 (5) 3 (3) 1 (2) 
4 BALB/c 50/20/20 10/20 90/180 0 (5) 3 (3) 3 (3) 
4 BALB/cf 50/20/20 10/20 365 0 (5) 1 (1) 2 (2) 
5 BALB/c 50/20/20 20 365 0 (5) ND 1 (2) 
 
a Groups of mice were immunized i.v. with one dose of RAS or pb36p - sporozoites isolated from 
different mosquitoes batches. Multiple immunizations with RAS or pb36p- sporozoites were 
performed with weekly intervals. ND, not determined. 
b Mice were challenged with WT P. berghei sporozoites, isolated from different mosquitoes 
batches. The pre-patent period was monitored by FACS analysis. All unimmunized mice become 
positive on day 3 or 4 after challenge. 
c,d,e,f Mice were found dead during the time which experiments were performed, but cause of death 
is not related with malaria  
 
 
And, most remarkable, these mice were still fully protected when re-challenged 
i.v. with 20,000 WT P. berghei sporozoites 18 months after last boost, unlike 
matched naïve control mice (all positive on day 3.0 after challenge). The immune 
response elicited by pb36p- sporozoites was still able to fully protect BALB/c 
mice after 18 months (Table 2.2, group 1). 
C57BL6 mice immunized i.v. with three doses of RAS or pb36p- were protected 
against subsequent challenge with infectious sporozoites (Table 2.1). Like in 
BALB/c mice, we propose to determine the protective immune response 
persistence. After the final immunization, these mice received i.v. challenges of 
10,000 WT P. berghei parasites 1, 2 and 3 months post final immunization and, of 
20,000 WT sporozoites 6 months post final immunization. A complete absence of 
blood stage parasites up to 3 weeks post challenge was observed in mice 
immunized with either RAS or pb36p- sporozoites regarding all three subsequent 
challenges (Table 2.2, group 2; adapted from van Dijk, 2005). Blood stage 
parasites were detected in control mice after 3.0 days, for each challenge. pb36p- 
sporozoites were able to confer, like RAS-based immunizations, sterile protective 
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immunity that lasts up to 6 months in C57BL6 mice. These mice were re-
challenged, 12 months after last immunization, and 50% of pb36p- immunized 
mice were still fully protected (Table 2.2, group 2). Nevertheless, pb36p- 
immunized mice which developed parasitemia have a longer pre-patency period 
(4.5 days), when compared with naïve matched control (3.0 days). 
 
2.2.3. BALB/c mice immunized with pb36p- sporozoites do not require 
continuous challenges to maintain protection up to 6 months 
 
All the previous immunization experiments were performed with subsequent 
multiple challenges within the same groups of mice. Therefore, we investigated 
whether the long-lasting protection observed was due to the constant 
strengthening of the immune response, elicited by the continuous presentation of 
antigens during infectious sporozoite challenge. To test whether RAS and pb36p- 
based protective immunity could still be evoked when i.v. challenges were 
performed after long periods post immunization. Groups of BALB/c mice were 
immunized i.v. with three doses (50,000/20,000/20,000 weekly apart) of either 
RAS or pb36p- parasites, and only challenged once with 10,000 WT P. berghei 
sporozoites 2 or 3 months (60 or 90 days, respectively) or with 20,000 WT P. 
berghei sporozoites 6 months (180 days) after final immunization (Table 2.3). 
None of these immunized mice became ever positive for blood stage parasites 
whereas all control mice for each challenge experiment developed blood-stage 
parasitemias as expected. These results show that full and long-lasting protection 
does not require continuous challenges to be maintained up to 6 months in 
BALB/c mice, when using a prime plus 2 boosts immunization regimen.  
Furthermore, immunized mice which have shown to be protected 2 and 3 months 
after last immunization were re-challenged with 20,000 infectious parasites 6 
months (180 days) after last immunization (Table 2.2, groups 3-4). Not 
surprisingly, these mice were still protected and have never developed blood stage 
parasites, unlike their matched control. In addition they, as well as those which 
shown to be protected 6 months after final immunization were challenged again 
12 months subsequent to last immunization (Table 2.2, groups 3-5). After one 
year, protection starts waning, since only 50% of mice which suffer challenges at 
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2/6/12 months (Table 1, group 3) and at 6/12 months (Table 1, group 5) were still 
fully protected. Even so, pre-patency periods for immunized mice which became 
infected (Table 2.3, groups 3 and 5) is longer when compared with naïve control 
mice (6.0 and 5.0 days, respectively, versus 3.0 days for naïve matched control), 
as observed above for pb36p- immunized C57BL6 mice challenged 12 months 
after last immunization (Table 2.2, group 2). 
 
TABLE 2.3. Protection elicited by pb36p- sporozoites does not require subsequent 
multiple challenges to remain fully protective up to 6 months after last 
immunization in BALB/c mice 
 
No. protected           
(no. challenged) Immunization
a, 
RAS/pb36p -  × 
1,000 
Challengeb, 
× 1,000 
Challenge at 
... days post 
last 
immunization Control RAS pb36p- 
50/20/20 10 60 0 (5) 3 (3) 4 (4) 
50/20/20 10 90 0 (5) 3 (3) 3 (3) 
50/20/20 20 180 0 (5) 4 (4) 4 (4) 
 
a Groups of mice were immunized i.v. with one dose of RAS or pb36p- sporozoites isolated from 
different mosquitoes batches. Multiple immunizations with RAS or pb36p- sporozoites were 
performed with weekly intervals 
b Mice were challenged with WT P. berghei sporozoites, isolated from different mosquitoes 
batches. The pre-patent period was monitored by FACS analysis. All unimmunized mice become 
positive on day 3 or 4 after challenge. 
 
 
2.2.4. Lower doses of pb36p- sporozoites are still able to confer 
protection against subsequent challenge 
 
It is known that low doses of P. berghei RAS are sufficient to confer protection 
against malaria in mice. A single dose of 1,000 RAS is enough to protect BALB/c 
mice against a subsequent challenge with 10,000 WT sporozoites, while multiple 
doses of 10,000 RAS (but not of 1,000 RAS) are able to protect C57BL6 mice 
against a similar concurrent challenge with 10,000 sporozoites (Jaffe, 1990).  
Thus, we next sought to determine the minimum dose required of these attenuated 
parasites to protect against challenge with infectious WT sporozoites. C57BL6 
mice were divided in groups, and each group was immunized i.v. with three equal 
doses (with one week interval between them). Doses used were of 10,000, 5,000 
or 1,000 sporozoites, either RAS or pb36p-. Control mice were immunized i.v. 
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with a prime of 50,000 and two boosts of 20,000 (weekly apart) of either RAS or 
pb36p- sporozoites. Ten days after last immunization, mice were challenged i.v. 
with 10,000 WT sporozoites. A group of naïve mice was added at this point. As 
expected, mice immunized with three doses of 10,000 RAS sporozoites were fully 
protected against challenge with 10,000 WT sporozoites (Table 2.4). Similarly, 
mice immunized with three doses of 5,000 RAS sporozoites and challenged also 
with 10,000 P. berghei WT sporozoites, are also entirely protected against 
disease. Not surprisingly, immunizations using the same doses of pb36p- 
sporozoites (10,000 and 5,000) and challenged likewise were also able to prevent 
completely the emergence of blood stage parasites (Table 2.4). Matched controls 
became blood-stage positive 3.2 days post challenge.  
 
TABLE 2.4. Protection elicited by pb36p- sporozoites can be achieved even with low 
immunization doses in C57BL6 mice 
 
Pre-patency 
(days post 
infection)b
No. protected/no. 
challenged (%) Immunization
a, 
RAS/pb36p-  × 
1,000 
RAS pb36p- RAS pb36p- 
50/20/20 - - 5/5 (100%) 4/4 (100%) 
10/10/10 - - 5/5 (100%) 5/5 (100%) 
5/5/5 - - 5/5 (100%) 5/5 (100%) 
1/1/1 6.2 - 0/5 (0%) 5/5 (100%) 
None (Control) 3.2 0/5 (0%) 
 
a Groups of mice were immunized i.v. with RAS or pb36p - sporozoites isolated from different 
mosquitoes batches. Multiple immunizations with RAS or pb36p- sporozoites were performed 
with weekly intervals. Data from three independent experiments are shown.  
b Mice were challenged with 10,000 WT P. berghei sporozoites, isolated from different 
mosquitoes batches. Pre-patency is defined as the time until the first appearance of blood-stage 
parasites, and it was monitored by FACS analysis. 
 
As one could expect, three doses of 1,000 RAS sporozoites were not sufficient to 
protect mice against a challenge with 10,000 sporozoites. Nevertheless, a delay in 
pre-patency was observed (6.2 days), when compared to naïve control infected 
mice (3.2 days), indicating some extent of protection, which is able to reduce 
intrahepatic parasite burden (although not enough to provide complete immunity). 
But, most amazing, and unlike occur in RAS immunized mice, three doses of 
1,000 pb36p- sporozoites confer full protection to mice posterior infected with 
10,000 P. berghei sporozoites. Low immunization doses of pb36p- (1,000 pb36p- 
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sporozoites per dose) are, therefore, required to fully immunize mice against 
subsequent challenge with infectious P. berghei sporozoites. 
 
2.2.5. Different routes of administration of pb36p- and RAS sporozoites 
partially protect against infection 
 
All vaccines used as public health measures are administered using intradermal, 
subcutaneous or intramuscular routes. Studies are being done to prove that a RAS-
based vaccine can be safely administered using one of the conventional routes 
(Luke, 2003). Previous studies in A/J mice (Kramer, 1975) demonstrated that 
protection can be achieved administrating RAS sporozoites intramuscularly (but 
not subcutaneously), being some mice fully protected. To verify if a pb36p- 
mediated vaccine fulfils this requirement, we immunize C57BL6 mice 
intramuscularly (i.m.), subcutaneously (s.c.) and intradermally (i.d), using a prime 
plus 2 boots regimen (50,000/20,000/20,000 P. berghei RAS or pb36p- 
sporozoites, one week interval between them). Control mice were immunized i.v. 
using the same regimen. Ten days after last boost, mice were challenged i.v with 
10,000 WT P. berghei sporozoites. At this time, a group of naïve mice was added. 
All mice immunized i.v with either RAS or pb36p- sporozoites were fully 
protected against challenge with infectious P. berghei sporozoites, as expected 
(Table 2.5). Some sterile protection was achieved in i.m. immunizations (20% and 
13% for RAS and pb36p- immunized mice, respectively) and for RAS i.d. 
immunized mice (20%), as can be observed on Table 2.5. The remaining 
immunized mice (both RAS and pb36p-) which became positive had a strong 
delay in pre-patency period, ranging from 4.5 to 5.3 days, while naïve mice 
developed blood-stage parasitemia 3.2 days after challenge (Table 2.5). The delay 
in pre-patency of immunized mice which became blood-stage positives strongly 
suggests a partial inhibition of intrahepatic development of parasites (as seen 
above with mice which were immunized with 1,000 RAS sporozoites), indicating 
therefore these mice are partially protected against challenge with P. berghei 
infectious parasites.  
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TABLE 2.5. pb36p- sporozoites administered intramuscularly, subcutaneously and 
intradermally are able to confer protection against intravenous challenge with 
infectious P. berghei sporozoites in C57BL6 mice 
 
Pre-patency 
(days post 
infection)b
No. protected/no. 
challenged (%) Type of 
immunizationa
RAS pb36p- RAS pb36p- 
intravenous  - - 5/5 (100%) 4/4 (100%) 
intramuscular 4.5 5.3 1/5 (20%) 1/8 (13%) 
subcutaneous 4.8 5.0 0/5 (0%) 0/5 (0%) 
intradermal 4.5 4.8 1/5 (20%) 0/5 (0%) 
None (Control) 3.2 0/5 (0%) 
 
a Groups of mice were immunized as indicated with RAS or pb36- sporozoites isolated from 
different mosquitoes batches. Multiple immunizations with RAS or pb36p- sporozoites were 
performed with weekly intervals. Data from two independent experiments are shown.  
b Mice were challenged with 10,000 WT P. berghei sporozoites, isolated from different 
mosquitoes batches. Pre-patency is defined as the time until the first appearance of blood-stage 
parasites, and it was monitored by FACS analysis. 
 
 
None of these routes conferred the same level of sterile protection which can be 
achieved with intravenous route. However, the challenges with WT parasites were 
performed intravenously, which does not correspond to the natural route of 
infection, and therefore not providing practical data about the efficiency of these 
different routes of immunization with attenuated parasites if applied in the field. 
Since malaria is naturally transmitted through infected Anopheles mosquitoes bite, 
we decided to repeat pb36p- immunizations applying these different routes 
(intramuscular, subcutaneous and intradermal) as before, and challenging the mice 
by allowing P. berghei infected mosquitoes to feed on them. Consequently, the 
efficacy of these routes of administration using these genetically-attenuated 
sporozoites against the natural course of infection versus challenge performed 
intravenously could be assessed. C57BL6 mice were immunized i.v., i.m., s.c. and 
i.d with pb36p- sporozoites (50,000/20,000/20,000, weekly apart) as above. Ten 
days later, P. berghei infected mosquitoes were allowed to feed on these mice, as 
well as in a control unimmunized group. Mice were checked daily for blood stage 
parasites up to two weeks post blood feed. As expected, mice immunized i.v. were 
fully protected, and naïve control mice became all positive. Mice immunized i.m., 
s.c. and i.d. reached much higher levels of sterile protection (83%, 80% and 75%, 
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respectively) when compared to mice immunized likewise which suffer i.v. 
challenge, as one would expected (Table 2.6).  
 
TABLE 2.6. pb36p- sporozoites administered intramuscularly, subcutaneously and 
intradermally are able to confer protection against WT P. berghei sporozoites 
infected mosquitoes bite challenge with in C57BL6 mice 
 
Type of 
immunizationa
No. protected/no. 
challengedb (%) 
intravenous  4/4 (100%) 
intramuscular 5/6 (83%) 
subcutaneous 4/5 (80%) 
intradermal 3/4 (75%) 
None (Control) 0/4 (0%) 
 
a Groups of mice were immunized as indicated with pb36p- sporozoites isolated from different 
mosquitoes batches. Multiple immunizations were performed with weekly intervals. Data from 
two independent experiments are shown.  
b Six highly infected mosquitoes (around 50,000-80,000 sporozoites per salivary gland, as 
confirmed posterior) were allowed to feed on mice. Sterile protection is defined as the complete 
absence of blood-stage parasites, and it was monitored by FACS analysis. 
 
 
2.2.6. pb36p- and RAS confer partial protection against challenge with 
P. yoelii sporozoites 
 
Until now, our knowledge regarding cross-species protection with attenuated 
sporozoites relies on a preliminary study, where one volunteer was immunized 
with P. falciparum RAS infected mosquitoes and subsequently infected by 
mosquitoes harbouring infectious P. vivax sporozoites (Hoffman, 2002). The 
volunteer eventually developed blood-stage parasites, meaning, in this particular 
episode, P. falciparum RAS administered through mosquitoes bite were unable to 
confer sterile protection against another Plasmodium species, P. vivax.   
We tested whether cross-species protection could be conferred by P. berghei 
pb36p- sporozoites, by immunizing mice i.v. with these attenuated parasites and 
challenging them with another rodent Plasmodium species, P. yoelii. BALB/c 
mice were divided in different groups, according to immunization protocol used: 
single immunization dose of 50,000 pb36p- sporozoites, prime-boost regimen 
(50,000/20,000 pb36p- sporozoites, weekly apart), and full immunization regimen 
(50,000/20,000/20,000 pb36p- sporozoites, one week interval between them). 
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Cross-species protection was also assessed for RAS immunizations (prime-boost 
and prime-2 boosts regimens). As seen above, a single dose of 50,000 RAS or 
pb36p- sporozoites is able to confer sterile protection against a homologous 
challenge with 10,000 P. berghei sporozoites in BALB/c mice, so we chose this 
dose as a start point for cross-species protection experiments. Additional boosts 
(up to two) were also performed, in order to confirm if protection against P. yoelii 
requires multiple immunizations. Three weeks after last boost, mice were 
challenged with 100, 1,000 or 10,000 P. yoelii 265 BY sporozoites. P. yoelii is 
known to be 2,000× more infective in BALB/c mice than P. berghei (Khan, 
1991), so we also used lower number of P. yoelii sporozoites for challenge. Naïve 
controls were challenged with the same number of P. yoelii sporozoites. Forty 
hours after infection, half of the animals of groups which received a single 
immunization and prime-boost regimen (n=3) was sacrificed and liver collected 
for assess the parasite burden by RT-PCR (Fig. 2.1). Prime-boost immunization 
with RAS reduces significantly parasite burden in liver compared with naïve 
controls, achieving levels of inhibition of 99.9% (P<0.001) and 94.8% (P=0.042), 
against challenges of 100 and 1,000 P. yoelii, in that order (Fig. 2.1A and 2.1B, 
respectively). Mice which suffered only a single immunization with pb36p- 
sporozoites and challenged with 100 and 1,000 P. yoelii sporozoites, parasite 
burden suffered a reduction of 58.5% and 51.1%, correspondingly, (Fig. 2.1A and 
2.1B, respectively), although not statistically significant (P>0.05). However, mice 
which suffered an extra boost of pb36p- sporozoites, like in RAS immunized 
mice, had a significant higher level of inhibition of P. yoelii intrahepatic 
development, reaching 94.6% (P=0.001) and 88.6% (P=0.049) versus challenge 
with 100 and 1,000 P. yoelii, correspondingly (Fig. 2.1A and 2.1B, respectively).  
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Figure 2.1. Level of inhibition of infection with P. yoelii 265 BY sporozoites in mice 
immunized with P. berghei RAS and pb36p- sporozoites. BALB/c mice were immunized with 
RAS sporozoites (prime plus boost) or with pb36p- sporozoites (single immunization and prime 
plus boost) and challenged 3 weeks after last immunization with 100 (A) or 1,000 (B) P. yoelii 
sporozoites. Livers were collected 40 hours post challenge and parasite burden was assessed by 
Real Time PCR. Control mice have no inhibition in infection. 
 
Blood-stage parasitemia were evaluated daily up to 2 weeks post infection, for all 
immunization regimens tried in this mouse strain. In mice challenged with 100 P. 
yoelii sporozoites, control naïve infected mice had a maximum parasitemia 
average of 7.57% ± 0.75 and a pre-patency period of 5.2 days (Fig. 2.2 and Table 
2.7, groups 1-3). Mice which suffered a single immunization with pb36p- 
sporozoites were all blood-stage positive on day 5.0, reaching a maximum 
parasitemia of 5.47% ± 3.67, not presenting a significant decrease when compared 
with non-immunized controls (Fig. 2.2A and Table 2.7, group 1). On other hand, 
mice which received an extra boost of pb36p- sporozoites only reached a 
maximum parasitemia of 1.30% ± 2.08 (Fig. 2.2A), showing an significant 
decrease in blood-stage parasitemia (P=0.019). Furthermore, one out of three of 
these mice failed to develop blood-stage parasitemia, being fully protected against 
a challenge with P. yoelii sporozoites.  The remaining mice immunized this way 
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had a delay in pre-patency period (7.0 days), when compared to naïve control 
(Table 2.7, group 2). But most remarkable, all mice immunized likewise with 
RAS presented sterile protection against P. yoelii challenge (Fig. 2.2B and Table 
2.7, group 2). These mice never developed parasitemia. BALB/c mice pb36p- 
immunized using a prime-2 boosts regimen did not present a delay on blood stage 
parasitemia (Table 2.7, group 3) when compared to naïve counterpart (5.0 days), 
although a significant marked inhibition in maximum parasitemia (Fig. 2.2A) is 
also observed (2.72% ± 0.87; P=0.047). In RAS immunized mice with a similar 
regimen, 75% of sterile protection was attained, and the only mouse which 
became positive had a pre-patency period of 6.0 days (Table 2.7, group 3). In 
addition, maximum parasitemia reached for this group was 0.88% ± 1.75 (Fig. 
2.2B), which is significantly lower (P=0.008), when compared to naïve control 
mice. 
Concerning challenge with 1,000 P. yoelii sporozoites, blood-stage parasites were 
already observed on day 4.0 post infection for both naïve (Table 2.7, groups 4-6) 
and pb36p- single-immunized mice (Table 2.7, group 4). In naïve mice, 
parasitemia reached a maximum of 12.17% ± 1.87 (Fig. 2). pb36p- single-
immunized mice present an decrease in maximum parasitemia, only reaching 
6.00% ± 2.01 (Fig. 2.2A), although not significant (P>0.05). In pb36p- prime-
boost immunized mice, this value reaches 5.60% ± 1.45 (Fig. 2.2A), presenting a 
significant decrease (P=0.035), as well as a higher pre-patency period (4.7 days), 
when compared with naïve control mice (Table 2.7, group 5). RAS 
correspondingly immunized mice had a similar delay (5.5 days) on blood-stage 
parasites arise (Table 2.7, group 5). Maximum parasitemia achieved was 2.07% ± 
1.79 (Fig. 2.2B), significantly lower than matched unimmunized controls 
(P=0.004). Furthermore, one out of the three RAS immunized mice failed to 
develop blood-stage parasites, clearly indicating some sterile protection are still 
achieved with this immunization method when a 10× higher challenge dose of P. 
yoelii is used. Moreover, pb36p-and RAS prime-2 boosts immunizations also led 
to higher pre-patency periods, 5.2 and 7.0 days, respectively, when compared to 
naïve control (Table 2.7, group 6). Maximum parasitemia value achieved was also 
significantly lower for both types of attenuated parasites. pb36p- immunized mice 
reached 2.22% ± 1.24 (P=0.02), as can be observed in Fig. 2.2A. Like in RAS 
prime-2 boosts immunized which suffered a challenge with 100 P. yoelii, RAS 
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likewise immunized mice reached 75% of sterile protection against a challenge of 
1,000 P. yoelii, and the maximum parasitemia average was 0.28% ± 0.55 
(P=0.003) (Fig. 2.2B).  
In mice challenged with 10,000 P. yoelii sporozoites, control mice have a pre-
patency period of 4.0 days (Table 2.7, group 8) and a maximum parasitemia of 
14.38% ± 4.60 (Fig. 2.2). Not surprisingly, pb36p- and RAS prime-2 boosts 
immunized mice have longer pre-patency periods of 4.6 and 5 days, respectively 
(Table 2.7, group 8),  as well as significant lower values for maximum 
parasitemia, only achieving 2.32% ± 0.52 (P=0.01) and 1.30% ± 0.34 (P=0.008), 
respectively. 
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Figure 2.2. Maximum blood-stage parasitemias levels achieved in P. berghei p36p- and RAS 
immunized BALB/c mice which were subsequently challenged with P. yoelii 265 BY 
sporozoites. BALB/c mice were immunized with pb36p- sporozoites (single immunization, prime 
plus boost and prime plus 2 boosts) and with RAS sporozoites (prime plus boost and prime plus 2 
boosts) and challenged 3 weeks after last immunization with 100, 1,000 or 10,000 P. yoelii 
sporozoites (only prime plus 2 boosts for the later). pb36p- (A) is able to decrease maximum 
blood-stage parasitemia after challenge with different doses of P. yoelii sporozoites in BALB/c 
mice, although at least two immunization doses are required to achieve significant reduction. RAS 
(B) equally induce diminution on maximum parasitemias observed in the same conditions, even 
achieving sterile protection in some cases. Parasitemias are expressed as the mean ± the standard 
deviation of individual animals. Data from two independent experiments are shown. * P<0.05. 
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Partial protection against challenge with P. yoelii is also observed in C57BL6 
mice immunized with either P. berghei RAS or pb36p- sporozoites. C57BL6 mice 
were immunized according to a regimen of prime plus two boosts with either P. 
berghei RAS or pb36p- sporozoites (50,000/20,000/20,000), weekly apart. 
Unlikely BALB/c, C57BL6 mice require this regimen, as mentioned previously, 
to become fully protected against a challenge with WT P. berghei sporozoites. As 
so, we immunize mice according to this routine, to assess its degree of protection 
against challenge with the heterologous species P. yoelii. No additional boots 
were performed, since that treatment would be too fierce to mice. 3 weeks later, 
mice were challenged i.v. with 1,000 P. yoelii sporozoites. Naïve unimmunized 
mice were challenged likewise. As in BALB/c mice, blood-stage parasites were 
verified daily from day 3 to day 14 post infection. Naïve control mice were all 
blood-stage positive already at day 4.0 post infection (Table 2.7, group 7) and 
reached a maximum parasitemia of 14.60% ± 3.36 (Fig. 2.3). RAS and pb36p- 
immunized mice, as expected, had longer pre-patency periods (6.3 and 5.3 days, 
respectively) and reaching significant lower values for maximum parasitemia 
observed (5.1% ± 1.16, P=0.038 and 4.5 ± 1.14, P=0.033, correspondingly), when 
compared to naïve control mice (Fig. 2.3). 
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Figure 2.3. Maximum blood-stage parasitemias levels achieved in P. berghei RAS and pb36p- 
immunized C57BL6 mice which were subsequently challenged with P. yoelii 265 BY 
sporozoites. C57BL6 mice were immunized with either RAS or pb36p- sporozoites (prime plus 2 
boosts) and challenged 3 weeks after last immunization with 1,000 P. yoelii sporozoites. Both 
RAS and pb36p- are able to decrease maximum blood-stage parasitemia when challenged with P. 
yoelii sporozoites, attaining significant reduction. Parasitemias are expressed as the mean ± the 
standard deviation of individual animals. Data from two independent experiments are shown. * 
P<0.05 
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Our preliminary observations show that pb36p- mediated cross-species protection 
is also observed against another (lethal) strain of this parasite, P. yoelii 17XL. 
BALB/c mice were immunized with a single dose of 50,000 pb36p- sporozoites. 
Three weeks later, these mice were challenged with 10,000 P. yoelii 17XL 
sporozoites. Naïve control mice were infected likewise. Blood-stage parasitemia 
were assessed from days 3 to 11 days post infection. Control mice have a pre-
patency period of 3.0 days (Table 2.7, group 9) and a maximum parasitemia of 
57.11% ± 10.23 (Fig. 2.4). Not surprisingly, pb36p- immunized mice have lower 
pre-patency period of 4.6 days (Table 2.7, group 9), and present a decrease in 
maximum parasitemia achieved, only reaching 36.50% ± 10.14 (Fig. 2.4). 
However, this reduction in parasitemia is not statistically significant. 
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Figure 2.4. Maximum blood-stage parasitemias levels achieved in pb36p- immunized BALB/c 
mice which were subsequently challenged with P. yoelii 17XL sporozoites. BALB/c mice were 
immunized with pb36p- sporozoites (single immunization) and challenged 3 weeks after last 
immunization with 10,000 P. yoelii 17XL sporozoites. pb36p- are able to decrease maximum 
blood-stage parasitemia when challenged with a lethal strain of P. yoelii sporozoites, although not 
significantly. Parasitemias are expressed as the mean ± the standard deviation of individual 
animals.  
 
Consequently, immunization with these both types of P. berghei live-attenuated 
parasites can confer protection against challenge with another rodent Plasmodium 
species, P. yoelii. Both delays in pre-patency periods and maximum parasitemia 
observed indicate a partial inhibition in P. yoelii liver burden, as clearly confirmed 
by RT-PCR (Fig. 2.1), strong enough in some cases to even induce sterile 
protection against this heterologous-species challenge. 
Additionally, we intended to assess the level of pb36p- cross-species protection 
against another rodent heterologous species, P. chabaudi chabaudi AS and P. 
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vinckei petteri, but we did not obtained an adequate amount of sporozoites to 
perform this kind of experiment.  
 
TABLE 2.7. Immunization with P. berghei RAS and pb36p- sporozoites lead to a 
delay on parasitemia onset in BALB/c and C57BL6 mice challenged with the 
heterologous species P. yoelii, and some even achieve sterile protection. 
 
 
Pre-patency 
(days)  
No. protected (no. 
challenged) Groups Mouse Strain 
Immunization 
× 1,000a
Challenge 
Dose 
(P. yoelii 
sporozoites)b pb36p- RAS Control pb36p- RAS Control 
1 BALB/c 50 100 5.0 ND 5.2 0 (3) ND 0 (3) 
2 BALB/c 50/20 100 7.0 - 5.2 1 (3) 3 (3) 0 (3) 
3 BALB/c 50/20/20 100 5.0 6.0 5.2 0 (5) 3 (4) 0 (5) 
4 BALB/c 50 1,000 4.0 ND 4.0 0 (3) ND 0 (3) 
5 BALB/c 50/20 1,000 4.7 5.5 4.0 0 (3) 1 (3) 0 (3) 
6 BALB/c 50/20/20 1,000 5.2 7.0 4.0 0 (5) 3 (4) 0 (5) 
7 C57BL6 50/20/20 1,000 4.8 5.5 4.0 0 (5) 0 (5) 0 (5) 
8 BALB/c 50/20/20 10,000 4.6 5.0 4.0 0 (5) 0 (4) 0 (5) 
9 BALB/c 50 10,000 4.6 ND 3.0 0 (6) ND 0 (5) 
a Groups of mice were immunized as described before with P. berghei RAS or pb36p- sporozoites. 
ND, not determined. 
b Mice were challenged with P. yoelii 265 BY sporozoites, a non lethal strain (groups 1-8). Data 
from two independent experiments are shown for these groups. Group 9 was challenged with P. 
yoelii lethal strain 17XL sporozoites. This experiment was only performed once. 
 
For all experiments described above, control mice groups (both BALB/c and 
C57BL6, 3-5 animals per group) immunized likewise with either RAS or pb36p- 
sporozoites from the same mosquitoes’ batch and challenged with 10,000 
homologous P. berghei sporozoites each fail to develop blood stage parasites, 
confirming that these sporozoites were fully protective in homologous challenge 
in these conditions. All control naïve mice (3-5 animals per group) challenged 
equally with WT P. berghei sporozoites developed blood stage parasitemia 3-4 
days later, as expected.  
 
2.3. Conclusions
 
The lack of significant progress with (recombinant) subunit vaccines that contain 
only (parts of) single proteins of sporozoites has led to renewed interest in 
vaccines based on live, attenuated whole sporozoites (Luke, 2003). Recently, it 
has been shown that GAS, like RAS, produced by engineered inactivation of 
sporozoite-specific genes can induce protective immunity in the P. berghei rodent 
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model of malaria (Mueller, 2005; Mueller and Camargo, 2005; van Dijk, 2005). 
Specifically, our studies demonstrate that a GAS produced through the 
inactivation of the sporozoite-specific protein P36p induces protective immunity. 
P36p is a member of the P48/45 family of surface proteins (Thompson, 2001) that 
include a number of promising vaccine candidate antigens, such as P48/45 and 
P230 that are expressed on the surface of gametes (Thompson, 2001; van Dijk, 
2001). P36p has no function in sporozoite motility and invasion of both salivary 
glands and hepatocytes (Ishino, 2005B; van Dijk, 2005), and instead plays an 
essential role during development of the liver trophozoite (van Dijk, 2005). 
pb36p- parasites apparently fail to maintain a parasitophorous vacuole (PV), 
arresting early during intrahepatocytic development (van Dijk, 2005).  
Importantly, immunization with pb36p- sporozoites induces a fully protective 
immune response against subsequent challenge with WT sporozoites. 
Interestingly, as has been shown for RAS (Chatterjee, 2001), only a single 
immunizing dose of pb36p- sporozoites is required to elicit a protective immune 
response in BALB/c mice. As in the immunization studies performed with uis3- 
and uis4- GAS (Mueller, 2005; Mueller and Camargo, 2005) and RAS 
(Chatterjee, 2001), three immunizing doses of pb36p- sporozoites are required to 
completely protect C57BL6 mice. This protective immune response, as shown 
before for RAS, uis3- and uis4- (Mueller, 2005; Mueller and Camargo, 2005; 
Clyde, 1975), is parasite stage specific, not preventing infection when mice are 
challenged with infected erythrocytes.  
Intriguingly, pb36p- sporozoites, like uis4- GAS (Mueller and Camargo, 2005), 
albeit at a lower frequency, initiated a delayed blood stage infection in some mice. 
The reasons for this are unclear and are currently under investigation (Milly van 
Dijk, personal communication).  
The protection elicited by pb36p- sporozoites may last up to 12 and 18 months in 
C57BL6 and BALB/c, respectively. The length of the protection induced by these 
parasites is quite outstanding. Mice live in average 18 months and can reach 3 
years-old (Fox, 1984). Thus, experiments were stopped due to the low number of 
mice that reached the last time points.  On the later time points, protection 
conferred by RAS was always stronger than by pb36p- sporozoites. The 
prominent differences observed above between BALB/c and C57BL6 regarding 
immunization with RAS and pb36p- clearly demonstrate that the choice of the 
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host strain in studying the mechanisms of protective immunity induced by 
attenuated sporozoites is critical, as has been shown by earlier studies (Chatterjee, 
2001). 
Similarly to RAS-induced protection, lower doses than those currently tested of 
pb36p- sporozoites are sufficient to confer sterile protection. Immunization of 
C57BL6 mice with 3 doses of 10,000 or 5,000 pb36p- sporozoites or RAS fully 
protects mice against challenge with 10,000 sporozoites. However, while 3 doses 
of 1,000 pb36p- sporozoites are able to confer fully protection to challenge with 
10,000 sporozoites, similar RAS immunizations only confer partial protection, 
confirming previous reports for RAS (Jaffe, 1990). This suggests that lower doses 
of pb36p- sporozoites are required than those required for RAS sporozoites, to 
induce the same level of protection. Moreover, RAS immunized mice present a 
higher pre-patency period when compared with naïve controls (6.2 days vs. 3.2 
days, correspondingly), which lead to think that even low doses as 1,000 RAS 
sporozoites are sufficient to induce a partial inhibition on parasites intrahepatic 
development (most probably, induced by apoptosis, although that remains to be 
elucidated), but unable to enough to confer sterile protection, as clearly 
demonstrated.  
All vaccines used as public health measures are administered intramuscularly, 
subcutaneously or intradermally (Luke, 2003). A vaccine based on live attenuated 
sporozoites should also accomplish this requirement. Our results, as well as other 
studies for RAS (Kramer, 1975), clearly demonstrated that protection can be 
achieved administrating RAS and pb36p- sporozoites intramuscularly, being some 
mice fully protected. Protection is also achieved using subcutaneous route in both 
types of attenuated parasites, as clearly demonstrated by delay in patency period. 
This is not been observed in previous studies (Kramer, 1975), but different mouse 
strains and immunization regimens were used, which could explain these 
differences.  Another GAS, P. berghei uis3-, contrastingly, when administered 
subcutaneously, confer full sterile protection against intravenous challenge with 
WT P. berghei sporozoites (Mueller, 2005), which leads to think its protection 
mechanisms differ greatly from those induced by RAS or pb36p- itself. To our 
knowledge, no studies regarding intradermal immunization with live attenuated 
Plasmodium sporozoites were described previously. Our results show that both 
RAS and pb36p- sporozoite confer some level of protection when administered by 
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this route, with only a small proportion of RAS immunized mice being fully 
protected. 
Mice immunized with pb36p- sporozoites through all these routes followed by 
mosquito bite challenge (the natural course of infection) have a higher level of 
sterile protection, around 80%, which supports the potential as an experimental 
vaccine against malaria of this particular GAS. Unfortunately, none of these 
routes confer the same level of sterile protection as immunizations performed 
intravenously, which is undoubtedly desirable. Although at the moment these 
routes do not lead to complete protection, the results are quite encouraging and 
promising, strengthening the potential of a human live attenuated parasites-based 
vaccine. Optimization of the conditions used (e.g., higher immunization doses) 
may increase (or even lead to full) protection, which ought to be further 
investigated. 
Our results show for the first time the potential of attenuated malaria sporozoites 
to induce cross-species protection. We clearly demonstrated that immunization 
with P. berghei RAS and pb36p- sporozoites is able to partially inhibit the 
development of P. yoelii in both BALB/c and C57BL6 mice. Immunization with 
either RAS or pb36p- sporozoites lead to a significant decrease both in P. yoelii 
liver burden and of values of maximum blood-stage parasitemia, achieving, in 
some cases, sterile protection. However, significant levels of partial cross-species 
protection are only attained with, at least, one extra boost. These results confirm 
the potential of live-attenuated parasites as a multi-species vaccine against 
Malaria.  
Here, we show the immunization potential of P. berghei p36p- as an experimental 
vaccine against Malaria, able to induce long-lasting immunity and cross-species 
protection against P. yoelii. Furthermore, protection with this GAS can be 
achieved even with low immunization doses and using practicable routes of 
immunization commonly used as public health measures in humans.  
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Chapter III 
 
Mechanisms of protection induced by pb36p- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      MECHANISMS OF PROTECTION INDUCED BY pb36p-  
3.1. Introduction 
 
In the previous chapter, we have described the potential of pb36p- sporozoites as 
an experimental vaccine against the preerythrocytic stage of Malaria. To make it 
more accurate, whenever possible, we compared it with the golden standard for 
Malaria vaccine, Radiation-Attenuated Sporozoites (RAS). For decades, RAS 
induced immunity has been widely studied and is now known to be mediated by 
complex mechanisms involving antibody responses that inhibit sporozoite motility 
and host cell invasion and T cell responses directed against intrahepatocytic 
stages. Cytotoxic CD8+ T and CD4+ T helper cells lymphocytes recognizing 
Major Histocompatibility Complex I and II (MHC I and II), respectively, 
presented parasite-derived peptides, as well as cytokines (IL-2, IFN-γ, and IL-12; 
TNF- α, IL-1, and IL-6) and nitric oxide, have been shown to be critical effectors 
in protection against preerythrocytic malaria (reviewed in Morrot, 2004 and Tsuji, 
2003; Doolan, 1999). γδ T cells, although a component of early immunity against 
preerythrocytic malaria parasites, are not required for RAS mediated protection 
(McKenna, 2000).  Moreover, RAS induced long-lasting protection is 
characterized by the establishment of a specific subset of memory CD8+ T cells in 
the liver (but not of CD4+ T cells), CD44highCD45RBlowCD62LlowCD122low/high 
(Berenzon, 2003; Guebre-Xabier, 1999). No increase in splenic memory T cells is 
observed in RAS long lasting immunizations in C57BL6 mice (Guebre-Xabier, 
1999). B cells are known to be important in the establishment of immune 
protective mechanisms against liver stage malaria, since antibodies are paramount 
in conferring sterile protection against challenge with sporozoites (Schofield, 
1987). However, to the extent of our knowledge, nothing no studies have been 
done regarding the role of memory B cells in immunity against malaria liver 
stage. Although some authors suggest that memory B cells might be involved in 
liver protection using other immunization strategies, such as adenovirus and 
modified vaccinia virus (Bruña-Romero, 2001), that remains to be elucidated in 
RAS mediated immunity. Another mechanism which is most likely to be involved 
in RAS mediated protection is apoptosis of infected host cells. Recently, it has 
been shown that both P. berghei sporozoites are able to prevent apoptosis of the 
hepatocytes they infect, ensuring so their survival during intrahepatic 
development (Leirião, 2005; van de Sand, 2005). Furthermore, P. yoelii RAS, 
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which are unable to inhibit apoptosis pathways at the same level than non 
irradiated sporozoites, have be identified as a source of antigens for antigen 
presenting cells (APC), such as dendritic cells and macrophages (Leirião and 
Mota, 2005), initiating a protective immune response.  
As stated before, RAS mediated protection presents some concerning 
disadvantages. The use of GAS for vaccination might remove the uncertainty 
associated with RAS once a more thorough understanding of the mechanisms of 
immunity invoked by GAS and their developmental defect(s) are available. In this 
chapter, we describe an initial study of potential mechanisms which could lead to 
pb36p- induced immunity. Two main features were studied: apoptosis and 
immune factors required for mediate/maintain protection. We found evidence that 
pb36p- sporozoites have a much higher rate of apoptosis in HepG2 cells, when 
compared to RAS and WT sporozoites. pb36p- parasitized cell numbers are also 
progressively reduced in vivo and apparently fail to prevent host cell apoptosis, 
consequently leading to parasite clearance.  
Using deficient mice for either IFN-γ and TCRδ (T cell receptor δ), we assessed 
the requirements of these two factors involved in immune response against 
pathogens in pb36p- mediated protection. Like in RAS induced immunity, pb36p- 
requires IFN-γ to elicit an immune protective response. However, most 
surprisingly and, unlike observed in RAS protection (McKenna, 2000), pb36p- 
protective immunity is also dependent of γδ T cells. Moreover, pb36p- immunized 
BALB/c mice have an increase in intrahepatic memory CD8+ T cells 
(CD44highCD62Llow), but not of memory CD4+ T cells, 10 days after 
immunization, which eventually fades at 1 month and being scarcely detected 6 
months later. Splenic memory CD8+ T cells suffer similar increase, although at a 
lower rate. Contrastingly to what happens in RAS long lasting protection, pb36p- 
immunized BALB/c mice have a huge increase in splenic memory CD4+ T cells 
(CD44highCD62Llow) 1 month after immunization. TO CONTINUED W/ 6 MTHS 
DATA…Memory B cells are not increased in liver, spleen or lymph nodes 
following pb36p- immunization up to 6 months later. 
Our results, although preliminary, clearly demonstrate that pb36p- and RAS 
mediated protection have some prominent differences which need to be dissected 
in detail, so a vaccine based on this GAS may be accomplished.  
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3.2. Results 
 
3.2.1. pb36p- sporozoite infected Hepatocytes enter Apoptosis more 
frequently than RAS or WT parasite-infected Hepatocytes 
 
Host hepatocyte apoptosis is normally inhibited by WT parasites upon invasion 
and establishment of the PV (Leirião, 2005; van de Sand, 2005). Therefore, it was 
possible that the observed rapid disappearance of pb36p- sporozoite-infected 
HepG2 cells in culture was due to the inability of the parasite to prevent the 
hepatocyte from undergoing apoptosis. Thus, the level of apoptosis in pb36p- 
sporozoite invaded cells was examined (Fig. 3.1A).  
 
 
 
Figure 3.1. Apoptosis is increased in pb36p- parasitized liver cells. (A) Apoptosis rates 
represent the percentage of parasite-invaded cells that undergo apoptosis 6 hours after infection of 
HepG2 cells with WT, RAS, or pb36p- sporozoites. Non. Inf. indicates non infected HepG2 cell 
cultures. Rates are defined as the mean ± the standard deviation of each well. Data from three 
independent experiments is shown. (B and C) Visualization of pb36p- sporozoite (green, anti-
HSP70) infected hepatocytes displaying typical apoptotic signs as detected by DAPI staining 
(blue) in vitro (B) as well as in vivo (C). Active caspase-3 (red) detection was also performed in B. 
(Original magnification, × 1,260) (adapted from van Dijk, 2005). 
 
HepG2 cells were incubated with WT, RAS, or pb36p- sporozoites (20,000 
sporozoites per well), and apoptosis was determined 6 hours after infection by 
detection of active caspase-3 (the factor which will ultimately lead to apoptosis) in 
the infected host cell cytoplasm and by analysis of the nuclear morphology of the 
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infected cells after DAPI staining by observing chromatin condensation and/or 
nuclear fragmentation (Fig. 3.1B). Interestingly, we also detected apoptosis of 
pb36p- parasitized hepatocytes in vivo 6 hours after infection (Fig. 3.1C). The 
level of apoptosis in pb36p- parasitized cells was significantly higher (P<0.05) 
compared to that in RAS-infected cells, which was higher than the level observed 
in WT-infected cells (Fig. 3.1A). The different levels of apoptosis are consistent 
with the observed longer survival time of RAS in culture (Scheller, 1995). 
Our results also show that in HepG2 cells during infection with RAS or pb36p- 
parasites, high levels of procaspase-3, the precursor of active caspase-3 are 
detected (Fig. 3.2).  
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Figure 3.2. High levels of procaspase-3 are detected in HepG2 cells infected with RAS and 
pb36p- sporozoites. A) High levels of procaspase-3 (MW 32 kDa), the precursor of active 
caspase-3, which will lead to apoptosis, are detected in HepG2 cells infected with RAS or pb36p- 
sporozoites, but not in non infected neither in WT-infected HepG2, after 24 hours in culture, using 
Western Blot. B) Quantification of Procaspase-3 shows that this apoptotic protein is highly 
expressed in RAS and pb36p- infected HepG2, but not in WT P. berghei infected cells. Non Inf 
indicates non infected HepG2 cell cultures. To assure samples were equally loaded with the same 
quantities of protein, detection of actin (MW 42 kDa) was performed. The density of each band 
was determined using ImageJ (National Institute of Health, Bethesda, Maryland, USA). The values 
were normalized as the ratio of Procaspase-3 density to the Actin density in the corresponding 
sample. Results are expressed in arbitrary units.  
 
 
HepG2 cells were infected with either 150,000 WT, RAS or pb36p- sporozoites. 
After 24 hours, cells were collected and quantified. 50,000 cells of each type 
(including non infected HepG2) were used for detection of caspase-3 by Western 
Blot. Procaspase-3 (MW 32 kDa) is detected in cells infected by RAS and pb36p- 
 54 
                                      MECHANISMS OF PROTECTION INDUCED BY pb36p-  
sporozoites, but not in uninfected and WT infected hepatocytes (Fig. 3.2), 
strengthening the hypothesis that live attenuated parasites are unable to inhibit 
apoptosis in host cells, as others have shown (Leirião, 2005; van de Sand, 2005).   
 
3.2.2. pb36p- sporozoites have a higher Clearance Rate in Livers of 
infected BALB/c mice 
 
We determined in vivo the persistence of WT, RAS and pb36p- infected 
hepatocytes in whole liver extracts of BALB/c mice by using real-time PCR for 
liver schizont detection. WT parasites have a continuous growing liver burden up 
to 40 hours post infection, as expected (Fig. 3.3A). RAS parasites show an 
increasing development up to 18 hours after infection, although at a much slower 
rate compared to WT, which begun to decrease from that period onwards (Fig. 
3.3B). pb36p- parasites are hardly detected at 6 hours post infection and even 
barely at further time points (Fig. 3.3 C). Our results confirm the significantly 
more rapid clearance of pb36p- parasitized hepatocytes within 6 hours after 
infection compared to RAS-infected hepatocytes as has been observed in vitro 
(P=0.002). However, RAS and pb36p- infected hepatocytes are barely detected 1 
week after infection (Fig. 3.3B and C). 
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Figure 3.3. Hepatic Persistence of RAS and pb36p- sporozoites in BALB/c mice. Liver burden 
of P. berghei was quantified in BALB/c mice infected with (A) WT, (B) RAS and (C) pb36p- 
sporozoites, at several time points. WT parasites continuously grow up to 40 hours. RAS parasites 
also initiate intrahepatic development up to 18 hours post infection, although decreasing onwards. 
pb36p- parasites are only hardly detected at 6 hours post infection. After 1 week, very low 
numbers of copies of both attenuated parasites are detected. Number of copies of P. berghei 18S 
cDNA  are defined as the mean ± the standard deviation of each animal (n=3 per time point). Data 
from two independent experiments are shown.   
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3.2.3. pb36p- induced protection is dependent on IFN-γ and γδ T cells 
 
Our previous work has shown that a single immunization with 50,000 pb36p- 
sporozoites led to a reduction of parasite liver burden up to 90%, after challenge 
with infectious WT P. berghei sporozoites in C57BL6 mice (van Dijk, 2005). 
Using deficient mice for either IFN-γ (IFNg-/-) or γδ T cells (TCRδ-/-) in the same 
background, we confirmed if these two features were required to establish pb36p- 
induced immunity. IFNg-/- and TCRδ-/- C57BL6 mice (as well as a WT mice 
group) were immunized once with 50,000 pb36p- sporozoites and challenged with 
10,000 WT P. berghei sporozoites 10 days later. Mice were sacrificed 40 hours 
after challenge and livers collected and homogenised for quantification of parasite 
load by real time PCR. As expected, pb36p- single immunization reduced 
significantly liver parasite burden, in 90% (P<0.001), when compared to WT 
parasite load (Fig. 3.4). Not unanticipated, protection induced by this GAS in 
IFNg-/- is abolished (Fig. 3.4), as in RAS based immunizations (Doolan, 2000). 
These mice achieve no reduction in parasite liver burden, implicating a complete 
failure in attaining protection when immunized with pb36p- sporozoites. 
However, and quite unexpected, pb36p- induced protection requires also the 
presence of γδ T cells to became fully effective (Fig. 3.4). Like in IFNg-/- mice, no 
reduction in parasite load is observed in TCRδ-/- mice after immunization with 
pb36p-, indicating a similar lack of protection. RAS based immunization does not 
require this particular subset of T cells to confer full protection in C57BL6 mice 
(McKenna, 2000), which suggests that the immune mechanisms elicited by these 
two types of attenuated parasites present major differences. However, previous 
studies have been done using a different Plasmodium species (P. yoelii), which 
may also contribute to the observed differences. 
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Figure 3.4. Quantification of P. berghei liver load in pb36p- immunized IFNg-/- and TCRδ-/- 
mice after challenge with infectious P. berghei sporozoites. Liver burden of 50,000 pb36p- 
sporozoites immunized IFNg-/- (n=8) and TCRδ-/- (n=6) C57BL6 mice was quantified 40 hours 
after a challenge with 10,000 WT P. berghei sporozoites. Inf indicates naive infected mice (n=3) 
and Cont Imm WT immunized mice (n=5). Lack of either IFN-γ or γδ T cells abrogate pb36p- 
induced protective effect on C57BL6 mice. Parasite Loads are defined as the mean ± the standard 
deviation of each animal.  
 
3.2.4. Memory T and B Cells in pb36p- immunized BALB/c mice 
  
3.2.4.1. Increase in Memory T cells is observed in livers and spleens of pb36p- 
immunized BALB/c mice 
 
Memory in RAS immunized C57BL6 mice is associated with the establishment of 
a specific subset of memory CD8+ T cells (but not of CD4+ T cells) can be found 
in the liver, CD44highCD45RBlowCD62LlowCD122low/high (Berenzon, 2003; 
Guebre-Xabier, 1999). However, no difference was observed between 
unimmunized and immunized mice regarding splenic memory T cells (Guebre-
Xabier, 1999).  
Our results show that, concerning pb36p- immunizations, BALB/c mice are 
protected longer than C57BL6 mice (previous chapter), suggesting that immune 
memory cells might be easily established in that mouse strain. So, we immunize 
BALB/c mice with 50,000 pb36p- sporozoites (single dose) and memory CD8+ 
and CD4+ T and B cells were quantified at later time points in liver, spleen and 
lymph nodes of non immunized and immunized mice. Memory T cells were 
quantified as CD44highCD62Llow (Berenzon, 2003; Guebre-Xabier, 1999), using 
Flow Activated Cell Sorting (FACS).  
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CD8+ memory cells (CD44highCD62Llow) have an increase of nearly three-fold in 
the liver of immunized mice, compared to naïve mice, 10 days after immunization 
(Fig. 3.5). However, 1 month after immunization, CD8+CD44highCD62Llow cell 
population declines, being only 50% higher than in naïve mice (Fig. 3.5). DATA 
FOR 6 MONTHS. Contrastingly, CD4+ liver memory cells present no different 
phenotype in both unimmunized and immunized mice up to 6 months (Fig. 3.5). 
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Figure 3.5.  Memory CD8+ and CD4+ in livers of naïve and pb36p- immunized mice. Memory 
T cells in livers of 50,000 pb36p- sporozoites immunized BALB/c mice (n=3 per group) were 
assessed 10 days, 1 month and 6 months after immunization. CD8+ memory cells have a huge 
increase 10 days in immunized mice, eventually declining. CD4+ memory cells do not present 
major differences between non immunized and immunized mice. Cells were quantified by 
Fluorescence Activated Cell Sorting (FACS). A pool of cells from the three animals within the 
same group was analysed. Cell population is defined as percentage, being control (cell populations 
of naïve mice) stipulated as 100%.  
 
In spleens of pb36p- immunized mice, 10 days after immunization, both CD8+ 
and CD4+ memory cells suffer minor increases (Fig. 3.6), compared to naïve 
mice. CD8+CD44highCD62Llow cell population remains stable at further time 
points (1 and 6 months) in immunized mice (Fig. 3.6).  However, 
CD4+CD44highCD62Llow cell population present a huge increase, being 150% 
superior to what is observed in naïve mice. DATA FOR 6 MONTHS. 
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Figure 3.6. Memory CD8+ and CD4+ in spleen of naïve and pb36p- immunized mice. Memory 
T cells in spleens of 50,000 pb36p- sporozoites immunized BALB/c mice (n=3 per group) were 
assessed 10 days, 1 month and 6 months after immunization. CD8+ memory cells present a small 
increase 10 days in immunized mice, remaining stationary at later time points. CD4+ memory cells 
do not present major differences between non immunized and immunized mice 10 days later, but a 
huge increase is observed 1 month after immunization. Cells were quantified by FACS. A pool of 
cells from the three animals within the same group was analysed. Cell population is defined as 
percentage, being control (cell populations of naïve mice) stipulated as 100%.  
 
The initial site of induction of memory T cells resident in the liver is unclear. 
While some defend it is in the liver itself, others claim they are induced on a 
draining lymph node, migrating to the liver upon sporozoite challenge (reviewed 
in Krzych, 2005). So, we also assess memory T cells in lymph nodes of non 
immunized and pb36p- immunized mice, 10 days after immunization. No striking 
differences are observed in memory CD8+ and CD4+ T cells for each condition 
studied (Fig. 3.7). As so, we decided not to analyse memory populations at later 
time points in these organs.  
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Figure 3.7. Memory CD8+ and CD4+ in lymph nodes of naïve and pb36p- immunized mice. 
Memory T cells in lymph mnodes of 50,000 pb36p- sporozoites immunized BALB/c mice (n=3 
per group) were assessed 10 days after immunization. No striking differences were observed in 
both CD8+ and CD4+ memory cells between non immunized and immunized mice. Cells were 
quantified by FACS. A pool of cells from the three animals within the same group was analysed. 
Cell population is defined as percentage, being control (cell population of counter parties’ naïve 
mice) stipulated as 100%.  
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3.2.4.2. Memory B cells do not suffer an increase following pb36p- 
immunization in BALB/c mice 
 
Memory B cells have scarcely been studied in immunization regarding liver stage 
of malaria. In RAS immunizations, nothing is known concerning this cell 
population behaviour. However, it has been proposed that they play a prominent 
role in immunization with adenoviruses and recombinant vaccinia virus 
expressing malaria antigen P. yoelii CSP (Bruña-Romero, 2001).  To observe if 
memory B cells are increased after pb36p- immunization, we quantified them by 
FACS, in the same organs (liver, spleen and lymph nodes) and time points (10 
days, 1 month and 6 months) as done for memory T cells. Memory B cells were 
defined as CD19+CD27high (Fecteau, 2003). After 10 days, no difference in 
memory B cell populations is observed in non immunized and pb36p- immunized 
mice (Fig. 3.8), in all organs analysed. Memory B cells were also quantified 1 and 
6 months after immunization in liver and spleen of both unimmunized and pb36p- 
immunized mice. Again, no differences were observed between naïve and 
immunized mice (histograms are similar to those on Fig. 3.8, so we decided not to 
include them, since they would not provide further essential data). CONFIRM 
FOR 6 MONTHS 
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Figure 3.8. Memory B cells in liver, spleen and lymph nodes of naïve and pb36p- immunized 
mice. Memory B cells in (A) liver, (B) spleen and (C) lymph mnodes of 50,000 pb36p- 
sporozoites from naïve (filled histograms) and immunized (open histograms) BALB/c mice (n=3 
per group) were assessed 10 days after immunization. Memory B cells were defined as 
C19+CD27high (subpopulation defined as M1). No striking differences were observed in B memory 
cells between non immunized and immunized mice, in all organs analysed. Cells were quantified 
by FACS. A pool of cells from the three animals within the same group was analysed.  
 
3.3. Conclusions 
 
 
It is now possible to consider a comparative study of the intrahepatocytic 
development and the mechanism(s) of immunity invoked by different GAS and 
RAS. Like GAS, RAS sporozoites invade liver cells, although trophozoite 
development is arrested at a later stage and produces a visible PV compared to 
pb36p- sporozoites. Moreover, RAS-infected hepatocytes persist in culture longer 
than their GAS-infected counterparts, which, in the case of pb36p- parasites, 
results from their failure to prevent the host cell from entering apoptosis. 
Plasmodium sporozoites have the ability to prevent host cells from entering 
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apoptosis during intrahepatic development, to avoid their elimination (Leirião, 
2005; van de Sand, 2005). pb36p- sporozoites, in turn, are severely impaired in 
protecting hepatocytes from apoptosis, these cells being eliminated from the liver 
very early during parasite development (van Dijk, 2005). Host cell apoptosis has 
also been shown at early stages during RAS development (Leirião and Mota, 
2005). Although RAS populations provoke apoptosis to a greater degree than WT 
sporozoites, they do so to a significantly lower degree than pb36p- sporozoites. 
Accordingly, high levels of procaspase-3, the precursor of active caspase-3 which 
plays a prominent role in promoting apoptosis, are detected in HepG2 cells 
infected by both types of attenuated parasites, but not in WT infected cells.  We 
also determined in vivo the persistence of RAS and pb36p- infected hepatocytes in 
whole liver extracts of BALB/c mice by using real-time PCR for liver parasite 
load detection/quantification. Our results confirm the significantly more rapid 
clearance of pb36p- parasitized hepatocytes within 6 hours after infection 
compared to RAS-infected hepatocytes, similarly to what occurs in vitro. One 
week after immunization, similar low parasite loads of both attenuated parasites 
infected hepatocytes are detected.  
The differing biological characteristics of RAS and GAS described here suggest 
that the immune responses elicited by RAS and GAS could be different. 
Presentation of parasite antigens in the context of host cell apoptosis has recently 
been shown as an alternative mechanism involved in the induction of protective 
immunity by RAS (Leirião and Mota, 2005). As apoptosis of pb36p- infected 
hepatocytes was also detected in vivo, it might well be that host-cell apoptosis is 
associated with the ability of pb36p- sporozoites and other GAS to induce 
protective immune responses and needs further investigation. Since apoptotic 
infected-hepatocytes can provide a huge array of antigens to professional antigen 
presenting cells, like dendritic cells, (Leirião and Mota, 2005), one can consider 
that the protective effect mediated by pb36p- immunization might be at least 
partially initiated by these apoptotic infected hepatocytes.   
Immune responses against RAS are complex and involve both cell-mediated and 
humoral immunity (reviewed in Morrot, 2004 and Tsuji, 2003). One can only 
speculate about possible immune mechanisms that may lead to the protection 
induced by pb36p- against both homologous and heterologous species. Unlike 
RAS, which immune response in mice is well studied and documented (Doolan, 
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2000), the features that lead to pb36p- induced protection are still unknown (van 
Dijk, 2005), as well as for other GAS parasites (Mueller, 2005; Mueller and 
Camargo, 2005). Whether pb36p- induced immunity is dependent or not on CD8+ 
T cells, IFN-γ, CD4+ T cells, IL-12, NK cells and nitric oxide as seen for RAS 
(Doolan, 2000; Sedegah, 2002) in different genetic backgrounds remains to be 
elucidated. Our preliminary data points that pb36p- protection is dependent, like 
in RAS, of IFN-γ, but also of γδ T cells, which are known to not exert any effect 
on P. yoelii RAS-mediated protection (McKenna, 2000), suggesting therefore that 
some striking differences regarding the immune responses evoked by these two 
different live-attenuated parasites may occur. However, more detailed 
experiments must be undertaken to fully access all immunological features needed 
for pb36p- mediated protection and eventual differences when compared to RAS 
induced immunity. 
As seen for RAS, pb36p- immunizations induce a huge increase of 
CD8+CD44highCD62Llow memory T cells in the liver (Guebre-Xabier, 1999) 10 
days after immunization, fading at 1 month and barely detectable 6 months later. 
This subset of CD8+ T cells most probably is responsible for the long-lasting 
protective effect of pb36p- sporozoites described in the previous chapter. On 
contrast, memory T cells in the spleen of RAS immunized mice present no 
phenotypic differences when compared to counterparts from naïve mice up to 6 
months (Guebre-Xabier, 1999). However, our preliminary data shows that 
CD4+CD44highCD62Llow memory T cells in the spleen of pb36p- immunized mice 
increase at later time points after immunization, reaching values nearly three-fold 
higher. One could say that this is in agreement with the previous data, supporting 
that pb36p- and RAS immunizations are mediated through different mechanisms. 
Nonetheless, this experiment was done in a different mouse strain (BALB/c mice) 
than the one used in previous studies (Guebre-Xabier, 1999) and, moreover, it was 
only performed once. Memory T cells populations in lymph nodes in pb36p- 
immunized mice 10 days later do not suffer any considerable change. 
Furthermore, memory B cells in all organs analysed in pb36p- immunized mice 
show no differences from naïve mice up to 6 months after immunization. 
Nevertheless, only preliminary studies were performed and further analysis 
regarding pb36p- immune memory cells using both mouse strains (BALB/c and 
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C57BL6) must be performed so feasible data and final conclusions may be 
accomplished. 
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                   pbcrmp- AS POTENTIAL GAS BASED VACCINES FOR MALARIA 
4.1. Introduction 
 
Intracellular parasites are able to manipulate the host cell pathways into their own 
benefit, making them successful pathogens (reviewed in Nyalwhide, 2003). 
Nevertheless, these mechanisms are poorly known and understood for 
Plasmodium parasites, especially in the liver stage. In fact, our group was the first 
to elucidate one strategy maneuver performed by Plasmodium parasites during 
intrahepatocytic development in order to survive, the manipulation of apoptosis of 
infected cells (Leirião, 2005). In the last decade, several genetic tools for the study 
of malaria parasite biology were developed. Transfection systems for this haploid 
unicellular organism are now available, for human and animal Plasmodium spp, 
providing insight into the regulation of gene expression and elucidating the 
function of proteins by disrupting, modifying or replacing the genes encoding 
them. These genetic tools, added to the information now available of the P. 
falciparum genome, represent an important breakthrough for malaria research, 
contributing significantly to the understanding of the hugely complex biology of 
this parasite. Their potential is vast, since more rational approaches to vaccine and 
drug design can be achieved, by altering the parasite genome (Koning-Ward, 
2000). Intracellular development is essential for Plasmodium in the vertebrate 
host and, consequently two features are crucial for this parasite: invasion and 
adhesion. Using the recently genetic approaches to search for Plasmodium 
proteins containing motifs implicated in invasion or adhesion, a new family of 
genes was identified, pbcrmp (Plasmodium berghei cysteine repeat modular 
protein), consisting in 4 members, pbcrmp1-4, with homologues in P. falciparum 
(Thompson, submitted). pbcrmp1 and pbcrmp2 are transcribed in mature blood-
stage parasites, while pbcrmp3 and pbcrmp4 are only transcribed in gametocytes. 
Furthermore, in the mosquito stage, pbcrmp1 and pbcrmp2 are transcribed in 
sporulating oocysts. pbcrmp2 is also transcribed in sporozoites. pbcrmp parasites 
showed normal growth rates and formed ookinetes both in vitro and in vivo. 
Interestingly, sporozoites lacking pbcrmp1 and pbcrmp2 genes (pbcrmp1- and 
pbcrmp2-) are not able to efficiently invade mosquito salivary glands, most 
remaining in the haemolymph. On the other hand, parasites whose pbcrmp3 or 
pbcrmp4 genes were disrupted (pbcrmp3- and pbcrmp4-) are severely impaired in 
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disrupting the oocyst’s membrane being scarcely found in haemolymph and never 
in salivary glands (Thompson, submitted; K. D. Augustijn, personal 
communication). Thus, pbcrmp parasites are not able to transmit from the vector 
to the host, since they never reach salivary glands. It is anticipated that pbcrmp 
family members can mimic the structure of Tumor Necrosis Factor Receptors 
(TNFR), which would mean that Plasmodium parasites would be able to bind to 
host immune molecules and thereby modify the course of the immune response 
(Thompson, submitted). Nevertheless, this remains to be confirmed 
experimentally.   
We decided to extract pbcrmp3- and pbcrmp4- directly from oocysts and see if 
this attenuation presented a particular phenotype in the hepatic stage.  We 
observed that pbcrmp3- and pbcrmp4- sporozoites develop normally inside 
oocysts in mosquitos’ midgut like WT do. Nevertheless, pbcrmp3- and pbcrmp4- 
mature oocysts are still observed in midguts on day 18 after infective blood meal, 
unlike WT.  
To efficiently reach the liver, sporozoites need to be motile. Since they possess no 
cilia or flagella, they do so in a substrate-dependent manner, named gliding 
motility. This allows them, once in the liver, to migrate through several cells 
(hepatocytes and Kupffer cells), a crucial step which will permit an efficient 
infection (Mota, 2002; Mota, 2001). Our results show that pbcrmp3- and 
pbcrmp4- sporozoites extracted from oocysts are able to glide, migrate through 
several hepatocytes and infect a final one for further development. However, 
pbcrmp3- and pbcrmp4- intrahepatic development lead to small and aberrant-
shape EEFs, although these are found in similar number compared to WT control, 
namely EEFs derived from WT sporozoites from salivary glands. 
Recently, it has been shown P. berghei sporozoites which suffered genetic 
modifications are as efficient as radiation-attenuated sporozoites in immunization 
against malaria (Mueller, 2005; Mueller and Camargo, 2005; van Dijk, 2005). 
Importantly, these parasites are severely impaired in intrahepatocytic 
development, making them unable to progress to erythrocytic stages and, 
consequently, they do not cause disease, making them ideal candidates for a GAS 
based vaccine. Since pbcrmp3- and pbcrmp4- sporozoites also present an 
impaired development inside hepatocytes, we decided to evaluate their 
immunization potential. Both BALB/c and C57BL6 mice were immunized with 
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either pbcrmp3- and pbcrmp4- oocysts-derived sporozoites, according to regimens 
proved efficacious using pb36p- immunizations in these mouse strains. Both 
pbcrmp3- and pbcrmp4- oocysts-derived sporozoites immunizations failed 
completely in conferring protection to all mice tested, confirming therefore that 
these attenuated parasites are not suitable candidates for a GAS-based malaria 
vaccine. 
This chapter provides our results concerning the role of pbcrmp in parasite-host 
interactions and development, and is the first study regarding these deficient 
parasites in liver stage. Determining the role of this family may not only shed 
light on its mechanisms of infection but also provide potential new targets for 
therapy. 
 
4.2. Results 
 
4.2.1. pbcrmp3- and pbcrmp4- sporozoites develop normally inside 
oocysts 
 
When an anopheline feeds on an infected host, gametes fertilization occurs in the 
midgut. The resulting zygote, known as ookinete, will penetrate the midgut 
epithelium of the mosquito and continues its sporogonic development as an 
encapsulated oocyst attached to the epithelium. As described, a full grown oocyst 
is a spherical cell with 30-40 µm in diameter, limited by a plasma membrane and 
a thick capsule. It contains numerous dividing nuclei and cytoplasmatic 
membranes. Sporozoites will begin to fill oocysts days 10-12 after infective blood 
meal (Sherman, 1998). Upon extraction of oocysts, pbcrmp3- and pbcrmp4- 
sporozoites could be observed in light microscope, looking similar to WT salivary 
glands or haemolymph sporozoites (K. D. Augustijn, personal communication). 
So, we hypothesized that this attenuation in P. berghei could lead to deficient 
oocysts, presenting morphological differences which could be responsible for the 
differences observed between WT, pbcrmp3- and pbcrmp4- parasites. In order to 
confirm so, we extracted guts from WT, pbcrmp3- and pbcrmp4- infected 
mosquitoes (~5 guts per parasite type) at days 10 and 18 after infective blood 
meal and, using Electron Microscopy, checked for any differences between WT 
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and attenuated parasites oocysts. At day 10 after blood meal, for either WT or 
deficient parasites, we observed several oocysts in the external surface of 
mosquitoes gut. Like in WT, pbcrmp3- and pbcrmp4- oocysts were still in the 
formation process, containing already various nuclei, which would give rise to 
sporozoites (Fig. 4.1A-C, respectively). No morphological differences between 
WT and attenuated parasites oocysts were detected.  P. berghei sporozoites 
usually leave oocysts around day 14, and the vast majority of them are found in 
salivary glands day 15-16 onwards. At day 18 post infection, we observe almost 
none oocyst in WT infected mosquitoes, and those observed had very few nuclei 
and, mostly probably, had suffered melanization (Fig. 4.1D). Melanization is a 
standard defense mechanism for insects against microbial and parasitic invaders, 
leading to their destruction (Sherman, 1998). On the other hand, at the same time 
post infection, many pbcrmp3- and pbcrmp4- oocysts were still found, and full of 
mature sporozoites (Fig. 4.1E-F, respectively), looking structural-like WT P. 
berghei sporozoites found in guts days 12-13 after infective blood meal have been 
previously described (Sherman, 1998; Vanderberg, 1967). This leads to conclude 
that the attenuation done in pbcrmp3- and pbcrmp4- parasites does not induce any 
morphologically changes which render them unable to breach oocysts but, almost 
certainly, acts in some molecular pathway, strongly impairing their ability to burst 
oocysts and migrate to the salivary glands. 
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Figure 4.1. pbcrmp3- and pbcrmp4- mature oocysts are still found in mosquitoes gut 18 days 
after infective blood meal. WT (A), pbcrmp3-(B) and pbcrmp4-(C) oocysts are found in 
mosquitos’ guts 10 days after infective blood meal. Oocysts rely on the external part of the gut, 
between mosquito epithelium (mo) and haemocoel (h). Several nuclei (n), from which sporozoites 
will derive, can be observed. No morphological changes are observed between pbcrmp3- and 
pbcrmp4- oocysts when compared to their WT counterparts At day 18 post infection, very few WT 
oocysts were observed (D), and those which still remain in the gut, present very few nuclei and 
most probably are melanized.  Per turn, several pbcrmp3- and pbcrmp4- mature oocysts are still 
found in gut at this time (E and F, respectively), full of sporozoites (sp). These attenuated 
parasites, unlike WT, are not able to breach oocysts membrane and, therefore, to migrate to 
salivary glands. (bar 5µm). 
 
  
4.2.2. pbcrmp3- and pbcrmp4- sporozoites are able to glide and to 
migrate through several hepatocytes  
 
WT sporozoites have the ability of gliding, which they use as a motility 
mechanism, characterized by spiral movements across the substrate that propel the 
parasite forward (Mota, 2002; Mota, 2001). While executing this process, they 
leave a trail of CSP behind. This last feature has been routinely used to detect and 
quantify Plasmodium sporozoites motility. After incubating pbcrmp3- and 
pbcrmp4- sporozoites (extracted from oocysts 21 days after infective blood meal) 
in gelatin-coated coverslips (6,000 sporozoites per coverslip), they were stained 
for CSP (which became attached to gelatin). pbcrmp3- and pbcrmp4- sporozoites 
performed several spiral trails (around 2-6 per sporozoite), as in WT salivary 
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glands matched control. These results show that pbcrmp3- and pbcrmp4- 
sporozoites are motile as WT sporozoites. 
As mentioned before, Plasmodium sporozoites migrate through several cells 
before the invasion of a last one. This feature is dependent on sporozoite motility 
(Mota, 2002; Mota, 2001). Thus, we decided to check whether pbcrmp3- and 
pbcrmp4- sporozoites are able to migrate through cells as WT sporozoites. WT 
salivary glands and pbcrmp3- and pbcrmp4- oocysts sporozoites (extracted from 
mosquitoes 21 days after infective blood meal) were incubated 2 hours with 
HepG2cells (seeded 24 hours before in coverslips in 24 wells plate), in the 
presence of a cell-impermeant fluorescent tracer, rhodamine-dextran (6,000 
sporozoites per coverslip). Sporozoites enter and leave hepatocytes by disrupting 
their membrane, which is rapidly repaired, while in infection, sporozoites entry 
occurs with formation of a parasitophorous vacuole surrounding the parasite. 
Thus, it is possible to determine which cells were traversed, using rhodamine-
dextran, a tracer which enters the cell immediately after membrane disruption, and 
becomes trapped inside after its repair (Mota, 2002; Mota, 2001). Rhodamine-
dextran uninfected positive cells, which were those traversed by sporozoites, were 
quantified (Fig. 4.2). Surprisingly, these two attenuated parasites lead to distinct 
results. Both are able to efficiently perform migration. However, pbcrmp3- 
sporozoites present a significant decrease in traversed cells compared to WT 
sporozoites (P=0.003), while pbcrmp4- sporozoites significantly migrate through 
more cells than their WT counterparts (P=0.03).  
 
 
 
 74 
                   pbcrmp- AS POTENTIAL GAS BASED VACCINES FOR MALARIA 
0
10
20
30
40
WT pbcrmp3- pbcrmp4-
%
 tr
av
er
se
d 
ce
lls
*
*
WT pbcrmp3- pbcrmp4-
%
 tr
av
er
se
d 
ce
lls
%
 tr
av
er
se
d 
ce
lls
%
 tr
av
er
se
d 
ce
lls
 
Figure 4.2. pbcrmp3- and pbcrmp4- sporozoites are able to migrate through cells as WT 
sporozoites, although present different migration rates. HepG2 cells were incubated with either 
WT salivary glands sporozoites, pbcrmp3- or pbcrmp4- oocysts sporozoites. Using a cell-
impermeant fluorescent tracer, rhodamine-dextran, the migration rate of these attenuated parasites 
was quantified. pbcrmp3- sporozoites have a significant decrease in their migration ability 
compared to WT sporozoites. Contrastingly, pbcrmp4- sporozoites migrate through more cells 
significantly compared to WT sporozoites. Traversed cells are expressed as the mean ± the 
standard deviation for each coverslip. * P<0.05. 
 
 
4.2.3. pbcrmp3- and pbcrmp4- sporozoites are not able to fully develop 
into mature EEFs 
 
Our results show that pbcrmp3- and pbcrmp4- sporozoites are able to move and 
migrate through host cells. In order to reach the next step, WT sporozoites need 
develop into EEFs once inside the hepatocyte, forming, trophozoites, schizonts 
and, at a later stage, merozoites, which will reach the bloodstream. Thus, we 
decided to determine whether pbcrmp3- and pbcrmp4- sporozoites were able to 
develop regular-form EEFs. pbcrmp3- and pbcrmp4- oocysts sporozoites, as well 
as a control (WT salivary glands sporozoites) were incubated for 24 hours with 
HepG2 cells (as done for migration essays; 6,000 sporozoites per coverslip), and 
the number of EEFs was quantified (Fig. 4.3).  
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Figure 4.3. pbcrmp3- and pbcrmp4- sporozoites have the same infection rate in HepG2 cells 
than WT sporozoites.  HepG2 cells were incubated with either WT salivary glands sporozoites, 
pbcrmp3- or pbcrmp4- oocysts sporozoites. 24 hours later, infection was quantified. pbcrmp3- and 
pbcrmp4- parasites present no difference in infection rate when compared to WT matched control. 
Infected cells are expressed as the mean ± the standard deviation for each coverslip.  
 
No major differences were observed in the level of infection regarding WT 
salivary glands and these attenuated oocysts sporozoites, being quite similar. 
However, attenuated parasites EEFs are quite small and present aberrant forms, 
when compared to WT EEFs (Fig. 4.4), similar to what occurs with pb36p- 
sporozoites (van Dijk, 2005). 
 
A B C
 
 
Figure 4.4. pbcrmp3- and pbcrmp4- infection lead to small and aberrant-like EEFs in HepG2 
cells.  Although the level of infection of pbcrmp3- and pbcrmp4- in HepG2 cells is quite similar to 
WT, EEFs derived from both attenuated parasites have a smaller compared to WT and possess 
abnormal forms. WT EEFs (A) are quite large and present a normal spherical form, contrasting 
with pbcrmp3- (B) and pbcrmp4- (C) EEFs. Fluorescence pictures of EEF (green), hepatocyte 
nucleus (blue), DNA labeled with DAPI. (bar 5µm). 
 
However, and unlike what happens with pb36p- infections, the level of infection 
of pbcrmp3- and pbcrmp4- in HepG2 cells is quite similar to WT. Thus, the small 
size observed of these attenuated parasites could simply mean that they had a 
delay in intrahepatic development. As so, we decide to check the intrahepatocytic 
stage of these deficient parasites at later time points, to confirm whether or not 
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they could still fully develop. As done previously, HepG2 cells were infected with 
WT salivary glands and pbcrmp3- and pbcrmp4- oocysts sporozoites, and 
incubated at 24, 48 and 56 hours post infection. WT parasites, as expected, 
develop normally, their size increasing through the time (Fig. 4.5A-C). At 56 
hours, WT merozoites are easily observed within the Parasitophorous Vacuole 
(Fig. 4.5C). Differently, no change in size is observed from 24 to 56 hours in 
pbcrmp3- and pbcrmp4- parasites (Fig. 4.5D-F and G-I, respectively). EEFs 
originated by these attenuated parasites possess a small size and anomalous form, 
which is maintained up to 56 hours post infection.  
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Figure 4.5. pbcrmp3- and pbcrmp4- intrahepatic development is already impaired at 24 hours 
post infection.  WT parasites show normal development in EEFs at 24 hours post infection (A), 
increasing successively size at 48 hours (B) and 56 hours (C) post infection. pbcrmp3- (D-F) and 
pbcrmp4- (G-I), at the same time points, correspondingly, do not show any difference in size 
throughout all the infection, remaining small and with irregular shapes. Fluorescence pictures of 
EEF (green), hepatocyte nucleus (blue), DNA labeled with DAPI. (bar 5µm). 
 
 
4.2.4. pbcrmp3- and pbcrmp4- sporozoites are not able to confer 
protection to mice upon challenge with WT sporozoites 
 
Immunization with radiation-attenuated sporozoites (RAS), which are still able to 
invade cells and form a parasitophorous vacuole, but do not develop into mature 
EEFs, leads to full protection against a consequent infection (Luke, 2003; 
Hoffman, 2000). More recently, genetically-attenuated sporozoites (GAS) in P. 
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berghei, which are also impaired in liver development but are capable of 
conferring immunity to mice against challenge with infectious sporozoites have 
been described (Mueller, 2005; Mueller and Camargo, 2005; van Dijk, 2005). 
Since pbcrmp3- and pbcrmp4- parasites present an in vitro infection phenotype 
similar to the one observed with RAS and other GAS, we decided to confirm if 
these two attenuated parasites could be used as a vaccine strategy against the pre-
erythrocytic stage of malaria, 
Balb/c and C57BL6 mice were immunized intravenously (i.v.) with pbcrmp3- and 
pbcrmp4- sporozoites accordingly to regimens proven effective to other GAS 
(single dose of 50,000 attenuated sporozoites for BALB/c and 
50,000/20,000/20,000 attenuated sporozoites, weekly apart, for C57BL6). Mice 
immunized with pbcrmp3- and pbcrmp4- sporozoites were checked before 
challenge for blood stage parasites, and all were negative, which confirms the 
inability of these attenuated parasites to develop patent blood stage infection. 
Mice were challenged i.v. with 10,000 WT P. berghei sporozoites per mouse 10 
days after last immunization. Parasitemia was determined by thin smearing tail 
blood from the infected mice daily day 4 after infection onwards (Fig. 4.6).  
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Figure 4.6. pbcrmp3- and pbcrmp4- immunized C57BL6 mice develop blood-stage 
parasitemia similarly to naïve control.  C57BL6 mice immunized with pbcrmp3- (-■-) and 
pbcrmp4- (-▲-) are not protected against posterior challenge with WT infectious sporozoites, and 
develop a patent blood stage infection similar to the one observed in naïve challenged mice (-♦-). 
 
All mice immunized with pbcrmp3- and pbcrmp4- sporozoites developed 
parasitemias similar to the ones observed in the control groups used (both Balb/c 
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and C57Bl6). Data regarding development of blood stage establishment 
parasitemia in BALB/c immunized mice is similar to the one observed in C57BL6 
mice and we consider redundant to show it.  
Thus, pbcrmp3- and pbcrmp4- sporozoites are not able to confer protection 
against challenge with infectious sporozoites (Table 4.1), and, therefore, do not 
present any immunization potential to be used as an experimental GAS-based 
malaria vaccine. 
 
TABLE 4.1. Immunization with pbcrmp3- and pbcrmp4- sporozoites do not protect 
BALB/c and C57BL6 mice against a subsequent infection with WT sporozoites 
No. protected  (no. challenged) Mouse 
Strain 
Immunizationa, 
pbcrmp3-/ pbcrmp4- 
× 1,000 
Challengeb, 
× 1,000 Control pbcrmp3- pbcrmp4-
BALB/c 50 10 0 (6) 0 (6) 0 (6) 
C57BL6 50/20/20 10 0 (6) 0 (6) 0 (6) 
 
a Groups of mice were immunized i.v. with one dose of pbcrmp3- and pbcrmp4- sporozoites 
isolated from different mosquitoes batches. Multiple immunizations with pbcrmp3- and pbcrmp4- 
sporozoites were performed with weekly intervals.  
b Mice were challenged with WT P. berghei sporozoites, isolated from different mosquitoes 
batches 10 days after last immunization. Parasitemias were monitored by giemsa staining/blood 
smear. All mice become positive on day 4 after challenge. 
 
4.3. Conclusions 
 
In this work, we characterized two genetically modified P. berghei parasites, 
pbcrmp3- and pbcrmp4-, unable to express proteins containing motifs implicated 
in invasion or adhesion (P. berghei cysteine repeat modular protein). These 
attenuated parasites are unable to breach oocysts membrane, never being found in 
mosquitoes salivary glands and, therefore, unable to be transmitted to the 
mammalian host (Thompson, submitted). Using Electron Microscopy, we 
observed that pbcrmp3- and pbcrmp4- oocysts have a normal structure similarly 
to what as been described to WT oocysts (Vanderberg, 1967), which lead us to 
think their inability to burst oocysts membrane rely in a molecular pathway(s) 
which is(are) strongly impaired due to the attenuation performed in these 
parasites. 
The hepatic stage of malaria infection in vitro was also studied, to observe if these 
deficient parasites present an unusual phenotype compared to WT sporozoites. 
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Using the hepatoma cell line HepG2, we demonstrate that these mutant 
sporozoites were able, as WT sporozoites to perform the known features which 
lead to hepatocytes invasion and infection: they are motile and migrate through 
several cells before reaching one for further development. pbcrmp3- parasites 
present a lower rate of hepatocyte traversion, which is not reflected in their 
infectivity (these disruptants parasites rate of EEF formation is similar to matched 
control). pbcrmp4- parasites behave differently, presenting a higher rate of 
migration through cells. That may be due to the fact of PbCRM 4 protein be a 
large protein (687 kDa), and its disruption originate lighter (and, consequently, 
swifter) parasites and, as so, able of migrate throughout more cells (J. Thompson, 
personal communication). However, the number of EEFs 24 hours post infection 
is quite similar to the WT salivary glands. 
Nevertheless, both pbcrmp3- and pbcrmp4- are not able to form regular EEFs. It 
was noticed impairment in the growth of these attenuated parasites EEFs. Longer 
time points post infection were also observed (48 and 56 hours), to determine 
whether there was a real impairment in these deficient parasites, or simply a delay 
in intrahepatic development. We confirmed that these deficient parasites can 
infect HepG2 cells, but impairment in EEF growth was noticed. Even at longer 
time-points, these EEFs do not show a significant increase in size. We assume 
these parasites lack the ability to mature once inside the hepatocytes, and arrest 
development at a very early stage post infection.  
It is known that immunization with RAS and GAS can confer protection against 
posterior challenge with infectious sporozoites (Mueller, 2005; Mueller and 
Camargo, 2005; van Dijk, 2005; Hoffman, 2000). Since pbcrmp3- and pbcrmp4- 
parasites are also arrested during intrahepatic development like RAS and GAS, we 
considered the hypothesis of they could confer protection as well. Regrettably, 
pbcrmp3- and pbcrmp4- parasites failed to confer protection against challenge 
with WT P. berghei, These deficient parasites may simply not have the same 
potential as other GAS studied (uis3-, uis4- and pb36p-), or maybe sporozoites 
from oocysts are just too immature to confer protection. We intended to use γ 
irradiated WT oocyst sporozoites (an irradiator was not available in the facilities 
where these experiments were performed) in immunization assays, to investigate 
its ability or not of inducing protection against malaria in mice. If so, it will be 
pointless to carry on these immunizations with pbcrmp3- and pbcrmp4- parasites. 
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Otherwise, if protection will be achieved using WT RAS from oocysts, lack of 
maturation of sporozoites is not what is abrogating the protection using pbcrmp3- 
and pbcrmp4- parasites and higher doses and/or other regimens of immunization 
should be tried. 
 The crucial question now is if pbcrmp3- and pbcrmp4- sporozoites are or not able 
to develop due to simple lack of maturation, since they do not reach the salivary 
glands. Some authors considered that this feature may be essential for maturation 
and consequently, to confer infectivity to Plasmodium sporozoites (Vanderberg, 
1975). The answer to this question will, with no doubt, contribute for a better 
understanding of the biology of Plasmodium-host interactions that until now are a 
“black hole” in our knowledge. This work is an example how genetic 
manipulations in Plasmodium can help to understand the several and complex 
mechanisms that underlie this parasite’s genome.  
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There are no doubts that novel intervention strategies are required to control 
malaria. For decades, since its discovery (Nussenzweig, 1967), immunization with 
RAS has been considered the golden standard for a malaria preerythrocytic 
vaccine. So far, they conferred sterile protection to 93% of vaccinees (human, 
non-human primates and mice), making them the most promising vaccine of all 
which are being (or have been) developed (Luke, 2003). Due to its immunization 
potential, the immune response elicited by these attenuated parasites has been 
widely studied and described (Berenzon, 2003; Doolan, 2000; Guebre-Xabier, 
1999; Schofield; 1987). However, large scale immunization with RAS was 
considered unfeasible and clinically, technically and logistically impracticable 
since sporozoites had to be delivered alive through mosquito bite or intravenously 
in order to immunize large numbers of individuals (Luke, 2003). Shortly after the 
discovery of the immunization potential of RAS, scientists have discovered the 
potential of genetic manipulation: the DNA recombinant era was born. 
Performing genetic engineering seemed to be the answer for all major hurdles in 
medicine, including the synthesis of new vaccines, containing parts of genes 
which code for major virulent proteins of certain pathogens. Malaria vaccine was 
not excluded. Subunit vaccines against this disease were developed, but all failed 
in conferring sterile protection at the same level RAS did years before (reviewed 
in Hill, 2005). Even the leading candidate, RTS,S/AS02, containing the B cell 
epitope of CSP fused with the hepatitis B virus surface antigen only achieved 30% 
of protection, which faded rapidly in the following months (Alonso, 2004). The 
constant failures and disappointments in subunit vaccines against the 
preerythrocytic stage of malaria led some researchers to focus again on a P. 
falciparum RAS based vaccine (Luke, 2003). They are currently developing a 
vaccine using cryopreserved RAS, and studying the efficacy of this vaccine, in 
addition to overcome the major obstacles presented, meaning routes of 
administration, production of adequate sporozoites numbers and physical 
requirements (namely safety and potency), to achieve such a vaccine (Luke, 
2003). Nevertheless, this approach suffers from significant disadvantages, not 
least the question of safety and reproducibility because the amount of radiation 
that generates the attenuated state is strictly defined. Parasites that are 
underirradiated remain infectious, and those that are overirradiated do not induce 
protective immunity (Suhrbier, 1990). Recently, an alternative for RAS has been 
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found. Genetically attenuated sporozoites (GAS) that lack sporozoite specific 
conserved genes (uis3- and uis4-) that are apparently important for sporozoite 
development in the hepatocyte can induce significant or complete protective 
immunity in the P. berghei rodent model of malaria when different immunization 
protocols are used (Mueller, 2005; Mueller and Camargo, 2005). Like RAS, these 
attenuated sporozoites are nonreplicating and metabolically active during 
intrahepatocytic development. Moreover, since attenuation is done using genetic 
engineering, they do not require strict control of radiation dose as RAS do, 
making them more feasible for a vaccine based on attenuated sporozoites. 
In this study, we characterized three other P. berghei GAS, pb36p-, pbcrmp3- and 
pbcrmp4-, to assess their potential as an experimental vaccine against malaria. 
Our previous work has shown that pb36p- sporozoites are not able to fully 
develop after hepatocytes infection and, moreover, previous inoculations led to a 
huge reduction in parasites liver burden upon posterior challenge with infectious 
WT sporozoites (van Dijk, 2005). Here, we also observed that pbcrmp3- and 
pbcrmp4- parasites are arrested during intrahepatic development. Thus, since 
pb36p-, pbcrmp3- and pbcrmp4- parasites are strongly impaired in intrahepatic 
development like RAS and other GAS with proven immunization potential, we 
ought to confirm if they could also confer protection to mice against challenge 
with WT parasites. BALB/c and C57BL6 mice were immunized with pb36p-, 
pbcrmp3- or pbcrmp4- sporozoites. We observed that pb36p- sporozoites where 
able to protect both BALB/c and C57BL6 mice from later challenge with 
infectious WT parasites. BALB/c mice require only one single dose to be fully 
protected, while C57BL6 need three immunizations to achieve sterile protection. 
On the contrary, all mice immunized with pbcrmp3- or pbcrmp4- sporozoites 
develop a patent blood stage infection upon challenge with infectious WT 
sporozoites at the same level than naïve challenged mice.  
Since pbcrmp3- and pbcrmp4- sporozoites have no immunization potential, no 
further studies were done regarding these attenuated parasites. We focused next in 
characterizing pb36p- mediated protection and the mechanisms that could lead to 
such protection. Whenever possible, we establish comparisons between RAS and 
pb36p- induced protections and observed that, although many features are shared 
by both attenuated parasites, some differences were also observed. Like RAS, 
pb36p- confers full protection to two distinct mouse strains, BALB/c and 
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C57BL6. Moreover, like in RAS based immunizations, different immunizations 
regimens are required to confer protection to those different mouse strains 
(Chatterjee, 2001). Previous studies have shown that RAS immunity is stage 
specific (Clyde, 1975). Mice immunized with RAS sporozoites were not protected 
against posterior challenge with Plasmodium infected red blood cells. We 
observed the same phenotype using BALB/c mice immunized with either RAS or 
pb36p- sporozoites and challenged later with infected erythrocytes. Immunized 
mice developed a patent blood stage parasitemia like naïve challenged mice, 
showing no degree of protection, leading to conclude pb36p- induced protection is 
also stage-specific.  
Protection induced by these attenuated parasites is long lasting. BALB/c mice 
challenged with infectious sporozoites several times up to 18 months after last 
immunization were always protected. Moreover, BALB/c mice immunized with 
pb36p- using a prime plus 2 boosts regimen were found protected up to 6 months 
without any previous challenge. However, when those mice are re-challenged 12 
months after last immunization, some of them are no longer protected. RAS 
immunized mice in the same conditions, contrastingly, were always protected. 
Thus, BALB/c mice require no additional challenges to become fully protected up 
to 6 months. To achieve protection at longer time points, antigen presentation 
(through challenges) seems to be required, so the immune response against 
Plasmodium sporozoites can be maintained. Most likely, a source of antigens is 
necessary to keep the protective effect after 6 months. Berenzon and colleagues 
have shown that presence of antigen is needed to maintain the persistence of 
intrahepatic memory T cells (Berenzon, 2003), and, therefore, immunity against 
the parasite. An antigen depot in the liver would obviously re-stimulate the 
protective immune response and it may supplied either by undeveloped 
RAS/pb36p- parasites arrested in hepatocytes or through continuous challenges 
with WT sporozoites. P. berghei RAS can be found in livers of immunized mice 6 
months after immunization (Scheller, 1995), acting as a persistent source of 
antigens, at least, during that period. Moreover, when mice are treated with 
primaquine to eradicate these RAS persisting liver forms, protection is completely 
abrogated (Scheller, 1995), supporting that an antigen depot is in fact crucial for 
RAS based immunizations to be completely effective. Most probably, pb36p- 
parasites remain long enough in the liver, inducing the protection achieved 6 
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months after final immunization without the need of performing any additional 
challenge. The presence of pb36p- would elicit an immune response, strong 
enough to fully protect mice after 6 months without any other type of antigen 
presentation, and eventually, starts fading from this period onwards. Moreover, a 
higher number of challenges appear to be required to maintain full protection 
longer than 6 months in BALB/c mice, almost certainly acting synergistically with 
persistent pb36p- in the liver, thus eliciting a strong long lasting immune 
response. We have also shown that pb36p- has a higher apoptosis rate than RAS, 
being cleared in the liver sooner than RAS parasites. Most likely, these parasites 
would not last in the liver as long as RAS do in the same conditions, therefore 
exhausting sooner the supply of antigens and, consequently, the length of induced 
protection. Our results also show a decline in CD8+CD44highCD62Llow T cells 
(memory cells) in the liver from 10 days up to 6 months in pb36p- immunized 
BALB/c mice. As mentioned above, it has been shown that in RAS immunized 
C57BL6 mice, an antigen depot is necessary for maintenance of these CD8+ T 
memory cells (Berenzon, 2003). Although done in a different mouse strain, the 
results are quite similar, leading us to think that pb36p- induced immunity is 
maintained while these attenuated parasites remain in the liver (up to six months) 
and additional antigen presentation derived from challenges is required to achieve 
longer periods of sterile protection. Furthermore, intrahepatic memory CD8+ T 
cells in pb36p- immunized mice decrease with time, most probably due to 
exhaustion of antigen depot of these parasites in the liver. Therefore, as for RAS 
induced protection, pb36p- mediated immunity also relies in continuous antigen 
presentation, derived either from persisting attenuated parasites in the liver or, at a 
later stage, from WT parasites inoculated. Long lasting protection elicited by 
pb36p- is also observed in another mouse strain. pb36p- immunized C57BL6 mice 
are also protected against several challenges up to 6 months after last 
immunization, and 50% of these mice are still fully protected against a re-
challenge performed 12 months later. RAS immunized mice, in contrast, were 
always fully protected in these conditions. As in BALB/c mice, continuous 
antigen presentation must elicit a protracted immune response, which eventually 
declines, and lasting longer in RAS immunized mice most probably also due to 
pb36p- higher clearance in the liver. Even so, the length of this protection is quite 
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amazing for both mice strains studied, and for both types of attenuated parasites, 
strengthening their potential as a vaccination strategy against malaria. 
Nowadays, the development of a P. falciparum RAS based vaccine faces some 
hurdles, namely production of adequate quantities of sporozoites and 
administration through a route considered clinically practical (Luke, 2003). Thus, 
it is fundamental to determine the minimum quantity of attenuated sporozoites 
which can confer protection, since that will have serious implications in cost 
evaluation. Previous studies have shown that low immunizations doses of RAS 
(multiple doses of 10,000) can protect C57BL6 mice against a challenge with 
10,000 WT sporozoites (Jaffe, 1990). Our results confirmed these previous results 
and, furthermore, showed that protection can be achieved with even lower doses 
of either RAS or pb36p-. C57BL6 mice immunized with prime plus two boosts 
regimen with equal doses of 10,000 or 5,000 of either attenuated parasite were 
fully protected against a challenge of 10,000 WT P. berghei sporozoites. Using 
the same immunization protocol, we immunized C57BL6 with an even lower 
dose, 1,000 RAS or pb36p- sporozoites, and challenged them likewise with 
10,000 WT sporozoites. As some have already described (Jaffe, 1990), this dose is 
unable to protect C57BL6 mice against infection. Our results with RAS confirmed 
such, since all mice immunized this way developed blood stage infection. A 
strong delay (3 days) in the onset of blood stage parasitemia has been observed 
compared to naïve challenged mice, indicating some extent of protection, 
although obviously not enough to confer sterile protection. However, and most 
surprisingly, mice immunized similarly with pb36p- sporozoites achieved fully 
protection. Such difference is quite remarkable and clearly shows that pb36p- 
sporozoites require lower doses than RAS to attain similar level of protection. 
So far, mostly of immunizations using attenuated sporozoites have been 
performed either intravenously or through irradiated mosquitoes bite (Luke, 
2003). None of these is clinically accepted as a route of administration for a 
human vaccine. So far, public health measures state that a vaccine can only be 
administrated intramuscularly, subcutaneously or intradermally. Our studies show 
that all these routes conferred some extent of protection for either RAS or pb36p- 
sporozoites upon intravenous challenge with infectious parasites, as suggested by 
the delay on blood stage parasitemia onset in immunized mice. Furthermore, a 
proportion of sterile protection is achieved for both attenuated parasites using 
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intramuscular route and by RAS only in intradermally challenged mice. Previous 
studies concerning RAS immunized A/J mice intramuscularly showed similar 
results (Kramer, 1975). However, in the same study, mice immunized 
subcutaneously presented no protection, developing a patent blood stage infection 
as unimmunized challenged mice (Kramer, 1975). We assume that the 
discrepancy observed between such and our results derives from the fact of two 
distinct mouse strains have been used in these immunizations, leading to the 
differences observed. However, that remains to be elucidated. Contrastingly, 
another P. berghei GAS, uis3-, is able to confer full sterile protection to C57BL6 
when administered subcutaneously, using the same regimen (Mueller, 2005), 
suggesting that immune mechanisms elicited by uis3- differ greatly from those 
attained by either RAS or pb36p-. So far, to our knowledge, no studies regarding 
intradermal immunizations with RAS or other GAS have been done, being this the 
first study using this immunization route. However, these results are obtained by 
challenging with infectious sporozoites i.v. and not through the natural course of a 
malaria infection, the bite of an infected mosquito. Thus, to assess more 
realistically the efficacy of these routes, immunizations with pb36p- sporozoites 
were repeated, using all these clinically acceptable routes and mice were then 
challenged via mosquito bite. Immunized mice were shown to have a higher level 
of sterile protection, around 80% for all routes, which supports pb36p- parasites 
potential as an experimental vaccine against malaria. Unfortunately, none of these 
routes confer the same level of sterile protection as immunizations performed 
intravenously, which is undoubtedly desirable. Although at the moment these 
routes do not lead to complete protection, the results are quite encouraging and 
promising, strengthening the potential of a human live attenuated parasites-based 
vaccine.  
Our results show for the first time that protection elicited by attenuated 
sporozoites is not species specific. P. berghei RAS and pb36p- can confer 
protection to BALB/c and C57BL6 mice challenged with a different rodent 
Plasmodium species, P. yoelii, even achieving in some cases sterile protection (the 
later only observed in BALB/c so far). Cross-protection induced against one 
Plasmodium species by other different species has already been observed for the 
blood-stages of infection. Primary infection with P. chabaudi chabaudi AS 
infected erythrocytes led to protection against mortality and lower parasitemia 
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levels after a challenge with a lethal strain of P. yoelii (Legorreta-Herrera, 2004). 
Mice infected with blood stage P. berghei parasites and later re-infected with P. 
yoelii, P. vinckei and P. chabaudi parasitized erythrocytes show partial resistance 
against mortality (McColm, 1983; Jarra, 1985). In humans, there are similar 
evidences for this type of protection. Prior infections with P. malariae and P. 
vivax prevent the symptoms associated to subsequent P. falciparum infection, 
although not other forms of morbidity (Smith, 2001). Regarding Plasmodium liver 
stages of infection, it has been observed that, during treatment of neurosyphilis, 
previous infection with P. malariae sporozoites resulted in reduction of 
parasitemia levels and fever frequencies following secondary infection with P. 
falciparum sporozoites (Collins, 1999). However, there are no reports showing 
that immunization with attenuated parasites, including RAS, is able to elicit any 
type of cross-protection. So far, to the extent of our knowledge, immunization 
with P. falciparum RAS and subsequent challenge with P. vivax sporozoites has 
only been performed once, to a single subject, whom did not became protected 
(Hoffman, 2002). Our results show that the immune response elicited by both 
RAS and GAS P. berghei p36p- sporozoites also acts partially against another 
murine parasite, P. yoelii. Considering that BALB/c mice are 2,000 times more 
sensitive to P. yoelii than P. berghei sporozoites (Khan, 1991), the partial 
protection attained with pb36p- against P. yoelii sporozoites challenge is quite 
notable. One can only speculate about the mechanisms which are responsible for 
inducing cross-species protection. Most probably, CD8+ T cells are a key feature 
in this type of immunity. It has been reported that a cytotoxic T cell clone 
obtained from a BALB/c mouse immunized with P. yoelii irradiated sporozoites 
recognizes an epitope on both P. yoelii and P. berghei CSP (Weiss, 1992). When 
this clone is transferred to naïve mice, it confers protection against posterior 
challenge with either P. berghei or P. yoelii sporozoites, leading to believe that 
cross-species immunity elicited by RAS (and most likely also by pb36p- 
sporozoites) relies on CD8+ T cells.  
Apoptosis must also play a prominent role on cross-species protection. It is known 
that, in order to survive, Plasmodium sporozoites have the ability to prevent host 
cells from entering apoptosis during intrahepatic development (Leiriao, 2005; van 
de Sand, 2005). We have shown that pb36p- sporozoites, in turn, are severely 
impaired in protecting hepatocytes from apoptosis, these cells being eliminated 
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from the liver very early during parasite development. Host cell apoptosis has also 
been shown at early stages during RAS development (Leiriao and Mota, 2005) 
and we observed a similar phenotype, with a higher extent, during pb36p- 
intrahepatic growth. Since apoptotic infected-hepatocytes can provide a huge 
array of antigens to APC (e.g. dendritic cells) (Leiriao and Mota, 2005), one can 
consider that the protective effect mediated by pb36p- immunization against P. 
yoelii might be at least partially initiated by these apoptotic infected hepatocytes. 
P. berghei and P. yoelii have an average protein identity of 88.2% (Hall, 2005), 
which suggests that through apoptosis several conserved antigens common to P. 
berghei and P. yoelii would be presented to immune system, therefore eliciting an 
protective response strong enough to act against both parasite species. Since P. 
berghei and P. chabaudi have also a high average protein identity, 83.2% (Hall, 
2005), one might speculate this P. berghei attenuated sporozoite induced immune 
response might also exert a protective effect against infection with P. chabaudi 
sporozoites. Most likely, optimized immunization protocols, i.e., using other 
immunization protocols and/or higher doses of RAS or pb36p- sporozoites per 
immunization, might lead to complete sterile protection against P. yoelii and other 
murine Plasmodium species, and we are currently investigating those approaches. 
Immunization strategies using P. falciparum RAS have been considered 
impossible due to technical, clinical and logistical hurdles: route of 
administration, large quantities of sporozoites needed and regulatory, potency and 
safety requirements (Luke, 2003). However, some are pursuing this approach 
(Luke, 2003), which would be quite useful in a possible implementation of P. 
falciparum GAS immunization strategy. Orthologues of pb36p- in P. falciparum 
and P. vivax have already been described (Thompson, 2001), therefore being 
possible to perform this type of genetic modification in human parasites. 
Unfortunately, as observed in uis4- parasites (Mueller and Camargo, 2005), 
pb36p- sporozoites initiate a delayed blood in some mice, although at a lower 
frequency. GAS vaccine efficacy and safety could be improved by developing 
more complex GAS strains that lack multiple genes in a single parasite, as some 
defend (Matuschewski, 2006; Waters, 2005). There is a close paralogue of pb36p, 
pb36 that is also expressed in sporozoites (Thompson, 2001) and located directly 
adjacent to pb36p in the parasite genome. Improved levels of protection may be 
achieved by creating double mutants, like pb36-/pb36p- or uis3-/pb36p- parasites. 
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Each form of GAS must be evaluated for its immunization potential and the best 
single or combination one, taken forward to human trials.  
The characterization of pbcrmp3- and pbcrmp4- parasites intrahepatic 
development in the liver led us to think these two attenuated parasites could also 
be candidates for a GAS experimental vaccine. Like RAS and pb36p-, they arrest 
during liver development, never forming mature EEFs like WT sporozoites. 
Regrettably, this similarity is not reflected in their immunization potential. No 
protection is achieved with pbcrmp3- and pbcrmp4- parasites in either BALB/c or 
C57BL6 mice. pbcrmp3- and pbcrmp4- sporozoites were extracted from oocysts 
and, consequently never passed through the maturation stage in mosquito salivary 
glands, which some authors consider crucial to confer to sporozoites their 
infectivity (Vanderberg, 1975). So, the lack of protective effect demonstrated by 
pbcrmp3- and pbcrmp4- sporozoites could derive of their immature stage, not 
allowing an efficient infection in vivo, an essential step attenuated sporozoites 
must perform to confer immunity. However, that remains to be further 
investigated. The level of infection observed in pbcrmp3- and pbcrmp4- infections 
is quite similar to the one observed in the WT, which mean these attenuated 
parasites are able to efficiently inhibit apoptosis pathways as WT parasites do. 
The lack of apoptotic infected hepatocytes may also explain the deficiency on 
conferring protection of pbcrmp3- and pbcrmp4- sporozoites, but this ought to be 
confirmed. Nevertheless, although these attenuated parasites do not present any 
immunization potential, their phenotype in liver stage development is quite 
interesting and will provide undoubtedly new insights into parasite-host 
interactions. 
Our results clearly confirm the potential of pb36p- as an experimental vaccine 
against malaria, while pbcrmp3- and pbcrmp4- failed in achieve the same goal. 
Furthermore, pb36p- is able to confer long-lasting immunity and cross-species 
protection against P. yoelii. This protection can be achieved even with low 
immunization doses and using the most commonly used routes of immunization. 
Understanding the mechanisms by which pb36p- parasites induce immunity will 
help us to design a vaccine against malaria liver stage. We have already made an 
attempt to initiate studies regarding this issue, and observed that pb36p- mediated 
immunity is dependent on IFN-γ and γδ T cells. Moreover, apoptosis seems to be 
paramount in these attenuated parasites induced protection. These are just the first 
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steps on this subject, and further studies are already in course to unravel the 
mechanisms of this and other GAS mediated protection, which will no doubt 
provide ground-breaking relevant data for the development of a vaccine aimed for 
the pre-erythrocytic stage of Malaria.  
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                                                                                        MATERIAL AND METHODS 
6.1. Materials 
 
6.1.1. Chemical and General Reagents 
 
Analytical or molecular grade chemicals were purchased from Sigma, Merck, 
BioRad, Calbiochem, Roche, Riedel-de Haen, Fluka AG, BDH AnalaR, Carlo 
Erba Reagenti, Mallincrkodt and TAAB. Molecular biological reagents and 
enzymes were purchased from Roche, Applied Biosystems, Promega and New 
England Biolabs. Culture media was purchased from Gibco or Sigma. Primers 
were acquired from MWG. Antibodies for immunofluorescence were obtained 
from Molecular Probes or Jackson Biolabs. Antibodies for Blotting were 
purchased from Amersham or Zymed. Antibodies for flow activated cell sorting 
(FACS) were purchased from Pharmingen or Serotec. 
 
6.1.2. Cells 
 
For all in vitro experiments, the hepatoma cell line HepG2 (ATCC, HB8065)., 
which is efficiently infected by P. berghei parasites and sustains their complete 
development (Hollingdale , 1983) was used. Cells were maintained in DMEM 
supplemented with 10% Fetal Calf Serum (FCS) and 1% Penicilin-Streptomycin 
(P/S) (complete DMEM), in an atmosphere containing 5% CO2. Cells were 
periodically tested for mycoplasma infections, as previously described (Uphoff, 
2002).  
 
6.1.3. Parasites 
 
Anopheles stephensi mosquitoes infected with P. berghei parasites (clone 15cy1; 
ANKA strain) expressing GFP (Franke-Fayard, 2004) and pb36p- P. berghei 
parasites (clone 1; ANKA strain) expressing GFP (van Dijk 2005) were either 
reared in our own insectary or supplied by Dr. Robert Sauerwein (Department of 
Medical Microbiology, University Medical Center St. Radboud, Nijmegen, The 
Netherlands.). Anopheles stephensi mosquitoes infected with P. yoelii (265 BY 
strain) were supplied by Dr. Dominique Mazier (Inserm U511, Immunobiologie 
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Cellulaire et Moléculaire des Infections Parasitaires, Centre Hospitalo-
Universitaire Pitié-Salpêtrière, Université Pierre and Marie Curie, Paris, France). 
Anopheles stephensi mosquitoes infected with P. yoelii (17XL strain), P. 
chabaudi chabaudi (AS strain) and P. vinckei petteri were supplied by Dr. 
Richard Culleton (Institute of Immunology and Infection Research, Ashworth 
Laboratories, School of Biological Science, University of Edinburgh, Edinburgh, 
United Kingdom). Parasites were maintained by alternating passage of the 
parasites in A. stephensi mosquitoes and BALB/c or C57BL6 mice (Gwadz, 
1980).  
Disruption of pb36p- or pbcrmp3-/pbcrmp4- in P. berghei were performed by Dr. 
Milly van Dijk or Dr. Kevin Augustijn (Department of Parasitology, Leiden 
University Medical Center, Leiden, The Netherlands), respectively.  
Sporozoites were obtained by hand dissection of infected mosquitoes 17-25 days 
(P. berghei, P. chabaudi and P. vinckei) or 14-18 days (P. yoelii) after mosquitoes 
had taken an infectious blood meal. Salivary glands were collected in an 
eppendorf containing RPMI medium, disrupted and centrifuged thrice, 5 minutes 
at 800 rpm RT each. The supernatant containing the sporozoites was collected and 
placed in other eppendorf. Sporozoites were counted using a haemacytometer 
(Ozaki, 1984). 
 
6.1.4. Mice
 
BALB/c (H-2Kd) and C57BL6 (H-2Kb) were supplied by Instituto Gulbenkian de 
Ciência (Oeiras, Portugal) or purchased to Harlan Ibèrica (Barcelona, Spain). 
C57BL6 IFN-γ and TCRδ deficient mice (Ifngtm1Ts and TcrdtmMom targeted 
mutation, respectively) were purchased from The Jackson Laboratory (Bar 
Harbor, Maine, USA) and have been described earlier (Itohara, 1993; Dalton, 
1993). For all experiments, 6-8 weeks old mice were used (except for long-lasting 
protection, due to obvious reasons). Animal were kept in pathogen-free 
environment facilities. All animal care and procedures were in accordance with 
European regulations.  
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6.2. Methods 
 
6.2.1. Immunizations 
 
Balb/c and C57Bl/6 mice were immunized with either RAS or GAS (pb36p-, 
pbcrmp3- and pbcrmp4-). RAS were previously submitted to a radiation dose of 
16,000 rad in a Co source, using a γ irradiator (Oris Industrie IBL 437C, Gif-sur-
Yvette, France). Immunizations were performed according to a standard protocol 
(Orjih, 1982). Briefly, intravenous administration was performed (ocular vein), 
with a single dose of 50,000 of attenuated sporozoites for BALB/c and three doses 
of 50,000/20,000/20,000 of attenuated sporozoites for C57BL6 (weekly apart). 
Other administration routes (intramuscular, subcutaneous and intradermal) were 
also performed for RAS and pb36p- immunizations. Immunized mice were 
challenged 10 days later with 10,000 WT P. berghei sporozoites (standard 
procedure). A naïve control mice group was added at this time for all experiments 
performed. As described in chapter 2, different doses and parasites were also used 
for challenge of RAS and pb36p- immunized mice. 
Parasitemias in blood were detected/measured by FACS analysis (when GFP 
expressing parasites were available) or by blood smears and Giemsa staining (van 
Dijk, 2005). 
 
6.2.2. Quantification of  Liver Infection 
 
Livers were dissected 40 hours post infection, and immediately suspended in 4 ml 
volume of Denaturing Solution (4M Guanidium Thiocyanate, 25mM Sodium 
Citrate pH 7, and 0.5% N-Laurosyl-sarcosine) plus 0.1M β-mercaptoethanol, and 
stored at 4ºC until homogenization. Livers were homogenized with a Tissue 
Tearer bladder. Liver homogenates were aliquoted (3×300µl per sacrificed 
animal) and stored at -80ºC (Witney, 2001). Total RNA of the samples obtained 
was purified using the RNeasy Mini Kit (Qiagen), according to standard protocols 
supplied by the manufacturer. RNA was quantified using a Nanodrop 
Spectrometer. 1 µg of total RNA (per sample) was reverse transcribed using a 
First Strand cDNA Synthesis Kit for RT-PCR, in a 20µl reaction volume, 
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according to standard protocols supplied by the manufacturer. cDNA synthesis 
was performed at 25ºC for 10 minutes, then 42ºC for 60 minutes, following heat 
inactivation at 99ºC for 10 minutes (Witney, 2001), in a BioRad MyCycler 
Thermal Cycler. 2 µl of sample cDNA was submitted to real time fluorescent 
detection of PCR products, using a Power SyBrGreen PCR Master Mix (12.5 µl), 
P. yoelii 18S rRNA specific forward (5’ – GGG GAT TGG TTT TGA CGT TTT 
TGC G – 3’, Tm 64.6ºC) and reverse (5’ – AAG CAT TAA ATA AAG CGA 
ATA CAT CCT TAT – 3’, Tm 59.2ºC) or P. berghei 18S rRNA specific forward 
(5’ – GGA GAT TGG TTT TGA CGT TTA TGT G – 3’, Tm 59.7ºC) and reverse 
(5’ – AAG CAT TAA ATA AAG CGA ATA CAT CCT TAC – 3’, Tm 59.9ºC) 
primers 10 mg/ml (2 µl of each) and nuclease free water (6.5 µl), in a total 25µl 
reaction volume. RT-PCR was performed using a ABI Prism 7000 thermocycler 
(Applied Biosystems), using the following thermocycling conditions: 1 cycle of 
95ºC for 10 minutes and 45 cycles of 95ºC for 15 seconds (denaturation) and 60ºC 
for 1 minute (annealing/extension) (Bruña-Romero, 2001; Witney, 2001). Control 
plasmids with standard concentrations of 18S rRNA gene, from 101 to 108 copies 
were used in the assay and were synthesized as described elsewhere. A similar 
RT-PCR was performed for a house-keeping gene, HPRT, for standardization of 
values obtained (Witney, 2001).     
 
6.2.3. Sporozoite Infection in vitro
 
P. berghei sporozoites were added to cell monolayers (seeded previously and used 
when confluence was ~80-90%) in complete DMEM, in 24 well plates, and 
centrifuged 10 minutes at 3000 rpm. Plates were then incubated at 37ºC, in an 
atmosphere containing 5% CO2. At different time points after infection, such as 2 
hours (migration essays), 6 and 24 hours (Apoptosis detection and EEF 
development) and 48 and 56 hours (EEF development), cells were fixed with 
paraformaldehyde 2% (PFA) and absolute methanol at room temperature (RT), 
and stained afterwards.  
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6.2.4. Immunofluorescence Assay 
 
After fixation, coverslips containing infected cells were incubated with a protein 
blocking solution (3% Bovine Serum Albumin, 100mM Glycine, 10% FCS) to 
avoid unspecific reaction, containing 0.1% Saponin (Sigma) for permeabilization, 
for 30 minutes, rinsed twice shortly in PBS, and incubated 45 minutes RT with a 
monoclonal antibody (mAb) against anti HSP70 (also known as 2E6, produced by 
a hybridoma cell line; Tsuji, 1994) and, when apoptosis detection was required, 
simultaneously with a mAb against active caspase-3. After smooth rinsing of the 
coverslips to remove exceeding mAb, they were incubated with mAb Cy2 Alexa 
Fluor® 488 for mice IgG (dilution 1:2000) and, when apoptosis detection was 
performed, simultaneously with  mAb anti Rabbit IgG Texas Red, for 45 minutes 
RT, light protected. Following removal of exceeding mAb, the coverslips were 
incubated with 20 ng/µl of diamidino-phenyl-indole (DAPI), a DNA stain, up to 2 
minutes RT. Then, the coverslips are mounted in glass slides, with a mounting 
medium, Mowiole and then observed in a Fluorescence Microscope. Infection rate 
was quantified by counting the number of parasite infected cells per coverslip. 
Fluorescence pictures were taken using Metamorph software (Molecular Devices, 
Sunnyvale, California, USA). 
 
6.2.5. In vitro Analysis of Apoptosis in RAS and pb36p- Parasite-
Invaded Hepatocytes 
 
Two distinct fluorescent methods for apoptosis detection were used: (i) active 
caspase-3 detection, and (ii) nuclear morphology by DAPI staining as described 
(Leirião, 2005). P. berghei sporozoites (WT, pb36p- or RAS) were added to 
HepG2 cells for 6 h before staining with anti-HSP70 mAb (as described in 6.2.3 
and 6.2.4) for parasite detection. Apoptotic cells were visualized 6 h after 
infection by active caspase-3 detection and DAPI staining. Infection and apoptosis 
rates were quantified by counting the number of parasite infected cells per 
coverslip and apoptotic parasite-infected cells per coverslip, respectively. 
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6.2.6. In vivo Analysis of Apoptosis in pb36p- Parasite-Invaded 
Hepatocytes 
 
C57BL6 mice were infected with 500,000 pb36p- or WT P. berghei sporozoites 
by i.v. injection. Livers were removed 6 h after infection and snap-frozen in 
Tissue Tek (Sakura) in dry ice. Twenty histological sections from each mouse 
were obtained with a cryostat (Leica CM 3050 S), and placed in Super Frost Plus 
slides (Menzel-Glaser). Afterwards, these slides were fixed and stained for both 
parasite detection and nuclear morphology by DAPI staining (as described in 
6.2.4 and 6.2.5). All sections were examined for the presence of infected cells 
with signs of apoptosis. 
 
6.2.7. Western Blot for Caspase-3 detection 
 
Protein separation was accomplished using a polyacrylamide gel electrophoresis 
system composed by a stacking and a resolving gel in tris-glycine running buffer 
with 20%. SDS. Protein sample from whole cell lysates (HepG2 uninfected or 
incubated 24 hours with 150,000 WT, RAS or pb36p- sporozoites, as described in 
6.2.3) in 2x Laemmli buffer were boiled (5 minutes, 100ºC) and loaded into 12 % 
SDS-PAGE gels (Burnette, 1981). Pre-stained SDS-PAGE protein standards were 
also loaded to determine molecular mass of analyzed proteins. Proteins were 
resolved by running the gel using Mini Protean II (BioRad) at 110 V. After 
separation by electrophoresis proteins were transferred to a nitrocellulose 
membrane through a wet electroblotting  (200 mA 90 minutes) using mini protean 
II (BioRad) (Burnette, 1981). Membranes were washed in tris-buffered saline 
(TBS) and incubated for 1 hour in blocking solution (5% fat-free powder milk in 
TBS). Membranes were washed in TBS and probed with primary antibodies in 
blocking solution (90 minutes, RT). The primary antibodies used were anti 
procaspase-3 and actin (loading control) (both 1:5000), identified by a molecular 
weight around 32 and 42 kDa, respectively. After incubation with the primary 
antibodies, membranes were washed in TBS (3 times 10 minutes) and all primary 
antibodies were detected using horseradish peroxidase conjugated donkey anti–
rabbit (1:4000) or goat anti-mouse (1:4000) secondary antibodies (60 minutes, 
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RT). After membranes were washed in TBS (3 times 10-15 minutes), HRP 
enzymatic activity was visualized using the SuperSignal West Pico 
Chemiluminescent substrate (Pierce) according to the manufacturer instructions. 
Results were obtained in the form of photo-radiographs (Amersham Hyperfilm) in 
a developer (Curix 60, Agfa). 
 
6.2.8. Memory cells and FACS 
 
BALB/c mice immunized as described (6.2.1) were sacrificed (at 10 days, 1 and 6 
months after immunization) to collect livers, spleens and lymph nodes for 
memory cells quantification.   
Livers were perfused via the hepatic portal vein using a Liver Perfusion Medium 
(Gibco) and digested using Liver Digestion Medium (Gibco). Livers were then 
resected and cells were teased from the tissue using a stainless steel wire mesh. 
Cells were centrifuged at 10 minutes and 1500 rpm (4ºC) in complete RPMI 
(supplemented with 10% FCS, 1% PS, 1% HEPES, 1% Sodium Pyruvate and 
0.1% β-mercaptoethanol). The pellet was ressupended in complete RPMI and, to 
eliminate hepatocytes, centrifuged twice over Percoll (60% and 30%, 
respectively) 2000 rpm and 10 minutes (20ºC), without brake. Pelleted 
lymphocytes were washed once in complete RPMI and treated with ACK 
(ammonium, chloride and potassium; 0.15M NH4Cl, 1.0 mM KHCO3, 0.1 mM 
Na2 EDTA, pH 7.2), to eliminate erythrocytes (Guebre-Xabier, 1999). 
Spleens and lymph nodes suffered similar treatment as just described for liver: 
after removal, they were teased in a stainless steel wire mesh. Cells were 
centrifuged 1500 rpm for 15 minutes RT, no brake, over Ficoll, for elimination of 
red blood cells. Interfase was collected and washed (Guebre-Xabier, 1999). 
For FACS analysis, lymphocytes were resuspended PBS 0.2% FCS and incubated 
with FACS antibodies for 15 minutes RT. Per group, a pool of cells was analyzed. 
Stainings were done with the following conjugated antibodies: CD8+ PerCP 
Cy5/CD4+ PE/ CD44 APC/ CD62L FITC (memory T cells) or CD19+ APC/CD27 
PE (memory B cells). Cells were washed and resuspended in 200 µl for FACS 
acquisition on flow cytometer FACSCalibur (BD Biosciences) and data was 
analyzed afterwards using CellQuest software (Becton Dickinson, 
Immunocytometry Systems, San Jose, California, USA). 
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6.2.9. Electron Microscopy 
 
Guts from mosquitoes infected with WT, pbcrmp3- or pbcrmp4- parasites were 
hand dissected, as previously described (Sinden, 1976). Guts were then washed 
twice with PBS, and fixed at 4ºC, 30 minutes, with a solution of Sodium 
Cacodylate 0.1 M, Sucrose 3.7% and Glutaraldehyde 2%. Next, guts were washed 
3 times with a solution of Sodium Cacodylate 0.1 M plus Sucrose 3.7% (buffer 
SCS), pH 7.4, and stored overnight in fresh SCS. Then, guts were fixed with 
Osmic Acid 1% in buffer SCS, during 10 minutes RT. This process is followed by 
3 washes, 10 minutes each, with buffer SCS, and incubation with a solution of 
0.2% Tannic Acid in buffer SCS, 30 minutes RT. Guts were washed 3 times 
briefly with Sodium Cacodylate 0.1 M pH 7.4, and, next, treated with ethanol 70º 
twice, 5 minutes each. In a radioactive handling chemicals facility, guts were 
treated with a solution of 0.5% Uranyl Acetate plus 1% Phosphotungstic Acid in 
ethanol 70º, during 30 minutes, light protected. Afterwards, guts were dehydrated, 
with 2 washes with ethanol 70º, 2 washes with ethanol 95ºC and 3 washes with 
absolute ethanol, 5 minutes each, and treated with an pure epoxy resin, EPON, 
first once during 10 minutes, and then 4 times 30 minutes each. Then, guts were 
incubated at 60ºC overnight, with the remaining EPON. 24 hours later, the 
capsules were filled with fresh EPON, and incubated more 24 hours at 60ºC. After 
that, the guts were treated with liquid nitrogen, and remove the capsules 
containing the cells. The capsules were, afterwards, cut (Leica Reichter Ultracuts), 
mounted in Electron Microscopy 200 Mesh copper grids and observed in the 
Electron Microscope (TEM Jeol JEM – 100 CX II) (Vanderberg, 1967).    
 
6.2.10. Gliding Assays for pbcrmp3- and pbcrmp4- sporozoites 
 
WT, pbcrmp3- and pbcrmp4- sporozoites were spun for 10 minutes at 3000 rpm 
on glass coverslips, previously coated with gelatin 0.02% in water (for 30 
minutes, excess removed and left to dry overnight) in sterile conditions and 
incubated 2 hours, at 37ºC. After 2 hours incubation in complete DMEM, 
coverslips with sporozoites were stained for mAb anti CSP (produced by a 
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hybridoma cell line; Charoenvit, 1991), as described in 6.2.3 and 6.2.4, except for 
the DNA stain with DAPI, which was omitted. Sporozoites motility ability is 
considered, when CSP trails originated by parasite gliding trail on the gelatin are 
observed (Mota and Hafalla, 2002). 
 
6.2.11. Migration Assays for pbcrmp3- and pbcrmp4- sporozoites 
 
Sporozoite migration through cells was quantified by detection of parasite-
wounded hepatocytes using a cell-impermeant fluorescent tracer macromolecule, 
rhodamin-dextran. Sporozoites were incubated for 2 hours at 37ºC (as described 
in 6.2.3 and 6.2.4), in complete DMEM containing 1 mg/ml of rhodamine-dextran 
(red). After 2 hours, cells were washed twice in PBS, fixed with 2% PFA for 30 
minutes (followed by three washes in PBS, 10 minutes each) and in absolute 
methanol overnight. Cells were stained afterwards as described in 6.2.10 for CSP 
protein. Migration through host cells is quantified as percentage of dextran 
positive non infected cells, and the number of sporozoites that reach a final 
hepatocyte for infection and further development, as the percentage of parasites 
inside dextran negative cells (Mota and Hafalla, 2002). 
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Immunization with Plasmodium sporozoites that have been atten-
uated by -irradiation or specific genetic modification can induce
protective immunity against subsequent malaria infection. The
mechanism of protection is only known for radiation-attenuated
sporozoites, involving cell-mediated and humoral immune re-
sponses invoked by infected hepatocytes cells that contain long-
lived, partially developed parasites. Here we analyzed sporozoites
of Plasmodium berghei that are deficient in P36p (p36p), a
member of the P4845 family of surface proteins. P36p plays no
role in the ability of sporozoites to infect and traverse hepatocytes,
but p36p sporozoites abort during development within the he-
patocyte. Immunization with p36p sporozoites results in a pro-
tective immunity against subsequent challenge with infectious
wild-type sporozoites, another example of a specifically geneti-
cally attenuated sporozoite (GAS) conferring protective immunity.
Comparison of biological characteristics of p36p sporozoites with
radiation-attenuated sporozoites demonstrates that liver cells in-
fected with p36p sporozoites disappear rapidly as a result of
apoptosis of host cells that may potentiate the immune response.
Such knowledge of the biological characteristics of GAS and their
evoked immune responses are essential for further investigation of
the utility of an optimized GAS-based malaria vaccine.
apoptosis  attenuated vaccines  host–pathogen interaction  Plasmodium
Upon introduction into the bloodstream by the femaleAnopheline mosquito during blood feeding, the infectious
sporozoite of Plasmodium invades and multiplies within the hepa-
tocyte. Recognition and invasion of a hepatocyte is a complex
process involving traversal through macrophage-like Kupffer cells
(1) and several hepatocytes (2) before forming a parasitophorous
vacuole (PV) in the final hepatocyte. Currently, only a few proteins
of sporozoites have been described that play an essential role in
establishing infection of the liver but are thought to be conserved
in all species of Plasmodium. These include circumsporozoite
protein (CS), thrombospondin-related anonymous protein
(TRAP), microneme proteins essential for cell traversal (SPECT1,
SPECT2 or PPLP1, and CelTOS) and PbIMC1a, which variously
are involved in motility of sporozoites, recognition of surface
receptors on host cells, and traversal and invasion of host cells
(3–10). Within the PV, the sporozoite transforms and grows
(trophozoite stage) and multiplies (schizont stage) for a period of
a few days, resulting in the generation and release of thousands of
merozoites that invade red blood cells.
The current rationale for the characterization of Plasmodium
molecules involved in liver infection lies in the development of a
(subunit) vaccine that protects against liver and subsequent blood
stage infection (11). Immunization studies using complete radia-
tion-attenuated sporozoites (RAS) showed full protection against
subsequent challenge with infectious sporozoites in both animal
models of malaria and in human volunteers (12). The protective
immunity that is observed after immunization with RAS requires
that the sporozoites infect hepatocytes and transform into the
trophozoite stage (13). Such immunity is mediated by complex
mechanisms involving antibody responses that inhibit sporozoite
motility and host cell invasion and T cell responses directed against
intrahepatocytic stages. CD4 T helper cells and cytotoxic CD8 T
lymphocytes recognizing MHC presented parasite-derived pep-
tides, as well as cytokines (IL-2, IFN-, and IL-12; TNF-, IL-1, and
IL-6) and nitric oxide, have been shown to be critical effectors in
protection against preerythrocytic malaria (13–15).
However, vaccination studies with subunit vaccines that contain
only (parts of) single proteins of sporozoites have failed so far to
provide any significant, long-lasting protective immunity (11, 12).
The lack of significant progress with subunit vaccines stimulated
recent attempts to produce a vaccine based on the nonreplicating,
metabolically active RAS (12). However, such vaccines suffer from
significant drawbacks, not least the question of safety and repro-
ducibility because the amount of radiation that generates the
attenuated state is strictly defined. Parasites that are underirradi-
ated remain infectious, and those that are overirradiated do not
induce protective immunity. Recently, it has been shown that
genetically attenuated sporozoites (GAS) that lack sporozoite-
specific conserved genes (uis3 and uis4) that are apparently impor-
tant for sporozoite development in the hepatocyte can induce
significant or complete protective immunity in the P. berghei rodent
model of malaria when different immunization protocols are used
(16, 17). The use of GAS for vaccination might remove the
uncertainty associated with RAS once a more thorough under-
standing of the mechanisms of immunity invoked by GAS and their
developmental defect(s) are available.
In this study, we generated a GAS in P. berghei that lacks the
sporozoite-specific protein P36p (refs. 18 and 19, and E. Lasonder,
personal communication), which is a member of a small family of
10 Plasmodium surface proteins, the P4845 family, that include
other promising vaccine candidate antigens (20–22). Development
of p36p parasites aborts within the hepatocyte and immunization
with p36p sporozoites induces protective immune responses
against subsequent challenges with wild-type sporozoites. P36p-
deficient parasitized cell numbers are progressively reduced after
24 h in culture and in vivo and apparently fail to prevent host cell
apoptosis, consequently leading to parasite clearance. Generation
and analysis of biological and immunogenic characteristics of
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multiple GAS models are essential for further development of GAS
as a potential malaria vaccine.
Materials and Methods
Generation of the p36p Parasite Lines. To disrupt the p36p locus a
p36p replacement vector was constructed in vector b3D.DT.H.
Db containing the pyrimethamine-resistant Toxoplasma gondii
(tg) dhfrts gene. To introduce gfp into the genome of p36p
parasites, a vector was constructed with the human (h) dhfr select-
able marker and gfp under control of the constitutive pbef-1aa
promoter (23–25) and a fragment of 2 kb of the D-type small subunit
(dssu) rRNA gene of P. berghei (22). The linearized vector can
integrate in C-type small subunit (cssu) andor dssu. Integration
into cssu does not affect the phenotype of the parasites (26). For
further details, see Supporting Text, which is published as supporting
information on the PNAS web site.
P. berghei wild-type (WT) parasites (clone 15cy1; ANKA strain)
were used to generate p36p parasites. Transfection, selection, and
cloning of p36p parasites was performed as described (27). Two
independent transfection experiments were performed, and two
clones (KO1 and KO2) were selected for further analysis. p36p
parasites (KO1) were transfected with the gfp vector to create p36p
mutants expressing gfp constitutively throughout the life cycle.
Selection of transformed parasites was performed by treating
infected animals with WR99210 (16 mgkg bodyweight) as has been
described (25). One parasite clone (KOGFP) in which the gfp was
integrated into the cssu was selected for further analysis. Correct
integration of constructs into the genome of transformed parasites
was analyzed by RT-PCR and Southern analysis of restricted DNA
or separated chromosomes by field inversion gel electrophoresis
(27). PCR on DNA of WT and p36p parasites was performed by
using primers specific for the WT (L1362 5-CCGCTCGAGAC-
CTTAGGACACTTTGAAATTTG-3 and L1363 5-CCGCTC-
GAGCTACTCATAATAAGAAGAAGAGGTAC-3; amplify-
ing a fragment of 1.2 kb) and disrupted (L1389 5-ATTTTG-
CAACAATTTTATTCTTGG-3 and L313 5-ACGCAT-
TATATGAGTTCATTTTAC-3; amplifying a fragment of 1.0 kb)
locus. PCR on DNA of WT and p36p:gfp parasites was performed
by using primers specific for WT (L270 5-GTGTAGTAACAT-
CAGTTATTGTGTG-3 and L271 5-CTTAGTGTTTTGTAT-
TAATGACGATTTG-3, amplifying a fragment of 3 kb) and
disrupted cssu (L270 and L635 5-TTTCCCAGTCAC-
GACGTTG-3, amplifying a fragment of 3 kb). Primers 1389 and
313 amplified the expected fragment of 1.0 kb of the disrupted p36p
locus in KOGFP parasites. RT-PCR was performed on RNA
isolated from WT and p36p sporozoites as described by Invitro-
gen. To amplify cDNA derived from the p36p or circumsporozoite
(CS) gene, primers L1425 (5-GAAATGAATATGTCGGTAC-
TATG-3) and L1363 (5-CCGCTCGAGCTACTCATAATAA-
GAAGAAGAGGTAC-3), amplifying a fragment of 0.5 kb, and
L1502 (5-AGTCAACAGATTATTGCCGATG-3) and L1503
(5-TACAAATCCTAATGAATTGCTTAC-3), amplifying a
0.8-kb fragment, were used, respectively.
Phenotype Analysis of the p36p Parasite During Blood Stage and
Mosquito Stage Development. The phenotype of blood stage devel-
opment was analyzed in asynchronous infections in Swiss mice and
during standardized synchronized development in vivo and in vitro
as described (28). Gamete formation, fertilization and ookinete
production were studied in vitro as described (20). Oocyst formation
and sporozoite development were investigated by using Anopheles
stephensi and standard methodologies (29). The number of sporo-
zoites per salivary gland was determined by mixing the salivary
glands of 10 infected mosquitoes in 300 l of PBS and counting the
numbers of sporozoites in duplicate in a cell counter.
Analysis of Characteristics of the Infectivity of p36p Sporozoites.
The capacity of p36p sporozoites to establish blood stage infec-
tions was established by infection of mice (female BALBc and
C57BL6, 15–20 g) through bites of infected mosquitoes or i.v.
injection of 5  104 purified sporozoites, dissected from infected
mosquito salivary glands (30), per mouse. Twenty to 40 infected
mosquitoes were allowed to feed on each mouse 20 days after the
infectious blood meal. Blood stage infections were monitored in
Giemsa-stained bloodsmears or by FACS analysis of tail blood
when p36p:gfp parasites were used (23) on days 4–14 after
infection. Infection with WT sporozoites results in a 1–10% para-
Fig. 1. Generation of the p36p parasite lines. (A) Schematic representation
of the p36p-locus on chromosome 10 (containing p36 and the paralogue
p36p) (20) and the replacement vector MI4. Correct integration of the con-
struct results in the disrupted p36p gene as shown. Open box, untranslated
regions; black box, pb36p and pb36 coding regions; gray box, tgdhfrts SC. (B)
Disruption of p36p was shown by PCR (Right) and by Southern analysis of
separated chromosomes (Left). PCR on DNA of WT andp36p clones (KO1 and
KO2) results in the amplification of a 1.2-kb WT fragment and a 1.0-kb
disrupted fragment. Chromosomes hybridized to a P. berghei (pb) dhfrts 3
UTR region (DT-3) specific probe detect the endogenous dhfrts copy on
chromosome 7 and the integrated construct on chromosome 10. (C) The
absence of p36p transcripts in p36p parasites as shown by RT-PCR on RNA
from WT and p36p sporozoites with () or without () reverse transcriptase.
(D) Schematic representation of the gfp insertion construct pl0019 and the
cssu of the rRNA gene unit on chromosome 5 that serves as target locus for
integration of the gfp vector by a single crossover. Black box, cssu; gray box,
hdhfr SC; open box, gfp expression cassette. (E) Correct integration of the gfp
construct in the genome of p36p parasites (KO1) shown by PCR (Right) and
by Southern analysis of separated chromosomes (Left). PCR on DNA of WT and
p36p gfp parasites (KOGFP) results in the amplification of a 3-kb WT frag-
ment, a 3-kb fragment of the disrupted cssu, and a 1-kb fragment of the
disrupted p36p locus. Separated chromosomes were hybridized to the DT-3-
probe, detecting pbdhfrts on chromosome 7, the gfp construct on chromo-
some 5, and the MI4 construct on chromosome 10. (F) GFP-fluorescent oocysts
and sporozoites (Left) and blood stages (Right) of the p36pgfp parasites.
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sitemia at day 4–6 after mosquito feeding and a 0.5–5% parasitemia
on day 4 or 5 after i.v. injection.
Gliding motility of sporozoites was analyzed by counting the
average number of circles performed by single sporozoites (31).
Sporozoites (4 104) were spun for 10 min at 1,800 g onto glass
coverslips previously coated with 0.02% gelatin in water, followed
by incubation for 2 h at 37°C and staining with anti-CS 3D11
antibody (Ab) for sporozoite and trail visualization. Quantification
was performed by counting the average number of circles per-
formed by 100 sporozoites in three independent coverslips. Hepa-
tocyte invasion and traversal were studied in vitro by adding purified
sporozoites to confluent monolayers of HepG2 cells in supple-
mented MEM medium as described (32). Cell traversal was quan-
tified by counting parasite-wounded hepatocytes using a cell-
impermeant fluorescent tracer macromolecule, rhodamine-dextran
(1 mgml) (2). Hepatocyte invasion was determined by counting
the percentage of sporozoites inside dextran-negative cells as
described (33). Sporozoite development within HepG2 cells in vitro
was determined by staining cells using different Abs: anti-PbEXP-1,
detecting a PVM-resident protein (V.H., unpublished results); and
anti-HSP90 (V.H., unpublished results) or anti-HSP70 (2), detect-
ing the parasite cytoplasmic heat shock protein 90 or 70, respec-
tively. Cells were stained with DAPI to visualize the nuclei.
Trophozoite development was quantified by counting the numbers
of trophozoites 24 h after invasion of sporozoites in a whole
coverslip.
In Vitro Analysis of Apoptosis in RAS and p36p Parasite-Invaded
Hepatocytes. Two distinct fluorescent methods for apoptosis detec-
tion were used: (i) active caspase-3 detection, and (ii) nuclear
morphology by DAPI staining as described (34). A total of 3 104
sporozoites (WT, p36p, or RAS; gamma source, 16 Krad, ref. 35)
were added to monolayers of 2  105 HepG2 cells (DMEM10%
FCS1% penicillinstreptomycin1 mM glutamine) for 6 h before
staining with anti-HSP70 Ab (2) for parasite detection. Apoptotic
cells were visualized 6 h after infection by using an active caspase-3
detection kit (Promega) and DAPI staining. Infection and apopto-
sis rates were quantified by counting the number of parasite-
infected cells per coverslip and apoptotic parasite-infected cells per
coverslip respectively, in triplicate.
In Vivo Analysis of Apoptosis in p36p Parasite-Invaded Hepatocytes.
Two C57BL6 mice per group were infected with 5 105 p36p or
WT sporozoites by i.v. injection. Livers were removed 6 h after
infection and snap-frozen, and 20 histological sections from each
mouse were stained for both parasite detection (anti-HSP70; ref. 2)
and nuclear morphology by DAPI staining. All sections were
examined for the presence of infected cells with signs of apoptosis.
Analysis of the Immunization Potential of p36p Sporozoites. Groups
of BALBc and C57BL6 mice were immunized by i.v. injection of
p36p sporozoites or RAS (35) or PBS and monitored for blood
stage parasitaemia in Giemsa-stained bloodsmears. Mice were
challenged with different doses of WT sporozoites on different time
points. Animals were either monitored for blood stage parasitemia
in bloodsmears every other day starting from day 3 to 3 weeks after
challenge or killed 40 h after challenge for liver extraction and
quantification of infection by real-time PCR quantification of
A-type 18S ribosomal RNA copies (36). For each set of experi-
ments, groups of naı¨ve mice were included to verify infectivity of the
sporozoite challenge dose.
Results
Generation and Characterization of p36p and p36p:gfp P. berghei
Parasites. To investigate the function of P36p, we created two
independent, cloned lines of P. berghei parasites that are deficient
in P36p (p36p) by using targeted disruption of the P36p gene
through double crossover homologous recombination (27) (Fig. 1).
In addition, to better visualize and count the p36p parasites, we
introduced gfp under control of a constitutive promoter in the
genome of one of the p36p lines (p36p:gfp; Fig. 1). The inability
of the p36p parasites to produce transcripts of p36p and thus
express P36p in sporozoites was shown by RT-PCR (Fig. 1). All
three p36p lines show no phenotype that is different from WT
parasites during blood stage development (results not shown) and
development in the mosquito. The characteristics of fertilization
and zygote development as well as oocyst and sporozoite produc-
tion in the mosquito were not affected in the independent p36p
lines (Table 1).
P36p Is Essential for Sporozoite Development within the Hepatocyte.
The infectivity of p36p sporozoites to the host (BALBc and
C57BL6 mice) was strongly affected, as was shown by the complete
absence of a blood stage infection after infection through the bite
of mosquitoes or after i.v. inoculation of purified salivary gland
sporozoites (Table 1). However, occasionally, some mice from both
host strains (10% C57BL6, i.e., 5 of 48 mice; 4% BALBc, i.e., 1 of
Table 1. Mosquito development, gliding motility, hepatocyte traversal, and invasion of p36p sporozoites
Parasite
Ookinete
production
in vitro,* %
Oocyst, no.
mean (range)†
Sporozoite no.
per salivary
gland†
Mosquito
infection,
no of mice
infected‡
Sporozoite
injection: no of
mice infected§
Gliding
motility¶
Traversal
through
cells**
Hepatocyte
invasion**
Liver
trophozoites
at 24 h**††
WT 78% (60–85) 165 (8–200) 114,000 4 (4) 5 (5) 4.1  1.2 38.3  7.6 32.4  14.9 248  8.1
174 (21–230) 72,000 4 (4) 15 (15) 6.4  2.1 26.2  5.6 38.5  12.9 330  20.1
KO1 69% (60–75) 210 (120–350) 128,000 0 (5) 0 (3) 4.3  1.3 37.3  15.4 30.1  9.2 1.3  1.5
183 (112–240) 99,000 0 (3) 0 (15)
KO2 75% (65–80) 120 (35–160) 108,000 0 (4) 0 (3)
KOGFP 66% (55–70) 160 (20–260) 98,000 0 (2) 0 (20) 6.1  2.3 27.6  1.2 39.7  16.3 0
*Percentage of female gametocytes that transform into ookinetes in vitro under standard culture conditions as described (19).
†Mean number (and range) of oocysts in mosquitoes at day 10 after feeding on infected mice and mean number of sporozoites per salivary gland in glands
dissected from mosquitoes at day 20 after the infectious blood meal.
‡Number of mice that became positive after feeding of 20–40 infected mosquitoes at day 20 after the infectious blood meal. The total number of mice that were
exposed to mosquito infection are shown in parentheses. In experiments using WT parasites, all mice became positive with a parasitemia of 1–10% on day 4
or 6 after infection.
§Number of mice that became positive after i.v. injection of 5  104 sporozoites. The total number of mice that were injected with sporozoites are shown in
parentheses. In experiments using WT sporozoites, all mice became positive with a parasitemia of 0.5–5% on day 4 or 5 after infection.
¶The gliding motility of sporozoites is defined as the average number of circles performed by a single sporozoite.
The capacity of sporozoites to traverse hepatocytes is defined as the percentage of dextran positive hepatocytes in vitro 2 h after adding sporozoites to hepatocytes.
**Hepatocyte invasion was determined by counting the number dextran-negative hepatocytes containing sporozoites, 2 h after adding sporozoites to
hepatocytes in vitro.
††Parasite development in hepatocytes was determined by counting trophozoites present at 24 h after invasion of sporozoites into hepatocytes in vitro.
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26 mice) did develop a 7-day delayed blood stage infection upon i.v.
injection of p36p sporozoites in a parasite dose-independent
fashion (data not shown). Interestingly, blood stage infections were
never observed when p36p sporozoites were transmitted naturally
through mosquito bites. The resulting blood stage parasites still
contained the knockout genotype, as analyzed by PCR (data not
shown).
Gliding motility is a feature of Plasmodium sporozoites and
associated with invasion of both salivary glands and hepatocytes (4).
p36p sporozoites are unaffected in their ability to glide (Table 1)
and, therefore, the loss of infectivity of these sporozoites is not due
to disrupted motility.
We analyzed the ability of p36p sporozoites to traverse and
infect human hepatocyte cells (HepG2) in culture. HepG2 cells
support full exoerythrocytic development of P. berghei sporozoites
into mature schizonts containing erythrocyte-infectious merozoites
(37). p36p sporozoites were able to traverse and infect hepatocytes
as well as WT sporozoites (Table 1).
Sporozoite invasion of hepatocytes requires sporozoite apical
secretion, permitting the subsequent formation of a PV within
which the developing parasite resides (38). Induction of apical
secretion by incubation of sporozoites with HepG2 cell extracts
showed that both WT and p36p sporozoites present a similar level
of activation of the apical complex (data not shown). Immunoflu-
orescent antibody test analysis revealed that WT sporozoites gen-
erate a clearly visible PV membrane (PVM) formation containing
PbExp1, a PVM-resident protein, in infected HepG2 cells that is
completely absent in HepG2 cells at 15 and 24 h after infection by
p36psporozoites (Fig. 2). In sharp contrast to WT sporozoites,
which gave rise to mature schizonts after 60–72 h of in vitro culture
in HepG2 cells, p36p sporozoites develop poorly (Fig. 2), and most
parasitised hepatocytes could no longer be detected after 24 h
(Table 1). Equal numbers of p36p, RAS, and WT sporozoites were
observed in dextran-impermeant hepatocytes; therefore, p36p
sporozoites might initiate but not maintain a PVM in HepG2 cells.
The aborted development of p36p sporozoites shows several
similar characteristics to the aborted development of RAS, yet
trophozoite development of p36p parasites is aborted at an earlier
stage compared to RAS (Fig. 2).
p36p Sporozoite-Infected Hepatocytes Enter Apoptosis More Fre-
quently than RAS or WT Parasite-Infected Hepatocytes. Host
hepatocyte apoptosis is normally inhibited by WT parasites
upon invasion and establishment of the PV (34). Therefore, it
was possible that the observed rapid disappearance of p36p
sporozoite-infected HepG2 cells in culture was due to the inability
of the parasite to prevent the hepatocyte from undergoing apopto-
sis. Consequently, the level of apoptosis in p36p sporozoite-
invaded cells was examined (Fig. 3A). In three independent exper-
iments, HepG2 cells were incubated with WT, RAS, or p36p
sporozoites, and apoptosis was determined 6 h after infection by
detection of active caspase-3 in the infected host cell cytoplasm and
by analysis of the nuclear morphology of the infected cells after
DAPI staining by observing chromatin condensation andor nu-
clear fragmentation (Fig. 3B). Interestingly, we also detected apo-
ptosis of p36p parasitized hepatocytes in vivo 6 h after infection
(Fig. 3C). The level of apoptosis in p36p parasitized cells was
significantly higher (P  0.05) compared to that in RAS-infected
cells, which was higher than the level observed in WT-infected cells
(Fig. 3A). The different levels of apoptosis are consistent with the
observed longer survival time of RAS in culture (39).
Immunization with p36p Sporozoites Protects BALBc and C57BL6
Mice Against Subsequent Infection. Because RAS has been success-
fully used in immunization studies for generation of protection
Fig. 2. Development of WT, RAS, andp36p sporozoites in hepatocytes invitro.
Cells were stained by using anti-PbEXP-1 to detect the PVM, anti-HSP90, or HSP70
to visualize the parasite cytoplasm and DAPI to stain the nuclei (blue fluores-
cence). (A) Visualization of the PVM (green, anti-PbEXP-1) in trophozoites of WT
andp36pparasites (red, anti-HSP90) at 15 and 24 h after infection, respectively.
(B) Trophozoite development of WT (a–f ), RAS (g–l), andp36p (m–r) parasites at
6, 12, 15, 18, 21, and 24 h after invasion using anti-HSP70 (green; bar, 10 m).
Fig. 3. Apoptosis is increased in p36p parasitized liver cells. (A) Apoptosis
rates represent the percentage of parasite-invaded cells that undergo apo-
ptosis 6 h after infection of HepG2 cells with WT, RAS, or p36p sporozoites.
Non. Inf. indicates noninfected HepG2 cell cultures. Error bars represent SD. (B
and C) Visualization of p36p sporozoite (green, anti-HSP70) infected hepa-
tocytes displaying typical apoptotic signs as detected by DAPI staining (blue)
in vitro (B) as well as in vivo (C). Active caspase-3 (red) detection was also
performed in B. (Original magnification, 1,260.)
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against subsequent challenge with WT sporozoites, we investigated
the immunization potential of p36p sporozoites. Mice were i.v.
immunized with p36p sporozoites by using different immunization
protocols and subsequently challenged with WT parasites. Protec-
tion was determined by using two different detection assays. (i) In
three independent experiments, groups of four BALBc mice were
infected with either 105 p36p sporozoites or 105 RAS. After 10
days, mice were challenged with 5  104 WT sporozoites and
assessed for liver stage development by using real-time PCR assays
to quantify A-type ribosomal RNA transcripts produced by devel-
oping trophozoites (36). Mice immunized with RAS and p36p
sporozoites showed a very strong and comparable reduction
(99%) in liver stage development of WT parasites compared to
nonimmunized mice (Fig. 4, which is published as supporting
information on the PNAS web site). (ii) In several independent
experiments groups of BALBc and C57BL6 mice were immunized
with a single dose of 10 to 5  104 p36p sporozoites or multiple
times (one to three immunizations) with 5 to 2  104 p36p
sporozoites, respectively, and challenged with different doses of
WT sporozoites on different days after immunization (Table 2).
Protection was determined by monitoring mice intermittently for
blood stage parasitemia in bloodsmears or using FACS analysis
from day 3 to 3 weeks after challenge.
A single immunization dose of p36p sporozoites fully protected
BALBc mice (53 of 55) and induced a protective immune response
that lasted for at least 4 months (120 days), whereas three subse-
quent immunizations with p36p sporozoites were required to
completely protect C57BL6 mice (9 of 9), resulting in a protective
immune response that lasted for at least one month (30 days), as
shown by the absence of subsequent blood stage infection after
challenge with WT sporozoites. Furthermore, in two nonprotected
BALBc mice (Table 2; experiment 1) liver development was
strongly inhibited (103), as shown by a 3-day delay in patent
parasitemia. Five protected BALBc animals (Table 2; experiment
1) were rechallenged, 1 and 2 months after immunization, respec-
tively, with WT sporozoites and did not develop blood stage
infections up to 2 weeks after challenge. C57BL6 mice were
partially protected when immunized only twice with either RAS
(33%) or p36p sporozoites (25%) (Table 2).
The protective immune response induced by p36p sporozoites
as well as RAS sporozoites seemed to be parasite stage-specific,
because BALBc mice were not protected from a challenge with
parasite-infected red blood cells and developed a normal blood
stage infection comparable to the control group (Table 2).
Discussion
The lack of significant progress with (recombinant) subunit vac-
cines that contain only (parts of) single proteins of sporozoites has
led to renewed interest in vaccines based on live, attenuated whole
sporozoites (12). Recently, it has been shown that GAS, like RAS,
produced by engineered inactivation of sporozoite-specific genes
can induce protective immunity in the P. berghei rodent model of
malaria (16, 17). Our studies demonstrate another example of GAS
that is produced through the inactivation of the sporozoite-specific
protein P36p and induces protective immunity. P36p is a member
of the P4845 family of surface proteins (21) that include a number
of promising vaccine candidate antigens, such as P4845 and P230
that are expressed on the surface of gametes (20, 22). P36p has no
function in sporozoite motility and invasion of both salivary glands
and hepatocytes, and instead plays an essential role during devel-
opment of the liver trophozoite. P36p parasites apparently fail to
maintain a PV, arresting early during intrahepatocytic develop-
ment; importantly, immunization with p36p sporozoites induces a
fully protective immune response against subsequent challenge with
WT sporozoites. Interestingly, as has been shown for RAS, only a
single immunizing dose of p36p sporozoites is required to elicit a
long-lasting protective immune response in BALBc mice (40) and
induces a protective immune response that is parasite stage specific
(16, 17). As in the immunization studies performed with uis3 and
uis4GAS (16, 17) and RAS (40), three immunizing doses of p36p
sporozoites are required to completely protect C57BL6 mice for
minimally 1 month. Furthermore, our results demonstrate that the
choice of the host strain in studying the mechanisms of protective
immunity induced by attenuated sporozoites is critical, as has been
shown by earlier studies (40). Intriguingly, p36p sporozoites, like
uis4 GAS, albeit at a lower frequency, initiated a delayed blood
stage infection in some mice, but only when p36p sporozoites are
inoculated i.v. The reasons for this are unclear and await further
investigation. There is a close paralogue of p36p, p36 that is also
expressed in sporozoites (E. Lasonder, personal communication)
and located directly adjacent to p36p in the parasite genome.
Improved levels of protection may be achieved by creating a double
p36pp36p parasite.
It is now possible to consider a comparative study of the
intrahepatocytic development and the mechanism(s) of immunity
invoked by different GAS and RAS. Like GAS, RAS sporozoites
invade liver cells and transform into the rounded trophozoite stage,
but do not enter the process of schizogony. However, trophozoite
development of RAS arrests at a later stage and produces a visible
PV compared to p36p sporozoites. Moreover, RAS-infected hepa-
Table 2. Immunization with p36p sporozoites protects against a subsequent infection with WT sporozoites
Experiment
no. Mouse strain
Immunization,*
RASp36p  103
Challenge
dose†, WT  103
Time of
challenge, days
after final
immunization
No. protected
(no. challenged)
Control RAS p36p
1 BALBc 100 50 10 0 (10) ND 18 (20)
2 BALBc 50 25 10 0 (15) 15 (15) 15 (15)
3 BALBc 50 10 10 0 (5) ND 5 (5)
3 BALBc 50 10 30 0 (5) ND 5 (5)
3 BALBc 50 10 60 0 (5) ND 5 (5)
3 BALBc 50 10 120 0 (5) ND 5 (5)
4 BALBc 50 1,000 iRBC 10 0 (3) 0 (5) 0 (4)
1 C57BL6 50 10 10 0 (3) 0 (3) 0 (1)
1 C57BL6 5020 10 10 0 (3) 1 (3) 1 (4)
1 C57BL6 502020 10 10 0 (5) 5 (5) 4 (4)
1 C57BL6 502020 10 30 0 (5) 5 (5) 5 (5)
*Groups of mice were immunized intravenously with one of PBS (control), RAS, or p36p sporozoites isolated from different mosquito
batches. Multiple immunizations with RAS or p36p sporozoites were administered at 7-day intervals.
†Mice were challenged with WT sporozoites or parasite infected red blood cell (iRBC) stages and the prepatent period monitored by
either counting Giemsa-stained bloodsmears or FACS analysis. All control, unimmunized mice became positive on day 4 or 5 after
challenge. Sporozoites were isolated from different mosquito batches.
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tocytes persist in culture longer than their GAS-infected counter-
parts, which, in the case of p36p parasites, results from their failure
to prevent the host cell from entering apoptosis. Although RAS
populations provoke apoptosis to a greater degree than WT
sporozoites, they do so to a significantly lower degree than p36p
sporozoites. We also determined in vivo the persistence of RAS-
and p36p-infected hepatocytes in whole liver extracts of BALBc
mice by using real-time PCR for liver schizont detection (36). Our
results confirm the significantly more rapid clearance of p36p
parasitized hepatocytes within 6 h after infection compared to
RAS-infected hepatocytes as has been observed in vitro (data not
shown). However, similar low numbers of RAS- and p36p-infected
hepatocytes are observed 1 week after infection.
Immune responses against RAS are complex and involve both
cell-mediated and humoral immunity (13–15). However, the dif-
fering biological characteristics of RAS and GAS described here
suggest that the immune responses elicited by RAS and GAS could
be different. For example, cell death by apoptosis was originally
described to occur in the absence of inflammation. Interestingly, in
the context of infection, apoptosis is being redefined based on a
number of studies demonstrating that apoptotic death of host cells
after pathogen infection can trigger powerful innate and adaptive
immune responses. In fact, apoptosis-induced inflammation is
actively being investigated as a way of enhancing vaccine function
improving accessibility of the effector cells of the immune system
to the site of infection (41, 42). Moreover, presentation of parasite
antigens in the context of host cell apoptosis has recently been
shown as an alternative mechanism involved in the induction of
protective immunity by RAS (43). As apoptosis of p36p-infected
hepatocytes was also detected in vivo, it might well be that host-cell
apoptosis is associated with the ability of p36p sporozoites and
other GAS to induce protective immune responses and needs
further investigation.
The mechanisms and (parasite) molecules involved in preventing
host cell apoptosis by intracellular parasites including apicomplex-
ans are being investigated (44, 45). Recently, it has been shown that
Plasmodium parasites exploit the host molecule hepatocyte growth
factor (HGF), secreted exclusively by hepatocytes damaged by
parasite transit (32), to activate anti-apoptotic signaling pathways in
the host cell through HGFMET signaling (34). The ability of the
p36p sporozoites to invoke this pathway is currently unknown;
however, such interactions might now be explored in greater detail.
In particular, these studies will benefit from the use of a battery of
GFP-expressing parasites available in our laboratory, including
(radiation-attenuated) WT parasites expressing GFP constitutively
(PbGFPcon) (23) and the p36p:gfp parasites reported here. These
GFP-expressing lines will, for example, provide a means to purify
by flow sorting cultured, infected hepatocytes containing aborted
parasites allowing a detailed analysis of the transcriptome and
proteome of both parasite and host cells and as a consequence shed
more light on the parasite strategies used to influence host cell
apoptosis.
Furthermore, our studies show that p36p sporozoites are able to
invade hepatocytes but seem to be unable to produce a mature
PVM, which might be a critical step in the intracellular survival of
the parasite. It might well be that the presence of a PVM is essential
in escaping from host defense mechanisms (avoiding internal
cellular surveillance by the hepatocyte). Indeed, if the parasite
enters the host cell either without a PVM or with an incomplete
PVM, infection may be readily detected by the host cell, and this
may in turn trigger xenophagy, leading ultimately to an inflamma-
tory apoptotic response (46). Therefore, the attenuated parasite
may survive only as long as either the killing response of the host
cell allows or the parasite can avoid or neutralize the host cell
defense mechanisms.
P36p may be essential for intracellular survivaldevelopment
through being involved in an essential preceding step affecting
gene-expression through signaling; therefore, the absence of P36p
results in the lack of the necessary parasite mediators that control
parasite survival, formation andor maintenance of an effective PV,
and direct involvement in the regulation of the host cells apoptotic
machinery. Interestingly, P36p is anticipated to be a GPI-anchored
membrane protein and, therefore, may play a role in the interac-
tions between the developing trophozoite and its host cell.
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Genetically attenuated P36p-deficient Plasmodium berghei sporozoites 
confer long-lasting protection and partial cross-species immunity 
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Immunization with Plasmodium radiation-attenuated sporozoites (RAS) can confer 
sterile protection against malaria in humans, monkeys and mice. More recently, 
genetically-attenuated sporozoites (GAS) inducing the same protective immunity in 
mice were generated by genetic modification of P. berghei parasites.  
Our previous work with one of those GAS has demonstrated that sporozoites lacking the 
sporozoite specific protein Pb36p (pb36p-), induce a protective immune response in 
both C57BL6 and BALB/c mice,  that lasted for up to 1 and 4 months, respectively. 
Here, we show that protection induced by pb36p- sporozoites can last at least up to 12 
and 18 months, in C57BL6 and BALB/c mice, respectively (last time point tried for 
either strain). Protection is also achieved when pb36p-parasite numbers were reduced as 
low as 1,000 sporozoites per immunization or when different routes of immunization 
such as subcutaneous, intradermal or intramuscular were used. 
Moreover, immunization with either RAS or pb36p- sporozoites also protects against 
subsequent challenge with a heterologous rodent Plasmodium species, P. yoelii. To our 
knowledge, this is the first report of attenuated malaria sporozoites inducing cross-
species protection. These results reinforce the potential of using live attenuated 
sporozoites as a long-lasting and cross-species experimental vaccine against malaria.  
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Malaria claims the lives of nearly 2 millions African children annually and constitutes a 
huge impairment in social and economical development of countries where it is 
endemic.  
Malaria infection occurs when an infected anopheline mosquito bites a host and 
Plasmodium sporozoites reach the bloodstream, heading directly to the liver and invade 
the hepatocytes, their first obligatory target, for further development. Such process 
involves migration through several hepatocytes (Mota, 2001; Mota and Hafalla, 2002) 
and activation of signalling pathways such as HGF/MET (Carrolo, 2003), before 
establishing infection in a final hepatocyte with formation of a parasitophorous vacuole. 
Subsequently, they develop and mature into trophozoites, schizonts and finally into 
merozoites, which will be released to the bloodstream, initiating the symptomatic phase 
of infection.  
The hepatic stage of a Plasmodium infection constitutes an appealing target for the 
development of an intervention strategy, where the aim is to act before the onset of 
clinical symptoms. In fact, up to present, the only demonstrable effective vaccine shown 
to confer a sterile and lasting protection both in mice (Nussenzweig, 1967) and in 
humans (Clyde, 1973) relies upon the inoculation of radiation-attenuated sporozoites 
(RAS), that are able to invade but not fully mature inside the hepatocyte. For these 
reasons, the development of a vaccine targeting the pre-erythrocytic stage of infection 
has drawn much attention in recent years. The leading vaccine candidate, 
RTS,S/AS02A, a subunit vaccine, containing parts of the P. falciparum 
circumsporozoite protein (CSP) fused to the hepatitis B virus surface antigen, is already 
in Phase IIb trials (both in adults and in children). However, to date, the vast majority 
has only short-lived protection, achieving low efficacy (reviewed in Hill, 2005). A 
vaccine that would induce long-lasting protection against malaria is highly desirable, 
since single doses would be able to confer immunity for an extensive period, being ideal 
for sub-Saharan, military personnel and travellers. So far, only P. falciparum RAS 
immunizations have conferred long-lasting protection to human volunteers against 
challenge with infectious sporozoites, lasting up to 10.5 months (Hoffman, 2002). 
Additionally, RAS immunizations present some concerning disadvantages, namely 
safety and strict control of radiation dose. When high doses are applied to parasites, loss 
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of protective immunity is observed, and low doses do not lead to impairment on 
development of parasites in the liver, remaining therefore infectious.  
An additional major hurdle for developing a live-attenuated Plasmodium sporozoites 
vaccine is the production of adequate number of sporozoites (Luke, 2003). To overcome 
this obstacle, one must determine the minimum dose of attenuated parasites which can 
confer protection. In humans, it is estimated that the minimum dose of P. falciparum 
RAS to confer immunity would be approximately 104-105 sporozoites (Luke, 2003). 
To date, public health measures state that all vaccines must be administered by one of 
the following routes: subcutaneous, intramuscular or intradermal (Luke, 2003). 
Therefore, a vaccine based on live attenuated parasites should also fulfil this 
requirement. A small proportion of mice immunized intramuscularly with P. berghei 
RAS were fully protected while the remaining had a delay on blood-stage parasitemia. 
In similar conditions, no protection was attained using subcutaneous immunization 
(Kramer, 1975). Studies in human volunteers need to be performed to validate the 
feasibility of these routes of a P. falciparum RAS based vaccine (Luke, 2003). 
Recently, genetically-attenuated sporozoites (GAS) in P. berghei, which are also 
impaired in liver development but are capable of conferring immunity to mice against 
challenge with infectious sporozoites have been described (Mueller, 2005; Mueller and 
Camargo, 2005; van Dijk, 2005). One of those GAS suffered a genetic modification 
which made it unable to express Pb36p, a sporozoite’s microneme protein that is 
excreted to surface during gliding (Ishino, 2005). P36p is a member of the 6-cys protein 
family, which comprises 10 members, some of them constituting potential vaccine 
candidates (van Dijk, 2001; Thompson, 2001). Here we show that protection induced by 
pb36p- sporozoites can last up to 18 months and that a low immunization dose as 1,000 
pb36p- sporozoites is sufficient to confer protection. Furthermore, mice immunized 
intramuscularly, subcutaneously and intradermally with pb36p- sporozoites are found 
protected when challenged with infectious P. berghei sporozoites either intravenously 
or by mosquito bite. More surprisingly, this protection is not restricted to challenges 
with P. berghei homologous parasites. Both RAS and pb36p- sporozoites also protect 
mice against challenge with a heterologous rodent species, P. yoelii, with some mice 
even achieving sterile protection. To our best knowledge, this describes for the first time 
that experimental attenuated malaria sporozoite vaccines are capable of inducing cross-
species protection. These findings have important implications regarding new strategies 
in developing a vaccine against malaria.  
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Material and Methods 
 
Mice. BALB/c (H-2Kd) and C57BL6 (H-2Kb) were bred in the animal facility of 
Instituto Gulbenkian de Ciência (Oeiras, Portugal) or purchased to Harlan Ibèrica 
(Barcelona, Spain). For all experiments, 6-8 weeks old mice were use (except for long-
lasting protection experiments, due to obvious reasons). All animal care and procedures 
were in accordance with European regulations. 
 
Parasites. P. berghei parasites (clone 15cy1; ANKA strain) expressing GFP 
(PbGFPcon; Franke-Fayard, 2004), pb36p- P. berghei parasites (clone 1; ANKA strain) 
expressing GFP (p36p-:gfp; van Dijk 2005) and P. yoelii (265 BY strain) were 
maintained by alternating passage of the parasites in Anopheles stephensi mosquitoes 
and BALB/c mice. Sporozoites for immunizations/challenge studies were obtained by 
hand dissection of infected mosquitoes 18-21 days (P. berghei) or 14-17 days (P. yoelii) 
after mosquitoes had taken an infectious blood meal, as described elsewhere (Ozaki, 
1984). 
 
Immunization and Parasite Challenge Experiments. Mice were immunized with 
pb36p-:gfp sporozoites or PbGFPcon RAS (Orjih, 1982). According to the experiment 
performed, different immunization doses and administration routes (intravenous, 
intramuscular, subcutaneous or intradermal) were used.  Immunization protocols are 
described further. Mice were challenged intravenously (i.v.) with 10,000 P. berghei 
sporozoites or P. yoelii (different doses of sporozoites, according to the experiment 
performed), at different time points (as illustrated in next section) or by P. berghei 
infected mosquitoes bite (6 highly infected mosquitoes, as confirmed subsequently, per 
mouse). Animals were monitored daily for blood stage parasitemia either by 
bloodsmears or by FACS analysis (when GFP parasites were available) 2-3 weeks after 
challenge, starting day 3. Naive animals were included in all experiments to verify 
infectivity of the sporozoite challenge dose.  
 
Real-Time PCR. P. yoelii parasite burden in the liver was measured 40 h after 
challenge. Parasite-specific 18S rRNA was evaluated by a quantitative real-time reverse 
 
transcription method, as described somewhere else (Bruña-Romero, 2001). Protection 
was defined as the percent of liver infection inhibition, and was estimated according to: 
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immunized / rRNAnaive)×100, were rRNAimmunized and rRNAnaive represent the 
number of copies of parasite 18S rRNA in the livers of immunized and naïve challenged 
mice, respectively. 
 
Statistical analysis. Student’s t test was performed with the Prism version 4.03 
software (GraphPad Software, San Diego, CA). P values of less than 0.05 were 
considered statistically significant. 
 
RESULTS  
 
pb36p- sporozoites induce long-lasting protection against continuous challenges 
with P. berghei sporozoites 
BALB/c mice immunized with pb36p- sporozoites that were protected against challenge 
with wild-type (WT) P. berghei up to 4 months (120 days) (van Dijk, 2005) were re-
challenged i.v with 10,000 WT parasites 6 months (180 days) post final immunization, 
and are fully protected (none has developed blood-stage parasites up to 3 weeks after 
challenge). In contrast, blood stage parasites could be observed in control mice on day 
3.0 after challenge (Table 1, group 1). We next sought to test if this protection could last 
up to 1 year. The same group of protected BALB/c mice was again challenged i.v. with 
20,000 WT sporozoites nearly 12 months (351 days) after immunization. A higher dose 
was used, since although age has no effect on lethality in P. berghei in mice, older rats 
are able to completely control the infection (Pierrot, 2003; Greenberg, 1953; Singer, 
1955). All mice were fully protected and failed to develop blood stage parasites up to 3 
weeks after the challenge, while blood stage parasites could be detected on day 3.5 in 
control animals (Table 1; group 1). Moreover, these mice were still fully protected when 
re-challenged i.v. with 20,000 WT P. berghei sporozoites 18 months after last boost, 
unlike matched naïve control mice (all positive on day 3.0 after challenge). The immune 
response elicited by pb36p- sporozoites was still able to fully protect BALB/c mice after 
18 months (Table 1, group 1). 
C57BL6 mice immunized i.v. with three doses of RAS or pb36p- were protected at least 
up to 1 month (30 days) after the last immunization (van Dijk, 2005). Like in BALB/c 
mice, we propose to determine the protective immune response persistence. After the 
 
final immunization, these mice received i.v. challenges of 10,000 WT P. berghei 
parasites 2 and 3 months post final immunization and, of 20,000 WT sporozoites 6 
months post final immunization. A complete absence of blood stage parasites up to 3 
weeks post challenge was observed in 100% of the mice immunized with either RAS or 
pb36p-
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 sporozoites (Table 1, group 2). pb36p- sporozoites were able to confer, like 
RAS-based immunizations, sterile protective immunity that lasts up to 6 months in 
C57BL6 mice. These mice were re-challenged, 12 months after last immunization, and 
50% of pb36p- immunized mice were still fully protected (Table 1, group 2). 
Nevertheless, pb36p- immunized mice which developed parasitemia have a longer pre-
patency period (4.5 days), when compared with naïve matched control (3.0 days). 
 
BALB/c mice immunized with pb36p- sporozoites do not require continuous 
challenges to maintain protection up to 6 months 
Previous immunization experiments were performed with subsequent multiple 
challenges within the same groups of mice. We asked whether the long-lasting 
protection observed was due to the constant strengthening of the immune response, 
elicited by the continuous presentation of antigens during infectious sporozoite 
challenge. To test this, RAS and pb36p- immunized mice were challenged i.v. with a 
single challenge performed after longer periods post immunization. Groups of BALB/c 
mice were immunized i.v. (50,000/20,000/20,000 weekly apart) of either RAS or 
pb36p- parasites, and challenged with 10,000 WT P. berghei sporozoites 2 or 3 months 
(60 or 90 days, respectively) or with 20,000 WT P. berghei sporozoites 6 months (180 
days) after final immunization (Table 2). None of these immunized mice became ever 
positive for blood stage parasites whereas all control mice for each challenge 
experiment developed blood-stage parasitemias, as expected. These results show that 
full and long-lasting protection does not require continuous challenges to be maintained 
up to 6 months in BALB/c mice, when using a prime plus 2 boosts immunization 
regimen.  
Furthermore, immunized mice which have shown to be protected 2 and 3 months after 
last immunization were also re-challenged with 20,000 infectious parasites 6 months 
(180 days) after last immunization (Table 1, groups 3-4). These mice were still 
protected and did not developed blood stage parasites, unlike their matched controls. 
These mice, as well as those which shown to be protected 6 months after final 
immunization, were challenged again 12 months subsequent to last immunization 
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(Table 1, groups 3-5). The results show that, after one year, protection starts waning as 
not all mice are fully protected. Still, pre-patency periods for immunized mice which 
became infected (Table 2, groups 3 and 5) is longer when compared with naïve control 
mice (6.0 and 5.0 days, respectively, vs. 3.0 days for naïve matched control). 
 
Lower doses of pb36p- sporozoites confer protection against subsequent challenge 
In any attenuated whole-organism immunizations the determination of the minimum 
number of pathogens required to confer protection is crucial for vaccine design. 
C57BL6 mice were immunized i.v. with RAS or pb36p- in three equal doses (with one 
week interval between them), of 10,000, 5,000 or 1,000 sporozoites. Control mice were 
also immunized i.v. with RAS or pb36p- sporozoites but with the previous regimen 
(50,000/20,000/20,000). Ten days after last immunization, all mice were challenged i.v. 
with 10,000 WT sporozoites. Mice immunized with three doses of 5,000 or 10,000 of 
RAS or pb36p- sporozoites were fully protected (as controls) against challenge with 
10,000 WT sporozoites (Table 3). Matched naïve controls became blood-stage positive 
3.2 days post challenge.  
Three doses of 1,000 RAS sporozoites were not sufficient to protect mice against a 
challenge with 10,000 sporozoites. Nevertheless, they were partially protected as a 
delay in pre-patency was observed (6.2 days), when compared to naïve control infected 
mice (3.2 days). However, and contrary to RAS immunized mice, three doses of 1,000 
pb36p- sporozoites confer full protection to mice posterior challenged with 10,000 P. 
berghei sporozoites. This difference between RAS and pb36p- immunizations is 
reproducible and observed in different independent experiments. The results suggest 
that pb36p- can confer protection with lower number of sporozoites than RAS. 
 
Different routes of administration of pb36p- and RAS sporozoites partially protect 
against infection 
Intravenous or mosquito bite as routes for sporozoite administration are not acceptable 
currently for human vaccination. Thus, we sought to determine whether pb36p- 
sporozoites would confer protection when administered by suitable routes. C57BL6 
mice were immunized intramuscularly (i.m.), subcutaneously (s.c.) and intradermally 
(i.d) with P. berghei RAS or pb36p- sporozoites, using a prime plus 2 boots regimen 
(50,000/20,000/20,000, one week interval between them). Control mice were 
immunized i.v. using the same regimen. Ten days after last boost, mice were challenged 
 
i.v with 10,000 WT P. berghei sporozoites. All mice immunized i.v with either RAS or 
pb36p- sporozoites were fully protected against challenge with infectious P. berghei 
sporozoites, as expected (Table 4). Some sterile protection was achieved (Table 4), in 
both i.m immunizations (20% and 13% for RAS and pb36p- immunized mice, 
respectively) and for RAS i.d. immunized mice (20%). The remaining immunized mice 
(both RAS and pb36p-), which became positive had a strong delay in pre-patency 
period, ranging from 4.5 to 5.3 days, while naïve mice developed blood-stage 
parasitemia 3.2 days after challenge (Table 4). Altogether, the results show that 
although other routes of administration are not as efficient as i.v., a partial protection is 
still achieved. 
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All challenges until now were performed by i.v. injection with 10,000 sporozoites that 
do not mimic the natural infections. Thus, we decide to perform pb36p- immunizations 
using the same administrations routes as before but followed by mosquito bite 
challenges. C57BL6 mice were immunized i.v., i.m., s.c. and i.d with pb36p- 
sporozoites (50,000/20,000/20,000, weekly apart) as above. Ten days later, P. berghei 
infected mosquitoes were allowed to feed on these mice, as well as in a control 
unimmunized group. Mice were checked daily for blood stage parasites up to two weeks 
post blood feed. As expected, mice immunized i.v. were fully protected, and naïve 
control mice became all positive. Mice immunized i.m., s.c. and i.d. reached much 
higher levels of sterile protection (83%, 80% and 75%, respectively) when compared to 
mice immunized likewise which suffer i.v. challenge.  
 
pb36p- and RAS confer partial protection against challenge with P. yoelii 
sporozoites 
A vaccine that would confer protection to more than one Plasmodium species is highly 
desirable. We tested whether pb36p- or RAS could induce such cross-species 
protection. BALB/c mice were pb36p- immunized with 3 different regimens: (i) single 
immunization dose of sporozoites (50,000), (ii) prime-boost regimen (50,000/20,000, 
one week interval between them), and (iii) full immunization regimen 
(50,000/20,000/20,000, weekly apart). Cross-species protection was also assessed for 
RAS immunizations using the last 2 regimens. Three weeks after last boost, mice were 
challenged with 100, 1,000 or 10,000 P. yoelii sporozoites. Low numbers of P. yoelii 
sporozoites as 100 or 1,000 were also used, since this Plasmodia species is known to be 
 
2,000× more infective in BALB/c mice than P. berghei (Khan, 1991). Naïve controls 
were challenged with the same number of P. yoelii sporozoites.  
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Fourty hours after infection, some mice that received a single immunization or prime-
boost regimen were sacrificed and liver collected for parasite burden assess by 
quantitative RT-PCR (qRT-PCR). Prime-boost immunization with RAS reduces 
significantly infection in liver compared to naïve controls, achieving levels of inhibition 
of 99.9% (P<0.001) and 94.8% (P<0.05), against challenges of 100 and 1,000 P. yoelii, 
respectively (Fig. 1A and B). Similar pb36p- sporozoites immunization also show a 
significant higher level of P. yoelii infection inhibition when challenged with 100 and 
1,000 P. yoelii (94.6% (P<0.001) and 88.6% (P<0.05), correspondingly) (Fig. 1A and 
1B, respectively). On the other hand, although a single immunization with pb36p- 
sporozoites followed by challenge with 100 and 1,000 P. yoelii sporozoites leads to a 
reduction in liver infection (58.5% and 51.1%, respectively) this is not statistically 
significant (Fig. 1A and B) 
Blood-stage parasitemia were followed daily up to 2 weeks post infection, for all 
immunization regimens mentioned. A single immunization with pb36p- sporozoites did 
not lead to significant lower maximum blood-stage parasitemias neither to a higher pre-
patency period in mice challenged with either 100 or 1,000 P. yoelii sporozoites, when 
compared to naïve infected control (Fig. 2A and Table 5, groups 1 and 4). On other 
hand, mice which received an extra boost of pb36p- sporozoites have lower maximum 
parasitemias (Fig 2A), showing significant decreases, both regarding challenge with 100 
and 1,000 P. yoelii sporozoites (P<0.05 for both) when compared to control infected 
mice. Additionally, sterile protection is attained in a proportion of mice that were 
challenged with 100 P. yoelii sporozoites (Table 5, group 2).  The remaining immunized 
mice had a delay in pre-patency period, when compared to naïve control (Table 5, 
groups 2 and 5). All mice immunized likewise with RAS achieved sterile protection 
when challenged with 100 P. yoelii sporozoites (Fig. 2B and Table 5, group 2), never 
developing blood-stage parasitemia. Challenged with 1,000 P. yoelii sporozoites in RAS 
immunized mice only leads to partial protection, and mice which became blood stage 
positive have both a delay on parasitemia onset and significant lower levels of 
maximum parasitemia in the blood (P<0.05), compared to naïve control (Fig. 2B and 
Table 5, group 5).  
pb36p- immunized mice using a prime plus 2 boosts regimen challenged with 100 P. 
yoelii sporozoites did not present a delay on blood stage parasitemia (Table 5, group 3) 
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when compared to naïve counterpart, although a marked inhibition in maximum 
parasitemia (Fig. 2A) is also observed (P<0.05). Mice immunized with RAS in an 
identical regimen and also challenged with 100 P. yoelii sporozoites, 75% of sterile 
protection was attained, and the only mouse which became positive had a higher pre-
patency period (Table 5, group 3) presenting significantly low parasitemia (P<0.01, Fig. 
2B) when compared to naïve control mice.  
pb36p-and RAS prime plus 2 boosts immunizations also led to higher pre-patency 
periods, when compared to naïve control, regarding a challenge with 1,000 P. yoelii 
sporozoites (Table 5, group 6). Maximum parasitemia value achieved was also 
significantly lower for pb36p- (P<0.05, Fig. 2A). RAS likewise immunized mice 
reached 75% of sterile protection against a challenge of 1,000 P. yoelii, and the single 
mouse which developed blood stage parasites present a significant decrease in 
maximum parasitemia (P<0.01, Fig. 2B).  
In mice challenged with 10,000 P. yoelii sporozoites both pb36p- and RAS prime plus 2 
boosts immunized mice have lower pre-patency periods (Table 5, group 8),  as well as 
significant lower values for maximum parasitemia (P<0.01 for both, Fig. 2). 
Partial protection against challenge with P. yoelii is also observed in C57BL6 mice 
immunized with either P. berghei RAS or pb36p- sporozoites (regimen 
50,000/20,000/20,000 weekly apart). As in BALB/c mice, blood-stage parasites were 
verified daily and immunized mice showed longer pre-patency periods (Table 5, group 
7), reaching significant lower values for maximum parasitemia observed (P <0.05 for 
both RAS or pb36p-), when compared to naïve control mice (Fig. 3). 
Altogether the results show that both types of P. berghei live-attenuated parasites can 
confer protection against challenge with another rodent Plasmodia species, P. yoelii, in 
two different mouse strains, BALB/c and C57BL6. 
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There are no doubts that novel intervention strategies are required to control malaria. 
The results presented in this report, together with our own and others previous work 
(Luke, 2003; Mueller, 2005; van Dijk, 2005), illustrates the potential of an attenuated 
whole organism vaccine approach. 
The results presented in this report clearly show that at least for one of those 
genetically-attenuated sporozoites, obtained by deletion of pb36p, protection can be 
achieved for as long period of time as for RAS in 2 mouse strains. pb36p- sporozoites 
confer protection up to 12 and 18 months in C57BL6 and BALB/c, respectively, the last 
time tried to either strain. Mice live in average 18 months (Fox, 1984). Thus, 
experiments were stopped due to the low number of mice that reached the last time 
points.  On the later time points, protection conferred by RAS was always stronger than 
by pb36p- sporozoites. Berenzon and colleagues have shown that presence of antigen is 
needed to maintain the persistence of intrahepatic memory T cells (Berenzon, 2003), 
and, therefore, immunity against the parasite. Since pb36p- sporozoites induce high 
rates of infected hepatocyte apoptosis (van Dijk, 2005) and this might mean that 
infected hepatocytes disappear faster from the liver. Whether this is responsible for 
some loss in memory in the later time points needs to be further investigated. 
Similarly to RAS-induced protection, lower doses than those currently tested of pb36p- 
sporozoites are sufficient to confer sterile protection. Immunization of C57BL6 mice 
with 3 doses of 10,000 or 5,000 pb36p- sporozoites or RAS fully protects mice against 
challenge with 10,000 sporozoites. However, while 3 doses of 1,000 pb36p- sporozoites 
are able to confer fully protection to challenge with 10,000 sporozoites, similar RAS 
immunizations only confer partial protection, confirming previous reports for RAS 
(Jaffe, 1990). This suggests that lower doses of pb36p- sporozoites are required than 
those required for RAS sporozoites, to induce the same level of protection. We have 
shown previously that pb36p- has a higher clearance rate by apoptosis in the liver than 
RAS parasites (van Dijk, 2005). In addition, we have also proposed that apoptotic 
Plasmodium infected hepatocytes provide a source of parasite antigens for the initiation 
of the protective immune response (Leirião and Mota, 2005). Whether this explains the 
observed difference in protection remains to be elucidated.  
All vaccines used as public health measures are administered intramuscularly, 
subcutaneously or intradermally (Luke, 2003). A vaccine based on live attenuated 
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sporozoites should also accomplish this requirement. Our results, as well as other 
studies for RAS (Kramer, 1975), clearly demonstrated that protection can be achieved 
administrating RAS and pb36p- sporozoites intramuscularly, being some mice fully 
protected. Protection is also achieved using subcutaneous route in both types of 
attenuated parasites, as clearly demonstrated by delay in patency period. This is not 
been observed in previous studies (Kramer, 1975), but different mouse strains and 
immunization regimens were used, which could explain these differences.  Another 
GAS, P. berghei uis3-, contrastingly, when administered subcutaneously, confer full 
sterile protection against intravenous challenge with WT P. berghei sporozoites 
(Mueller, 2005), which leads to think its protection mechanisms differ greatly from 
those induced by RAS or pb36p- itself. To our knowledge, no studies regarding 
intradermal immunization with live attenuated Plasmodium sporozoites were described 
previously. Our results show that both RAS and pb36p- sporozoite confer some level of 
protection when administered by this route, with only a small proportion of RAS 
immunized mice being fully protected. 
Mice immunized with pb36p- sporozoites through all these routes followed by mosquito 
bite challenge (the natural course of infection) have a higher level of sterile protection, 
around 80%, which supports the potential as an experimental vaccine against malaria of 
this particular GAS. Unfortunately, none of these routes confer the same level of sterile 
protection as immunizations performed intravenously, which is undoubtedly desirable. 
Although at the moment these routes do not lead to complete protection, the results are 
quite encouraging and promising, strengthening the potential of a human live attenuated 
parasites-based vaccine. Optimization of the conditions used (e.g., higher immunization 
doses) may increase (or even lead to full) protection, which ought to be further 
investigated. 
Our results show for the first time the potential of attenuated malaria sporozoites to 
induce cross-species protection. We clearly demonstrated that immunization with P. 
berghei RAS and pb36p- sporozoites is able to partially inhibit the development of P. 
yoelii in both BALB/c and C57BL6 mice. Immunization with both RAS and pb36p- 
sporozoites lead to a significant decrease both in parasite liver burden and levels of 
blood parasitemia. In a proportion of the cases sterile protection was even achieved. 
However, significant levels of partial cross-species protection are only attained with, at 
least, one extra boost. These results confirm the potential of live-attenuated parasites as 
a multi-species vaccine against malaria. Cross-protection induced against one 
 
Plasmodium species by a different one has already been observed for the blood-stages 
of infection both in mice (Legorreta-Herrera, 2004; McColm, 1983; Jarra, 1985) and in 
humans (Smith, 2001). Regarding Plasmodium liver stages of infection, there are no 
reports showing that immunization with attenuated parasites, including RAS, are able to 
elicit any type of cross-protection. Immunization with P. falciparum RAS did not confer 
protection against subsequent challenge with P. vivax sporozoites as reported only once 
in a single human volunteer (Hoffman, 2002). Our results show that the immune 
response elicited by both RAS and GAS P. berghei p36p- sporozoites also acts partially 
against another murine parasite, P. yoelii. Considering that BALB/c mice are 2,000 
times more sensitive to P. yoelii than P. berghei sporozoites (Khan, 1991), the partial 
protection (completely sterile in some BALB/c mice) attained with pb36p- against P. 
yoelii sporozoites challenge is quite remarkable. P. berghei and P. yoelii have an 
average protein identity of 88.2% (Hall, 2005), which suggests that through apoptosis 
several conserved antigens common to P. berghei and P. yoelii would be presented to 
immune system, therefore eliciting an protective response strong enough to act against 
both parasite species. Since P. berghei and P. chabaudi have also a high average protein 
identity, 83.2% (Hall, 2005), one might speculate this P. berghei attenuated sporozoite 
induced immune response might also exert a protective effect against infection with P. 
chabaudi sporozoites, but that remains to be elucidated. Interestingly, a CD8 epitope 
present in CSP and known to be very important in RAS protection for P. yoelii is 
distinct in P. berghei and P. yoelii (Sano, 2001). Thus, other antigens with possibly 
common epitopes much be recognized. The crucial antigens and epitopes responsible 
for the cross-protection are an interesting subject of research. Optimized immunization 
protocols, i.e., using other immunization protocols and/or higher doses of RAS or 
pb36p- sporozoites per immunization, might lead to complete sterile protection against 
P. yoelii and other murine Plasmodium species, and require further investigation.  
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One can only speculate about possible immune mechanisms that may lead to the 
protection induced by pb36p- against both homologous and heterologous species. 
Unlike RAS, which immune response in mice is well studied and documented (Doolan, 
2000), the features that lead to pb36p- induced protection are still unknown (van Dijk, 
2005), as well as for other GAS parasites (Mueller, 2005; Mueller and Camargo, 2005). 
Immunization strategies using P. falciparum RAS have been considered impossible due 
to technical, clinical and logistical hurdles: route of administration, large quantities of 
sporozoites needed and regulatory, potency and safety requirements (Luke, 2003). 
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However, some are pursuing this approach (Luke, 2003), which would be quite useful 
in a possible implementation of P. falciparum GAS immunization strategy. Orthologues 
of p36p-, and other GAS, in P. falciparum or P. vivax have already been described 
(Thompson, 2001; Kaiser, 2004; Mueller and Camargo, 2005), therefore being possible 
to perform this type of genetic modification in human parasites. GAS vaccine efficacy 
and safety could be improved by developing more complex GAS strains that lack 
multiple genes in a single parasite (Waters, 2005; Matuschewski, 2006). Each form of 
GAS must be evaluated for its immunization potential and the best single or 
combination one, taken forward to human trials. 
Previously, we have shown the immunization potential of p36p- P. berghei (van Dijk, 
2005). In this report, we show that potential can be extended to long-lasting immunity 
and cross-species protection against P. yoelii. Furthermore, protection can be achieved 
even with low immunization doses and using practicable routes of immunization 
commonly used as public health measures in humans. Understanding the mechanisms 
by which these deficient parasites induce immunity will no doubt provide ground-
breaking relevant data for the development of a vaccine aimed for the pre-erythrocytic 
stage of Malaria. Those efforts may pave the way for new vaccination strategies.  
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FIG 1. Level of inhibition of an infection with P. yoelii 265 BY sporozoites in mice 
immunized with P. berghei RAS and pb36p- sporozoites. BALB/c mice were 
immunized with RAS sporozoites (prime plus boost) or with pb36p- sporozoites (single 
immunization and prime plus boost) and challenged 3 weeks after last immunization 
with 100 (A) or 1,000 (B) P. yoelii sporozoites. Livers were collected 40 hours post 
challenge and parasite burden was assessed by Real Time PCR. Control mice have no 
inhibition in infection. 
 
FIG. 2. Maximum blood-stage parasitemias levels achieved in P. berghei pb36p- and 
RAS immunized BALB/c mice which were subsequently challenged with P. yoelii 265 
BY sporozoites. BALB/c mice were immunized with pb36p- sporozoites (single 
immunization, prime plus boost and prime plus 2 boosts) and with RAS sporozoites 
(prime plus boost and prime plus 2 boosts) and challenged 3 weeks after last 
immunization with 100, 1,000 or 10,000 P. yoelii sporozoites (only prime plus 2 boosts 
for the later). pb36p- (A) is able to decrease maximum blood-stage parasitemia after 
challenge with different doses of P. yoelii sporozoites in BALB/c mice, although at least 
two immunization doses are required to achieve significant reduction. RAS (B) equally 
induce diminution on maximum parasitemias observed in the same conditions, even 
achieving sterile protection in some cases. Parasitemias are expressed as the mean ± the 
standard deviation of individual animals. Data from two independent experiments are 
shown. * P<0.05, ** P<0.1 
 
FIG. 3. Maximum blood-stage parasitemias levels achieved in P. berghei RAS and 
pb36p- immunized C57BL6 mice which were subsequently challenged with P. yoelii 
265 BY sporozoites. C57BL6 mice were immunized with either RAS or pb36p- 
sporozoites (prime plus 2 boosts) and challenged 3 weeks after last immunization with 
1,000 P. yoelii sporozoites. Both RAS and pb36p- are able to decrease maximum blood-
stage parasitemia when challenged with P. yoelii sporozoites, attaining significant 
reduction. Parasitemias are expressed as the mean ± the standard deviation of individual 
animals. Data from two independent experiments are shown. * P<0.05 
 
TABLE 1 – Immunization with pb36p- sporozoites lead to protection against 
subsequent multiple challenges 
 
No. protected           
(no. challenged) 
Group Mouse Strain 
Immunizationa, 
RAS/pb36p -  × 
1,000 
Challengeb
× 1,000 
Challenge at 
... days post 
last 
immunization Control RAS pb36p-
1 BALB/c 50 10/20 180/351 0 (5) ND 4 (4) 
1 BALB/c 50 20 531 0 (5) ND 3 (3) 
2 C57BL6 50/20/20 10/10/20 60/90/180 0 (5)  5 (5) 4 (4) 
2 C57BL6 50/20/20 20 365 0(5) 5 (5) 2 (4) 
3 BALB/c 50/20/20 10/20 60/180 0 (5) 3 (3) 4 (4) 
3 BALB/c 50/20/20 20 365 0 (5) 3 (3) 1 (2) 
4 BALB/c 50/20/20 10/20 90/180 0 (5) 3 (3) 3 (3) 
4 BALB/c 50/20/20 10/20 365 0 (5) 1 (1) 2 (2) 
5 BALB/c 50/20/20 20 365 0 (5) ND 1 (2) 
 
a Groups of mice were immunized i.v. with one dose of RAS or pb36p - sporozoites 
isolated from different mosquitoes batches. Multiple immunizations with RAS or 
pb36p- sporozoites were performed with weekly intervals. ND, not determined 
 
b Mice were challenged with WT P. berghei sporozoites, isolated from different 
mosquitoes batches. The pre-patent period was monitored by FACS analysis. All 
unimmunized mice become positive on day 3 or 4 after challenge. 
 
 
TABLE 2 – Protection elicited by pb36p- sporozoites does not require subsequent 
multiple challenges to remain fully protective up to 6 months after last immunization in 
BALB/c mice 
 
No. protected           
(no. challenged) Immunization
a, 
RAS/pb36 -  × 
1,000 
Challengeb, 
× 1,000 
Challenge at 
... days post 
last 
immunization Control RAS pb36p- 
50/20/20 10 60 0 (5) 3 (3) 4 (4) 
50/20/20 10 90 0 (5) 3 (3) 3 (3) 
50/20/20 20 180 0 (5) 4 (4) 4 (4) 
 
a Groups of mice were immunized i.v. with one dose of RAS or pb36p- sporozoites 
isolated from different mosquitoes batches. Multiple immunizations with RAS or 
pb36p- sporozoites were performed with weekly intervals 
 
b Mice were challenged with WT P. berghei sporozoites, isolated from different 
mosquitoes batches. The pre-patent period was monitored by FACS analysis. All 
unimmunized mice become positive on day 3 or 4 after challenge. 
 
 
 
 
 
 
 
TABLE 3 – Protection elicited by pb36p- sporozoites can be achieved even with low 
immunization doses in C57BL6 mice 
 
Pre-patency 
(days post 
infection)b
No. protected/no. 
challenged (%) Immunization
a, 
RAS/pb36p-  × 
1,000 
RAS pb36p- RAS pb36p- 
50/20/20 - - 5/5 (100%) 8/8 (100%) 
10/10/10 - - 5/5 (100%) 5/5 (100%) 
5/5/5 - - 5/5 (100%) 8/8 (100%) 
1/1/1 6.2 - 0/5 (0%) 10/10 (100%) 
None (Control) 3.2 0/8 (0%) 
 
a Groups of mice were immunized i.v. with RAS or pb36p - sporozoites isolated from 
different mosquitoes batches. Multiple immunizations with RAS or pb36p- sporozoites 
were performed with weekly intervals. Data from three independent experiments are 
shown.  
 
b Mice were challenged with 10,000 WT P. berghei sporozoites, isolated from different 
mosquitoes batches. Pre-patency is defined as the time until the first appearance of 
blood-stage parasites, and it was monitored by FACS analysis. 
 
 
TABLE 4 – pb36p- sporozoites administered intramuscularly, subcutaneously and 
intradermally are able to confer protection against intravenous challenge with infectious 
P. berghei sporozoites in C57BL6 mice 
 
Pre-patency 
(days post 
infection)b
No. protected/no. 
challenged i.v. (%) 
No. protected/no. 
challenged m.b.c (%) Type of 
immunizationa
RAS pb36p- RAS pb36p- pb36p- 
intravenous  - - 5/5 (100%) 5/5 (100%) 5/5 (100%) 
intramuscular 4.5 5.3 1/5 (20%) 1/8 (13%) 5/6 (83%) 
subcutaneous 4.8 5.0 0/5 (0%) 0/10 (0%) 8/10 (80%) 
intradermal 4.5 4.8 1/5 (20%) 0/9 (0%) 6/8 (75%) 
None (Control) 3.2 0/8 (0%) 0/8 (0%) 
 
a Groups of mice were immunized as indicated with RAS or pb36 - sporozoites isolated 
from different mosquitoes batches. Multiple immunizations with RAS or pb36p- 
sporozoites were performed with weekly intervals. Data from two independent 
experiments are shown.  
 
b Mice were challenged with 10,000 WT P. berghei sporozoites, isolated from different 
mosquitoes batches. Pre-patency is defined as the time until the first appearance of 
blood-stage parasites, and it was monitored by FACS analysis. Data concerning pre-
patency in this table only concerns i.v. challenge. 
 
c m.b., mosquito bite challenge. Highly infected mosquitoes (50,000-80,000 salivary 
gland sporozoites per mosquito) were allowed to feed on mice during 10-15 min (5 
mosquitoes per mouse)  
 
 
TABLE 5 – Immunization with P. berghei RAS and pb36p- sporozoites lead to a delay 
on parasitemia onset in BALB/c and C57BL6 mice challenged with the heterologous 
species P. yoelii, and some even achieve sterile protection. 
 
 
Pre-patency 
(days)  
No. protected (no. 
challenged) Groups Mouse Strain 
Immunization 
× 1,000a
Challenge 
Doseb
(P. yoelii 
sporozoites) pb36p- RAS Control pb36p- RAS Control 
1 BALB/c 50 100 5.0 ND 5.2 0 (3) ND 0 (3) 
2 BALB/c 50/20 100 7.0 - 5.2 1 (3) 3 (3) 0 (3) 
3 BALB/c 50/20/20 100 5.0 6.0 5.2 0 (5) 3 (4) 0 (5) 
4 BALB/c 50 1,000 4.0 ND 4.0 0 (3) ND 0 (3) 
5 BALB/c 50/20 1,000 4.7 5.5 4.0 0 (3) 1 (3) 0 (3) 
6 BALB/c 50/20/20 1,000 5.2 7.0 4.0 0 (5) 3 (4) 0 (5) 
7 C57BL6 50/20/20 1,000 4.8 5.5 4.0 0 (5) 0 (5) 0 (5) 
8 BALB/c 50/20/20 10,000 4.6 5.0 4.0 0 (5) 0 (4) 0 (5) 
a Groups of mice were immunized as described before with P. berghei RAS or pb36p- 
sporozoites. Data from two independent experiments are shown. ND, not determined. 
 
b For all experiments described above, matched control mice groups  immunized 
likewise with either RAS or pb36p- sporozoites from the same mosquitoes’ batch and 
challenged with 10,000 homologous P. berghei sporozoites each. All failed to develop 
blood stage parasites confirming that these sporozoites were fully protective in 
homologous challenge in these conditions. All control naïve mice challenged equally 
with P. berghei sporozoites developed blood stage parasitemia, as expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
